<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Aptos Display";}
@font-face
	{font-family:Aptos;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:20.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:4.0pt;
	margin-right:0cm;
	margin-bottom:2.0pt;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#2F5496;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:4.0pt;
	margin-right:0cm;
	margin-bottom:2.0pt;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#595959;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#595959;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#272727;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#272727;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0cm;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0cm;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	color:#595959;
	letter-spacing:.75pt;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0cm;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	text-align:center;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:18.0pt;
	margin-right:43.2pt;
	margin-bottom:18.0pt;
	margin-left:43.2pt;
	text-align:center;
	line-height:107%;
	border:none;
	padding:0cm;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#2F5496;
	font-style:italic;}
span.MsoIntenseEmphasis
	{color:#2F5496;
	font-style:italic;}
span.MsoIntenseReference
	{font-variant:small-caps;
	color:#2F5496;
	letter-spacing:.25pt;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	color:#2F5496;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	color:#2F5496;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	color:#2F5496;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	color:#595959;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	color:#595959;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	color:#272727;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Times New Roman",serif;
	color:#272727;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	letter-spacing:-.5pt;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Times New Roman",serif;
	color:#595959;
	letter-spacing:.75pt;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:#404040;
	font-style:italic;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#2F5496;
	font-style:italic;}
p.msonormal0, li.msonormal0, div.msonormal0
	{mso-style-name:msonormal;
	margin-right:0cm;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.term-highlight
	{mso-style-name:term-highlight;}
p.float-caption, li.float-caption, div.float-caption
	{mso-style-name:float-caption;
	margin-right:0cm;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.halfrhythm, li.halfrhythm, div.halfrhythm
	{mso-style-name:half_rhythm;
	margin-right:0cm;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:11.0pt;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=EN-GB link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><b>Introduction</b></p>

<p class=MsoNormal><b>Psoriatic</b>&nbsp;arthritis (PsA) is an inflammatory
musculoskeletal disease with a heterogenous presentation and disease course.
While it is associated with psoriasis, PsA also presents with variable clinical
features involving multiple domains, including peripheral arthritis, enthesitis
(tenderness and swelling at the insertion of tendons and ligaments into bone),
dactylitis (swelling of whole digits), and axial disease (inflammation of the
joints of the back)<sup>.1,2</sup>&nbsp;Pain and stiffness of the affected
joints are the most predominant presenting symptoms, with fatigue also
occurring in many patients.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>1</sup></a></p>

<p class=MsoNormal>The prevalence of PsA varies, depending on the case
definition and geography, but it is estimated to be 1 to 2 cases per 1,000 in
the general population<sup>.1</sup>&nbsp;A population-based Canadian study
estimated the age- and sex-standardized cumulative prevalence of PsA in Ontario
to range from 0.09% in 2008 to 0.15% in 2015.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>3</sup></a></p>

<p class=MsoNormal>Several drug classes are used in the pharmacologic treatment
of PsA, including nonsteroidal anti-inflammatory drugs (NSAIDs), conventional
disease-modifying antirheumatic drugs (cDMARDs) (i.e., methotrexate,
sulfasalazine, leflunomide), biologic disease-modifying antirheumatic drugs
(bDMARDs) (i.e., tumour necrosis factor [TNF] inhibitors, interleukin [IL]-23
inhibitors, IL-12/23 inhibitors, and IL-17 inhibitors), and targeted synthetic
DMARDs (e.g., apremilast, upadacitinib, or tofacitinib).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>4</sup></a></p>

<p class=MsoNormal>Guselkumab is a human immunoglobulin G1 lambda monoclonal
antibody that binds to the IL-23 protein and inhibits its binding with the cell
surface IL-23 receptor.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a>&nbsp;Guselkumab
is approved for the treatment of adult patients with active PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a>&nbsp;It
may be used alone or in combination with a cDMARD (e.g., methotrexate) and is
available as a 100 mg/mL solution for subcutaneous (SC) injection in either 1
mL pre-filled syringes or patient-controlled injector devices. The recommended
dose for PsA is 100 mg SC at week 0, week 4, and every 8 weeks thereafter.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a></p>

<p class=MsoNormal>The objective of this report was to perform a systematic
review of the beneficial and harmful effects of guselkumab SC injection for the
treatment of active PsA in adults.</p>

<p class=MsoNormal><b>Stakeholder Perspectives</b></p>

<p class=MsoNormal>The information in this section is a summary of the input
provided by the patient groups that responded to CADTH’s call for patient input
and from the clinical expert(s) consulted by CADTH for the purpose of this
review.</p>

<p class=MsoNormal><b>Patient Input</b></p>

<p class=MsoNormal>Three patient group inputs were submitted for this review by
6 different patient groups: Arthritis Consumer Experts, the Canadian
Association of Psoriasis Patients (CAPP) in partnership with the Canadian
Psoriasis Network (CPN), and the Canadian Arthritis Patient Alliance (CAPA) in
partnership with the Arthritis Society and CreakyJoints. Five patient
organizations (CAPP, CPN, CAPA, the Arthritis Society, and CreakyJoints Canada)
collaborated by collectively developing survey questions using SurveyMonkey for
the inputs submitted. Each of the 3 patient group inputs used the same survey
data. There were 71 respondents to the joint survey. In addition, Arthritis
Consumer Experts gathered information from 1 respondent through email on May 4,
2022 and from 5 respondents through an online survey from December 18, 2020 to
January 26, 2021.</p>

<p class=MsoNormal>Respondents reported a range of symptoms that are difficult
to manage, including joint stiffness (79%), fatigue (75%), changes in
fingernails and toes (63%), hip pain (61%), back pain (51%), anxiety (47%), and
stress (33%). With regards to the most significant impacts of PsA on their
daily quality of life, respondents expressed that PsA interfered with work
(54%), social connections (52%), self-esteem (50%), mental health (50%),
intimacy (50%), family life (38%), and friendships (24%). Other impacts included
embarrassment and self-consciousness from the symptoms caused by PsA. Given
that the disease would reduce their mobility and ability to participate in
activities and affect their mental and social health, respondents indicated
that there were additional tasks or chores for caregivers, such as cooking,
cleaning, shopping, and helping patients get to and from medical appointments.</p>

<p class=MsoNormal>Survey respondents indicated that they had experience with
several treatment approaches, including NSAIDs, corticosteroids, cDMARDs (such
as methotrexate), and bDMARDs. Among respondents, 32% considered biologics as
very effective, followed by oral steroids (23%) and other DMARDs (21%).
Respondents expressed their ongoing unmet needs for symptom management and more
tolerable side effects with current treatments.</p>

<p class=MsoNormal>Two respondents who had experience with guselkumab indicated
that the drug was effective in terms of improving psoriasis and arthritis and
slowing disease progression. Both respondents stated that they did not
experience side effects.</p>

<p class=MsoNormal>Respondents expected new treatments to improve the following
key outcomes: management of symptoms (e.g., reducing pain and fatigue,
increasing mobility); tolerability of side effects; ease of drug
administration; improved ability to work and carry out tasks and daily
activities; and quality of life.</p>

<p class=MsoNormal><b>Clinician Input</b></p>

<p class=MsoNormal><i>Input From the Clinical Expert Consulted by CADTH</i></p>

<p class=MsoNormal>A substantial proportion of patients lose their response to
therapy over time or do not achieve a minimal response with their first
therapy. In addition, some treatments have more adverse effects than others.
There is a need for medications with new mechanisms of action or a different
safety profile to offer alternate treatment options for these patients who have
an inadequate response or intolerance to therapy. According to the clinical
expert, guselkumab may be used as first- or second-line biologic therapy. It
may be a preferred first-line treatment for patients with moderate psoriasis in
addition to musculoskeletal disease. Guselkumab may be used in combination with
methotrexate or leflunomide; however, there is no evidence to support its use
in combination with other biologics.</p>

<p class=MsoNormal>Response to therapy is based on a reduction in the number of
inflamed joints, improvement in the skin, and improvements in patient-reported
outcomes (i.e., based on assessments of pain, function, and fatigue). According
to the clinical expert, a major improvement would constitute at least a 50%
improvement, but may also include achievement of minimal disease activity (MDA)
and remission as measured by specific instruments. An initial response may be
expected within 3 months, with more significant improvement by 6 months after
initiating therapy. The expert indicated that if a patient shows no change
within 3 to 6 months, they would be considered a nonresponder and may be
switched to another medication. The expert stated that ideally, guselkumab
would be prescribed by specialists who are familiar with the drug and its uses,
or at least in consultation with a dermatologist or rheumatologist.</p>

<p class=MsoNormal><i>Clinician Group Input</i></p>

<p class=MsoNormal>CADTH received 1 clinician group input submission from the
Canadian Rheumatologist&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Interest Group,
based on responses from 6 clinicians who practise in academic and community
settings. This clinician input largely agreed with the input received from the
clinician consulted by CADTH. No major contrary views among the views provided
by the clinical experts consulted by CADTH for this review were presented.</p>

<p class=MsoNormal><b>Drug Program Input</b></p>

<p class=MsoNormal>The drug programs identified the following issues that may
affect these programs’ ability to implement a recommendation: relevant
comparators, consideration for initiation of therapy, consideration for
continuation or renewal of therapy, consideration for discontinuation of
therapy, consideration for prescribing of therapy, and system and economic
issues. Refer to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t05/?report=objectonly"
target=object>Table 5</a>.</p>

<p class=MsoNormal><b>Clinical Evidence</b></p>

<p class=MsoNormal><b>Pivotal Studies and Protocol Selected Studies</b></p>

<p class=MsoNormal><i>Description of Studies</i></p>

<p class=MsoNormal>Three double-blind, placebo-controlled, randomized
controlled trials (RCTs) met the inclusion criteria for the systematic review.
The pivotal trials (DISCOVER-1 and DISCOVER-2) included patients with active
PsA who had experienced an inadequate response to cDMARDs, apremilast, and/or
NSAIDs. The DISCOVER-1 study (N&nbsp;= 381) enrolled a mixed population that
included patients with no prior biologic treatment experience; however, up to
30% of patients had previously received 1 or 2 TNF alpha inhibitors. In the DISCOVER-2
study, all enrolled patients were biologic-naive (N&nbsp;= 741). The COSMOS
study enrolled patients with active PsA who were intolerant to or had
experienced an inadequate response to 1 or 2 TNF alpha inhibitors (N&nbsp;=
285). The trials were conducted mainly in Europe, with some sites in Asia, the
US, Australia, Israel, and Canada (DISCOVER-1 only).</p>

<p class=MsoNormal>Patients were randomized to receive placebo or guselkumab
100 mg SC at week 0, week 4, and every 8 weeks thereafter for 24 weeks. The
DISCOVER trials included a third treatment group (guselkumab 100 mg every 4
weeks). However, the latter dosage is not consistent with the Health
Canada–recommended dose; therefore, results for this treatment group are not
included in this report. The total trial durations were 52 weeks (DISCOVER-1),
100 weeks (DISCOVER-2), and 48 weeks (COSMOS), with placebo patients switching
to guselkumab starting at week 24. During the trials, patients could continue
receiving methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, oral
corticosteroids, or NSAIDs if the doses were stable and did not exceed the
protocol-specified maximum doses. Early escape therapy consisting of cDMARDs,
corticosteroids, or NSAIDs — or a switch to guselkumab (COSMOS) — was available
at week 16 for patients who had an improvement of less than 5% in tender and
swollen joint counts.</p>

<p class=MsoNormal>The primary outcome in all trials was the proportion of
patients who achieved an American College of Rheumatology (ACR) 20% improvement
(ACR 20) at week 24. The ACR 20 was defined as a greater than or equal to 20%
improvement from baseline in both swollen joint count (66 joints) and tender
joint count (68 joints), and a greater than or equal to 20% improvement from
baseline in 3 of the 5 assessments: patient’s assessment of pain, patient’s
global assessment of disease activity, physician’s global assessment of disease
activity, the Health Assessment Questionnaire Disability Index (HAQ-DI), and
C-reactive protein (CRP). Other outcomes of interest included the change from
baseline in the HAQ-DI and Short Form (36) Health Survey (SF-36) Physical
Component Summary (PCS) and the impact on plaque psoriasis (as measured by the
Investigator’s Global Assessment of Psoriasis [IGA] or Psoriasis Area and
Severity Index [PASI] response).</p>

<p class=MsoNormal>The mean age of patients enrolled ranged from 44.9 years
(standard deviation [SD]&nbsp;= 11.9 years) to 49.1 years (SD&nbsp;= 12.3
years) across treatment groups in the 3 trials. The proportion of female
patients ranged from 46% to 55%, and most patients were White (89% to 98%; not
reported for the COSMOS study). The mean number of swollen joints ranged from
9.0 (SD&nbsp;= 5.7) to 12.3 (SD&nbsp;= 6.9), and the mean number of tender
joints ranged from 18.2 (SD&nbsp;= 10.7) to 21.6 (SD&nbsp;= 13.1). Approximately
2-thirds of patients had&nbsp;<b>psoriatic</b>&nbsp;involvement affecting at
least 3% of their body surface area (BSA). Two-thirds of patients reported
enthesitis, while approximately 40% had dactylitis at baseline. The majority of
patients (54% to 63%) were receiving methotrexate at baseline, with a lower
percentage (0% to 7%) receiving other permitted cDMARDs. In the DISCOVER
trials, 14% to 20% of patients were receiving oral corticosteroids at baseline
versus 4% to 5% of patients in the COSMOS study.</p>

<p class=MsoNormal><i>Efficacy Results</i></p>

<p class=MsoNormal>In the DISCOVER-1 study, 52.0% of patients in the group
receiving guselkumab every 8 weeks achieved ACR 20 at 24 weeks, compared with
22.2% of patients in the placebo group. The absolute difference was 29.8% (95%
confidence interval [CI], 18.6% to 41.1%; P&nbsp;&lt;&nbsp;0.001), favouring
guselkumab versus placebo (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). The proportion of patients who achieved at least an
American College of Rheumatology 50% improvement (ACR 50) was 29.9% versus 8.7%
(absolute difference&nbsp;= 21.4%; 95% CI, 12.1% to 30.7%) for guselkumab every
8 weeks versus placebo; the proportion of patients who achieved an American
College of Rheumatology 70% improvement (ACR 70) was 11.8% versus 5.6%
(absolute difference&nbsp;= 6.4%; 95% CI, &#8722;0.3% to 13.1%) for guselkumab
every 8 weeks versus placebo. However, ACR 50 and ACR 70 were not controlled
for multiple testing and should be interpreted considering the inflated risk of
type I error rate.</p>

<p class=MsoNormal>Among patients who were biologic-naive (DISCOVER-2), 64.1%
and 32.9% achieved ACR 20 at 24 weeks in the group receiving guselkumab every 8
weeks and the placebo group, respectively, with an absolute difference of 31.2%
(95% CI, 22.9% to 39.5%; P&nbsp;&lt;&nbsp;0.001) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). The proportion of patients who achieved ACR 50 was
31.5% versus 14.2% (absolute difference&nbsp;= 17.2%; 95% CI, 10.0% to 24.4%),
and the proportion of patients who achieved ACR 70 was 18.5% versus 4.1%
(absolute difference&nbsp;= 14.5%; 95% CI, 9.1% to 19.9%). ACR 50 and ACR 70
were not controlled for multiple testing (i.e., the type I error rate has not
been controlled).</p>

<p class=MsoNormal>For biologic-experienced patients who were enrolled in the
COSMOS study, 44.4% and 19.8% achieved ACR 20 at week 24 in the group receiving
guselkumab every 8 weeks and the placebo group, respectively. The absolute
difference between groups favoured guselkumab: 24.6% (95% CI, 14.1% to 35.2%;
P&nbsp;&lt;&nbsp;0.001) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). The difference also favoured guselkumab every 8
weeks versus placebo for the proportion who achieved ACR 50 (19.6% versus 5.2%;
absolute difference&nbsp;= 14.3%; 95% CI, 7.2% to 21.4%;
P&nbsp;&lt;&nbsp;0.001). ACR 70 was achieved by 7.9% versus 1.0% of patients in
the group receiving guselkumab every 8 weeks versus the placebo group, with an
absolute difference of 6.8% (95% CI, 2.6% to 11.1%). ACR 70 was not controlled
for multiple testing.</p>

<p class=MsoNormal>In the DISCOVER trials, the odds ratios of ACR 20 response
were generally consistent across subgroups based on prior TNF alpha inhibitor
use, use of non-biologic DMARDs, oral corticosteroids, or NSAIDs at baseline;
however, the trials may not have been powered to detect subgroup differences.
The COSMOS study did not report data for any subgroups of interest to this
review.</p>

<p class=MsoNormal>Disability was assessed using the HAQ-DI, a
patient-reported, 20-question instrument that assesses the degree of difficulty
a person has in accomplishing tasks in 8 functional areas (dressing, arising,
eating, walking, hygiene, reaching, gripping, and activities of daily living).
The overall score is the average of 8 domains ranging from 0 (no disability) to
3 (completely disabled). The change from baseline to week 24 in the HAQ-DI
favoured guselkumab every 8 weeks versus placebo in all trials (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). The least squares (LS) mean differences versus
placebo reported were &#8722;0.25 (95% CI, &#8722;0.36 to &#8722;0.13;
P&nbsp;&lt;&nbsp;0.001) in the DISCOVER-1 study; &#8722;0.24 (95% CI,
&#8722;0.32 to &#8722;0.15; P&nbsp;&lt;&nbsp;0.001) in the DISCOVER-2 study;
and &#8722;0.17 (95% CI, &#8722;0.28 to &#8722;0.06; P&nbsp;=&nbsp;0.003) in
the COSMOS study. Across the trials, the between-group and within-group
differences did not exceed the 0.35 minimal important difference (MID) cited by
the sponsor,<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>6</sup></a>&nbsp;with
the exception of the change from baseline within the group receiving guselkumab
every 8 weeks in the DISCOVER-2 study.</p>

<p class=MsoNormal>The change from baseline to week 24 in the SF-36 PCS
favoured guselkumab every 8 weeks versus placebo in all 3 studies (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). The LS mean differences were 4.1 (95% CI, 2.4 to
5.9; P&nbsp;&lt;&nbsp;0.001) in DISCOVER-1, 4.0 (95% CI, 2.7 to 5.2;
P&nbsp;=&nbsp;0.011) in DISCOVER-2, and 3.9 (95% CI, 2.5 to 5.4;
P&nbsp;&lt;&nbsp;0.001) in the COSMOS study. The Clinical Study Report defined
at least a 5-point increase as clinically meaningful, but a MID of 3.74 points
has also been reported in the literature.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>7</sup></a>&nbsp;No
statistically significant differences were detected between guselkumab every 8
weeks and placebo in the change from baseline to week 24 in the SF-36 Mental
Component Summary (MCS).</p>

<p class=MsoNormal>In all trials, psoriasis skin disease outcome measures were
analyzed in the subgroup of patients who had psoriasis affecting greater than
or equal to 3% BSA and an IGA score of greater than or equal to 2 at baseline
(55% to 74% of patients per treatment group). Psoriasis severity was assessed
using composite physician-reported assessments: IGA and PASI response. For the
IGA, the severity of a patient’s psoriasis is scored as cleared (0), minimal
(1), mild (2), moderate (3), or severe (4). IGA response was defined as a score
of 0 or 1, and at least a 2-point decrease from baseline. The PASI evaluates
the extent and severity of psoriasis and is scored from 0 to 72 points, with a
PASI score greater than 10 considered to represent severe disease. Patients
with 90% improvement in their PASI score (PASI 90) or 100% improvement in their
PASI score (PASI 100) would meet PASI 90 or PASI 100 response criteria,
respectively.</p>

<p class=MsoNormal>The proportion of patients who achieved an IGA response at
week 24 was higher in the groups receiving guselkumab every 8 weeks than in the
placebo groups in the DISCOVER-1 study (57.3% versus 15.4%; absolute
difference&nbsp;= 42.0% [95% CI, 28.9% to 55.1%; P&nbsp;&lt;&nbsp;0.001]) and
DISCOVER-2 study (70.5% versus 19.1%; absolute difference&nbsp;= 50.9% [95% CI,
42.2% to 59.7%; P&nbsp;&lt;&nbsp;0.001]) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a>). In the COSMOS study, 48.1% versus 9.4% of patients
in the guselkumab-every-8-weeks versus placebo group achieved in IGA response,
with an absolute difference of 38.8% (95% CI, 27.3% to 50.4%); however, the P
value has not been adjusted to control for multiple testing and should be
interpreted with caution because of the potential for inflated type I error
rate. PASI 100 response at week 24 was a secondary outcome in the COSMOS study.
In the guselkumab group, 30.8% of patients achieved a PASI 100 response
compared with 3.8% of patients in the placebo group (absolute difference&nbsp;=
27.4% [95% CI, 17.9% to 36.8%; P&nbsp;&lt;&nbsp;0.001). In the DISCOVER trials,
the proportion of patients who achieved a PASI 100 response was nominally
higher for the guselkumab versus placebo groups; however, these outcomes were
not controlled for multiple testing and should be interpreted considering the
inflated risk of type I error rate.</p>

<p class=MsoNormal>For patients with enthesitis or dactylitis at baseline, the
results of the DISCOVER-2 and COSMOS studies suggest an improvement in
enthesitis or dactylitis end points, with guselkumab every 8 weeks relative to
placebo, but no statistically significant difference was detected between
groups in DISCOVER-1. Based on the preplanned pooled analysis of data from
DISCOVER-1 and DISCOVER-2, 49.6% and 29.4% of patients in the
guselkumab-every-8-weeks and placebo groups had resolution of enthesitis at
week 24, with a between-group difference of 20.1% (95% CI, 11.8% to 28.5%;
P&nbsp;=&nbsp;0.03). The proportion of patients whose dactylitis resolved at
week 24 was 59.4% versus 42.2% in the guselkumab-every-8-weeks versus placebo
groups (between-group difference&nbsp;= 18.0%; (95% CI, 7.4% to 28.6%;
P&nbsp;=&nbsp;0.03). None of the trials detected a statistically significant
difference between guselkumab every 8 weeks and placebo in the proportion of
patients who reported a clinically important improvement in axial disease based
on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). It is
noteworthy that these outcomes were tested in subgroups of patients that may
not have been balanced with respect to baseline demographic and disease
characteristics between treatment groups, due to the lack of stratification at
randomization.</p>

<p class=MsoNormal>Symptoms of fatigue were assessed using the Functional
Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue). The
scores ranged from 0 to 52, with lower scores reflecting more severe fatigue.
Estimates of the MID ranged from 3.1 points to 4 points.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>9</sup></a>&nbsp;The
DISCOVER-1 study reported an LS mean difference of 3.4 points (95% CI, 1.4 to
5.4); DISCOVER-2 reported an LS mean difference of 4.0 (95% CI, 2.5 to 5.5);
and COSMOS reported an LS mean difference of 3.6 (95% CI, 1.7 to 5.4) for
guselkumab every 8 weeks versus placebo. This outcome was not controlled for
multiple testing (i.e., the type I error rate has not been controlled).</p>

<p class=MsoNormal>Radiographic progression was a major secondary outcome in
the DISCOVER-2 study. Progression was assessed using the modified van der
Heijde-Sharp (vdH-S) score, which ranges from 0 (best) to 528 (worst) and is
the sum of the joint erosion score and the joint space narrowing score.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>10</sup></a>&nbsp;At
24 weeks, the study failed to detect a statistically significant difference
between guselkumab every 8 weeks and placebo in the change from baseline in
vdH-S score. However, the duration of the trial may have been insufficient to
detect a difference.</p>

<p class=MsoNormal><i>Harms Results</i></p>

<p class=MsoNormal>The frequency of adverse events was generally similar
between groups in all trials, with 42% to 54% of patients in the groups
receiving guselkumab every 8 weeks and 41% to 60% of patients in the placebo
groups reporting 1 or more adverse events during the 24-week treatment period (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t03/?report=objectonly"
target=object>Table 3</a>). Nasopharyngitis (4% to 13%), upper respiratory
tract infection (2% to 5%), and increased alanine aminotransferase (2% to 6%)
were the most common adverse events in the guselkumab groups, with a comparable
frequency of these events reported in the placebo groups. Generally, the
frequency of infections was similar in the guselkumab groups (16% to 26%) and
placebo groups (18% to 25%) across trials. Few serious infections were reported
(0% to 0.5% in the guselkumab groups).</p>

<p class=MsoNormal>The frequency of serious adverse events ranged from 1% to 4%
in the groups receiving guselkumab every 8 weeks and 3% to 4% in the placebo
groups. No specific serious adverse events were reported in more than 1 patient
per treatment group. Adverse events that resulted in treatment discontinuation
were generally low and similar between groups (1% to 3%). In the DISCOVER-1
study, 1 patient in the placebo group died due to cardiac failure. No other
deaths were reported in the first 24 weeks of the trials.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
title="&quot;Table 2&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 114"
src="psoriasis%20test_files/image001.png"
alt="Table 2. Summary of Key Efficacy Results From Pivotal and Protocol Selected Studies."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t02/?report=objectonly"
target=object>Table 2</a></b></p>

<p class=MsoNormal>Summary of Key Efficacy Results From Pivotal and Protocol
Selected Studies.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t03/?report=objectonly"
title="&quot;Table 3&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 113"
src="psoriasis%20test_files/image002.png"
alt="Table 3. Summary of Key Safety Results From Pivotal and Protocol Selected Studies."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t03/?report=objectonly"
target=object>Table 3</a></b></p>

<p class=MsoNormal>Summary of Key Safety Results From Pivotal and Protocol
Selected Studies.</p>

<p class=MsoNormal><i>Critical Appraisal</i></p>

<p class=MsoNormal>The risk of bias related to randomization and treatment
allocation concealment was rated as low for all studies. In general, patient
characteristics and co-interventions appeared to be balanced between groups at
baseline. The trials were double blind and took steps to maintain blinding of
patients and investigators. Joint assessments were conducted by an independent
rater who was not otherwise involved in the trial. Therefore, the risk of bias
in the measurement of the outcomes was low for all trials. The frequency of
withdrawal in all trials was low and similar between groups; therefore, there
is a low risk of bias due to missing outcome data. The full analysis set (FAS),
which excluded only 1 randomized patient in DISCOVER-2, was used for all
efficacy outcomes; therefore, the analyses were appropriate for estimating the
effect of assignment to the intervention.</p>

<p class=MsoNormal>In all trials, the primary and other dichotomous end points
were analyzed using a Cochran-Mantel-Haenszel (CMH) test that was stratified by
randomization stratification factors, with missing data imputed as
nonresponders. The DISCOVER trials used an adjusted analysis of covariance
(ANCOVA) model, and the COSMOS study used an unadjusted mixed-effects model for
repeated measures (MMRM) to analyze continuous outcomes. Missing data were
imputed under the missing-at-random assumption. This assumption may not hold
true, but was not thought to be a major source of bias. Efficacy analyses were
based on the composite estimand, with any patients meeting treatment failure
criteria considered nonresponders for binary end points, or as no change from
baseline for continuous measures. Treatment failure criteria included early
study withdrawal or discontinuation of the study drug, or initiation of new
treatments for PsA. This estimand, which considers any treatment failure end
point to be an unfavourable outcome, may be considered a more conservative
estimate of treatment effects. Of note, the COSMOS study incorrectly assigned
20 patients to early escape despite these patients not having met the escape
criteria. Although the sponsor conducted sensitivity analyses to explore the
impact of this error, these analyses cannot fully address the potential bias.
The type I error rate was controlled for the primary and selected secondary
outcomes in all studies. However, several outcomes of interest to this review
were not controlled for multiplicity; these data should be interpreted with
caution, given the potential for inflated type I error rate. Randomization was
not stratified by the presence of psoriasis, enthesitis, dactylitis, or axial
disease; thus, interpretation of the results for these outcomes should consider
the possibility of imbalances in baseline demographic and disease
characteristics between treatment groups in these subpopulations. The primary
outcome was ACR 20 response; however, according to the clinical expert, this
represents the minimum level of improvement that may be relevant to patients.
In practice, the goal of therapy is to achieve higher levels of response.</p>

<p class=MsoNormal>Although the trials were 48 weeks to 100 weeks in duration,
the comparative period was limited to 24 weeks for this chronic condition. For
outcomes such as radiologic changes, the duration of treatment may have been
insufficient to detect the impact of guselkumab. Moreover, none of the trials
included an active control group; thus, direct evidence comparing guselkumab to
other DMARDs available in Canada is not available.</p>

<p class=MsoNormal>With regards to external validity, the clinical expert did
not identify any substantial limits to generalizability based on the patient
population enrolled. The guselkumab dosing regime used in the trials (i.e.,
once every 8 weeks) was consistent with the Health Canada–recommended dose, and
the expert stated that concomitant utilization of cDMARDs was similar to what
may be expected in clinical practice. However, the expert also noted that the
use of oral corticosteroids in the DISCOVER trials was higher than would be
expected in Canada (14% to 20%). The use of a placebo comparator as an add-on
to cDMARDs and NSAIDs is not consistent with Canadian practice for patients who
have demonstrated an inadequate response to cDMARDs or bDMARDs. The trials
excluded patients who had previously been treated with biologics other than TNF
inhibitors; thus, the efficacy in patients with intolerance or inadequate
response to other biologics, such as Janus kinase (JAK) or other IL inhibitors,
is not known.</p>

<p class=MsoNormal><b>Indirect Treatment Comparisons</b></p>

<p class=MsoNormal><i>Description of Studies</i></p>

<p class=MsoNormal>The sponsor conducted a network meta-analysis (NMA) of RCTs
that assessed the comparative efficacy and safety of guselkumab and 13 other
bDMARDs for the short-term treatment of acute PsA. The indirect treatment
comparison (ITC) was based on a systematic literature review, and 34 RCTs
provided data to inform the Bayesian NMA. Analyses were conducted for the
overall PsA population, with subgroup analyses restricted to patients who were
biologic-naive or biologic-experienced. Treatment durations were 12 weeks to 24
weeks.</p>

<p class=MsoNormal>One other NMA was identified by CADTH through a literature
search. The NMA by McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;evaluated
the efficacy and safety of licensed and unlicensed bDMARDs for patients with
active PsA. A total of 46 RCTs, which were identified through a systematic
review, were included in the Bayesian analyses. The MNA included 19 biologics
with outcomes assessed at 12 weeks to 26 weeks.</p>

<p class=MsoNormal><i>Efficacy Results</i></p>

<p class=MsoNormal>For the overall PsA population in the sponsor-submitted NMA,
the results suggest that patients who received guselkumab every 8 weeks ||| ||
|||| |||||| || ||||||| || ||| || |||||||| than those who received apremilast or
abatacept, but were |||| |||||| || respond than infliximab, golimumab, and
secukinumab 300 mg (34 RCTs; ordinal baseline risk-adjusted random-effects
model). Comparisons between guselkumab and other biologics had 95% credible
intervals (CrIs) that |||||||||| ||| |||| |||||. The NMA results for PASI 90
response |||||||| |||||||||| |||||| ||||||||||| ||| ||| ||| ||||| ||||||||||
||||||| |||||||||||| ||| ||||||||||| ||||||||| ||| ||||||||||. Other
comparisons with biologics reported 95% CrIs that |||||||| ||| ||||. For the
change in HAQ-DI, SF-36 PCS or MCS, or vdH-S scores, |||| || ||| |||||||||||
|||||||| guselkumab over other biologics, with analyses reporting 95% CrIs that
|||||||||| ||| ||||. Across all networks, many comparisons showed imprecise 95%
CrIs that included the possibility of appreciable benefit and/or worse
outcomes, and || |||||||||| ||||||| |||||||||| ||| ||||| |||||||||, which
limits the ability to draw conclusions from these data.</p>

<p class=MsoNormal>The results in the biologic-naive population were generally
|||||||||| |||| ||| |||||||| || ||| ||||||| ||||||||||, although the networks
were smaller (17 studies to 30 studies), not all comparators were available for
all outcomes, and with |||| || ||| |||||||| ||||||| ||||||| |||||||||. The NMAs
in biologic-experienced patients included fewer trials (8 studies to 16
studies) and the reported results were imprecise, limiting the ability to draw
conclusions.</p>

<p class=MsoNormal>The results for ACR 20 and PASI 90 in the NMA by McInnes et
al. (2022)<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;were
largely consistent with the findings of the sponsor-submitted NMA.</p>

<p class=MsoNormal><i>Harms Results</i></p>

<p class=MsoNormal>In the overall population, the analysis of serious adverse
events in the sponsor-submitted NMA |||||| ||| ||| |||| |||||||||| ||| |||| |||
|||| |||||||||||| |||| |||||||| ||||| |||| ||| |||||||||| |||||| |||||||||| ||
|||||||||||| ||| || |||| ||| |||||||| |||||||| ||||||||||||| |||||| |||||||
||||||. For all other comparisons, the 95% CrI was |||||||||| limiting the
ability to draw a conclusion. In most cases, ||| ||||||| || ||| ||| || |||||||
|||||| |||||| ||||||| ||||||||.</p>

<p class=MsoNormal>||| ||| ||| ||||||| |||||| || ||||||| ||||||| |||||| ||
|||||||||||||| ||| ||||||| ||| |||||||||||||||||||| |||||||| || ||||||| ||||||
||| ||| |||| |||||||||| ||| ||||| |||| |||| ||||||||||| ||||||| |||| ||||
|||||||| ||| ||||||| || |||| | ||||||||||. No comparative safety data for
guselkumab were reported in the NMA by McInnes et al. (2022).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a></p>

<p class=MsoNormal><i>Critical Appraisal</i></p>

<p class=MsoNormal>Although the sponsor-submitted ITC was based on a systematic
review, 46 RCTs were excluded from the NMA, and the criteria for selecting
trials or outcomes for analysis were not stated. Heterogeneity in patient and
study characteristics was identified, and it is unclear if the transitivity
assumption has been met. The authors of the NMA attempted to address potential
variability in effect modifiers by using a baseline risk-adjusted model, but it
is unclear if these effect modifiers have the same level of effect on the
active arms. Given that it is unclear to what extent placebo response is an
adequate proxy for specific characteristics or effect modifiers, uncertainty
remains in these analyses. Subgroup analyses based on prior treatment exposure
were conducted to create more homogenous patient populations, but some of these
analyses included data from a limited number of trials, and often showed
substantial uncertainty, with wide CrIs. There were no subgroup or sensitivity
analyses conducted to explore the potential impact of differences in the timing
of outcome assessment, duration of disease, background therapies, or year of
study.</p>

<p class=MsoNormal>ACR and PASI percentage improvements were analyzed using an
ordinal model, which assumed that the relative treatment effects were the same
for each response level. Thus, although data were reported separately for each
response level, the inferences for each comparison are the same across the ACR
20, ACR 50, and ACR 70 levels or PASI levels. It is not clear if this
assumption of the model holds true (i.e., if relative treatment effects are
consistent across response levels), given that data were pooled for different
time points. No sensitivity analyses were run to examine the impacts of this
assumption.</p>

<p class=MsoNormal>In the sponsor-submitted NMA, there was limited ability to
assess the consistency between direct and indirect evidence because there were
few closed loops (i.e., there were only 4 head-to-head studies), and the
statistical tests for inconsistency are generally underpowered. Further, most
of the contributing trials were judged to be at high or unclear risk of bias in
at least 1 domain.</p>

<p class=MsoNormal>Issues with heterogeneity in patient and study
characteristics, lack of ability to assess consistency, and potential bias in
the included RCTs were also identified as limitations for the NMA by McInnes et
al. (2022).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a></p>

<p class=MsoNormal>The indirect evidence was limited to short-term efficacy and
safety; thus, longer-term comparative effects are uncertain.</p>

<p class=MsoNormal><b>Other Relevant Evidence</b></p>

<p class=MsoNormal><i>Description of Studies</i></p>

<p class=MsoNormal>Efficacy and safety data were available for the uncontrolled
extension phase of DISCOVER-1 (52 weeks), DISCOVER-2 (100 weeks), and COSMOS
(48 weeks) trials. Descriptive results for patients who received guselkumab 100
mg every 8 weeks are summarized in this section, including results for patients
from the placebo group in the COSMOS study who crossed over to guselkumab.</p>

<p class=MsoNormal><i>Efficacy Results</i></p>

<p class=MsoNormal>The extension phase data suggest that treatment effects may
be maintained in patients who remain on guselkumab therapy every 8 weeks for 48
weeks to 100 weeks. In DISCOVER-1, 76 patients out of 112 patients (68%), and
in COSMOS, 120 patients out of 172 patients (70%), achieved ACR 20 at week 48
or week 52. In the DISCOVER-2 study, 85 patients out of 234 patients (79%)
achieved ACR 20 at week 52, and 183 patients out of 223 patients (82%) achieved
ACR 20 at week 100. PASI 100 response was reported by 36 patients out of 75
patients (48%) in DISCOVER-1 (week 52), by 94 patients out of 169 patients
(57%) in DISCOVER-2 (100 weeks), and by 80 patients out of 121 patients (66%)
in COSMOS (48 weeks).</p>

<p class=MsoNormal><i>Harms Results</i></p>

<p class=MsoNormal>During the extension period, 31% to 72% of patients reported
1 or more adverse event; 3% to 9% reported a serious adverse event; and 1% to
3% stopped treatment due to adverse events. No deaths were reported. Infections
were reported in 43% of patients in DISCOVER-1 and in 29% and 38% of patients
at week 52 and week 100 of the DISCOVER-2 study. Over the 48-week treatment
period of the COSMOS study, 22% of patients who received guselkumab every 8
weeks experienced an infection.</p>

<p class=MsoNormal><i>Critical Appraisal</i></p>

<p class=MsoNormal>Limitations of the extension study include selection bias
and lack of a control group. Data were available only as descriptive
statistics; and because there were no comparator groups, the interpretation of
the results is limited. The outcomes were based on observed case data, with no
imputation for missing data, and reflect treatment effects in patients who
continue on therapy. As such, the results may overestimate the response in the
broader population, given that patients who drop out are more likely to have
unfavourable outcomes or poor tolerance to therapy.</p>

<p class=MsoNormal><b>Conclusions</b></p>

<p class=MsoNormal>Based on data from 3 double-blind RCTs, adults with active
PsA who received guselkumab 100 mg every 8 weeks were more likely to show
clinically relevant improvements in PsA disease activity and tender and swollen
joint counts than patients who received placebo, based on the proportion who
achieved an ACR 20 response at week 24. Favourable clinical responses in PsA
activity and symptoms were observed among patients who were biologic-naive or
had prior intolerance or inadequate response to TNF alpha inhibitors. This was
also the case for a mixed population that included patients with and without
prior TNF inhibitor exposure.</p>

<p class=MsoNormal>Patients on guselkumab also showed statistically significant
improvements in disability as measured using the HAQ-DI, although the clinical
relevance of the difference versus placebo is uncertain. Improvements in the
physical component (but not the mental component) of the SF-36 were observed
favouring guselkumab versus placebo. Outcomes related to&nbsp;<b>psoriatic</b>&nbsp;skin
lesions demonstrated superiority of guselkumab every 8 weeks versus placebo at
24 weeks. Among patients with enthesitis or dactylitis at baseline, pooled data
from the pivotal trials suggest that patients who receive guselkumab every 8
weeks may be more likely to have enthesitis or dactylitis resolved at 24 weeks
than those receiving placebo. The impact of guselkumab on radiographic
progression is unclear, given that no statistically significant differences
were detected between guselkumab every 8 weeks and placebo for the change in
the modified vdH-S score at 24 weeks among patients with active PsA who were
biologic-naive.</p>

<p class=MsoNormal>No new safety signals were identified in the controlled or
extension phases of the PsA trials. The frequency of infection was similar in
the guselkumab and placebo groups up to 24 weeks.</p>

<p class=MsoNormal>There is no direct evidence comparing guselkumab to other
bDMARDs available in Canada. The indirect evidence for ACR response rates,
change in HAQ-DI scores, change in SF-36 PCS and MCS, and risk of adverse
events or serious adverse events for guselkumab versus most biologic
comparators showed imprecise results; this imprecision limits the ability to
draw conclusions from these data. Based on the indirect evidence, short-term
PASI response rates may favour guselkumab versus some other biologics. However,
there is uncertainty in these findings, given that several sources of
heterogeneity were identified across the trials included in the NMAs and that
it is unclear whether the methods used to control for potential bias were
adequate. In addition, many of the studies included in the NMAs were at an
unclear or a high risk of bias in 1 or more study domains.</p>

<p class=MsoNormal>The direct comparative evidence versus placebo and indirect
evidence versus other biologics was limited to short-term outcomes (i.e., up to
24 weeks). Although results from the extension phase of the trial suggest that
treatment effects may be maintained up to 100 weeks, these data are difficult
to interpret because of the lack of comparator group and bias due to attrition.
Thus, the longer-term comparative efficacy and safety of guselkumab in patients
with PsA is unclear.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Introduction</b></p>

<p class=MsoNormal><b>Disease Background</b></p>

<p class=MsoNormal>PsA is an inflammatory musculoskeletal disease with a
heterogenous presentation and disease course. While it is associated with
psoriasis, PsA also presents with variable clinical features involving multiple
domains, including peripheral arthritis, enthesitis (tenderness and swelling at
the insertion of tendons and ligaments into bone), dactylitis (swelling of the
whole digit), and axial disease (inflammation of the joints of the back).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>1</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>2</sup></a>&nbsp;Extra-articular
manifestations include inflammation of the eye and inflammatory bowel disease.
Diagnosis of PsA can be a challenge, given that there is no gold standard
diagnostic test; it is typically diagnosed based on clinical findings and imaging
features that evaluate specific patterns of joint inflammation or involvement
of the different domains. Patients with PsA also present with&nbsp;<b>psoriatic</b>&nbsp;skin
lesions and are usually seronegative for rheumatoid factor (95%).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>2</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>16</sup></a>&nbsp;Pain
and stiffness of the affected joints are the most predominant presenting
symptoms, with fatigue also occurring in many patients.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>1</sup></a>&nbsp;Patients
with psoriasis and PsA are at risk for the development of comorbidities,
including cardiovascular disease, diabetes, gout, metabolic syndrome, and
depression.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>1</sup></a></p>

<p class=MsoNormal>The prevalence of PsA varies, depending on the case
definition and geography, and is estimated to be 1 to 2 cases per 1,000 in the
general population.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>1</sup></a>&nbsp;A
population-based Canadian study estimated the age- and sex-standardized
cumulative prevalence of PsA in Ontario to range from 0.09% in 2008 to 0.15% in
2015. The same study estimated the age- and sex-standardized incidence in 2015
to be 14 per 100,000.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>3</sup></a></p>

<p class=MsoNormal>About 30% of patients with psoriasis develop PsA; skin
disease usually precedes manifestations of PsA by several years (10 years on
average); however, in some individuals, both can occur simultaneously, or PsA
may occur before the onset of psoriasis.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>2</sup></a>&nbsp;A
Canadian prospective cohort study estimated the annual incidence of PsA to be
2.7 cases per 100 psoriasis patients.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>17</sup></a>&nbsp;Over
time, PsA can lead to deformities and joint damage.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>2</sup></a>&nbsp;This
can lead to significant functional impairment, which in turn can affect work
productivity and reduce health-related quality of life (HRQoL).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>2</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>16</sup></a></p>

<p class=MsoNormal><b>Standards of Therapy</b></p>

<p class=MsoNormal>Treatment goals for patients with PsA include: achieving the
lowest possible level of disease activity in all domains of disease; optimizing
functional status; improving quality of life and well&#8208;being; preventing
structural damage to the greatest extent possible; and avoiding or minimizing
complications, both from untreated active disease and from therapy. This
disease affects more than just patients’ joints; therefore, treatment is
individualized based on various factors, including disease activity, structural
damage, comorbid conditions, and previous therapies.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>18</sup></a>&nbsp;Recent
recommendations by the Group for Research and Assessment of Psoriasis and&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
(GRAPPA) have suggested the use of a domain-based approach (peripheral
arthritic, axial disease, enthesitis, dactylitis, psoriasis, nail disease,
inflammatory bowel disease, and uveitis) that considers patient preference and
previous and/or concomitant therapies; the choice of therapy should address as
many domains as possible (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig01/?report=objectonly"
target=object>Figure 1</a>).</p>

<p class=MsoNormal>Several drug classes are employed in the pharmacologic
treatment of PsA, including NSAIDs, cDMARDs (i.e., methotrexate, sulfasalazine,
or leflunomide), bDMARDs (i.e., TNF inhibitors, IL-23 inhibitors, IL-12/23
inhibitors, and IL-17 inhibitors), and targeted synthetic DMARDs (e.g.,
apremilast, upadacitinib, or tofacitinib). Key characteristics of select drugs
used in the treatment of PsA that are relevant to this review are summarized
in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t04/?report=objectonly"
target=object>Table 4</a>.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig01/?report=objectonly"
title="&quot;Figure 1&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=39 id="Picture 112"
src="psoriasis%20test_files/image003.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig01/?report=objectonly"
target=object>Figure 1</a></b></p>

<p class=MsoNormal>GRAPPA Treatment Schema — Redacted.</p>

<p class=MsoNormal><b>Drug</b></p>

<p class=MsoNormal>Guselkumab is human immunoglobulin G1 lambda monoclonal
antibody that binds to the IL-23 protein and inhibits its binding with cell
surface IL-23 receptor.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a>&nbsp;IL-23
is a cytokine that is involved in normal inflammatory and immune response.
Guselkumab is approved for the treatment of adult patients with active PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a>&nbsp;It
may be used alone or in combination with a cDMARD (e.g., methotrexate).
Guselkumab is available as a 100 mg/mL solution for SC injection in either 1 mL
pre-filled syringes or patient-controlled injector devices. The recommended
dose is 100 mg SC at week 0, week 4, and every 8 weeks thereafter.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a></p>

<p class=MsoNormal>Guselkumab underwent a standard Health Canada review and was
approved by for PsA in September 2020. The sponsor has requested reimbursement
as per the Health Canada indication.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>20</sup></a></p>

<p class=MsoNormal>Guselkumab is also approved for the treatment of adult
patients with moderate to severe plaque psoriasis who are candidates for
systemic therapy or phototherapy.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a>&nbsp;In
2018, the CADTH Canadian Drug Expert Committee (CDEC) recommended that
guselkumab be reimbursed for adults with plaque psoriasis if the following
clinical criteria and conditions were met:</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>Reimburse in a manner similar to other biologics for the
     treatment of moderate to severe plaque psoriasis.</li>
 <li class=MsoNormal>Treatment should be discontinued if a response has not
     been demonstrated after 16 weeks.</li>
 <li class=MsoNormal>The drug plan cost for guselkumab should not exceed the
     drug plan cost of treatment with the least costly biologic reimbursed for
     moderate to severe plaque psoriasis.<a
     href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>21</sup></a></li>
</ul>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t04/?report=objectonly"
title="&quot;Table 4&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 111"
src="psoriasis%20test_files/image004.png"
alt="Table 4. Key Characteristics of Select Drugs Used in the Treatment of PsA."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t04/?report=objectonly"
target=object>Table 4</a></b></p>

<p class=MsoNormal>Key Characteristics of Select Drugs Used in the Treatment of
PsA.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Stakeholder Perspectives</b></p>

<p class=MsoNormal><b>Patient Group Input</b></p>

<p class=MsoNormal>This section was prepared by CADTH staff based on the input
provided by patient groups. The full original patient inputs received by CADTH
are included in the stakeholder section at the end of this report.</p>

<p class=MsoNormal>Three inputs were submitted for this review from 6 different
patient groups: Arthritis Consumer Experts, CAPP in partnership with CPN, and
CAPA in partnership with the Arthritis Society and CreakyJoints.</p>

<p class=MsoNormal>Arthritis Consumer Experts is Canada’s largest,
longest-running national arthritis patient organization. It is headquartered in
Vancouver, British Columbia, with 50,000 members from coast to coast. It
provides free, science-based information and education programs to people with
arthritis and those who care for and support them.</p>

<p class=MsoNormal>CAPP is a national, not-for-profit organization formed to
better serve the needs of psoriasis patients across the country. Its mission is
to be a resource and advocate for&nbsp;<b>psoriatic</b>&nbsp;patients and their
families to improve patient care and quality of life.</p>

<p class=MsoNormal>CPN is a national, not-for-profit organization dedicated to
improving the quality of life of people in Canada who live with psoriasis and
PsA. It does this by providing current information on research and treatment
options and by working with others to build awareness and advocacy about the
complexities of these conditions.</p>

<p class=MsoNormal>CAPA is a grassroots, patient-driven and managed,
independent, national education and advocacy organization with members and
supporters across Canada. It creates links between people in Canada with
arthritis, assists them to become more effective advocates, and seeks to
improve the quality of life of all people living with the disease.</p>

<p class=MsoNormal>The Arthritis Society is dedicated to a vision of a world
where people are free from the devastating effects of arthritis. It is Canada’s
principal health charity, providing education, programs, and support to the
more than 6 million people in Canada living with arthritis.</p>

<p class=MsoNormal>CreakyJoints Canada has served for more than 2 decades as a
digital community for millions of arthritis patients and caregivers worldwide
who seek education, support, advocacy, and patient-centred research. All of its
programming and services are provided free of charge. CreakyJoints is part of
the non-profit Global Healthy Living Foundation, whose mission is to improve
the quality of life for people living with chronic illnesses.</p>

<p class=MsoNormal>Five patient organizations (CAPP, CPN, CAPA, the Arthritis
Society, and CreakyJoints Canada) collaborated by collectively developing
survey questions using SurveyMonkey for the inputs submitted. Each organization
shared the surveys with its respective memberships or patient communities
through email, social media, and organization websites. CAPA, CreakyJoints
Canada, and the Arthritis Society submitted 1 collaborative patients’ input;
the CAPP and CPN analyzed data and prepared 1 submission collectively, while
the Arthritis Consumer Experts made its own submission based on survey response
data and its unique community perspectives. Survey data were collected from
April 20, 2022 to May 16, 2022. In addition, Arthritis Consumer Experts
gathered information from 1 respondent through email on May 4, 2022 and from 5
respondents through an online survey from December 18, 2020 to January 26,
2021.</p>

<p class=MsoNormal>There were 71 respondents to the joint survey: 12
respondents were from British Columbia (17%), 7 were from Alberta (10%), 3 were
from Manitoba (4%), 34 were from Ontario (49%), 4 were from Quebec (6%), 4 were
from New Brunswick (6%), 4 were from Nova Scotia (6%), and 3 were from
Newfoundland and Labrador (4%). Two survey participants had experience taking
guselkumab.</p>

<p class=MsoNormal>Respondents reported a range of symptoms that were difficult
to manage, including joint stiffness (79%), fatigue (75%), changes in
fingernails and toes (63%), hip pain (61%), back pain (51%), anxiety (47%), and
stress (33%). With regards to the most significant impacts of PsA on their
daily quality of life, respondents reported that PsA interfered with their work
(54%), social connections (52%), self-esteem (50%), mental health (50%),
intimacy (50%), family life (38%), and friendships (24%). Other impacts included
embarrassment and self-consciousness from symptoms caused by PsA. Because the
disease would reduce their mobility and ability to participate in activities
and affect their mental and social health, respondents indicated that
caregivers had to take on additional tasks or chores, such as cooking,
cleaning, shopping, and helping patients get to and from medical appointments.</p>

<p class=MsoNormal>Survey respondents indicated that they had experience with
several treatment approaches, including NSAIDs, corticosteroids, cDMARDs (such
as methotrexate), and bDMARDs. Among responders, 32% considered biologics to be
highly effective, followed by oral steroids (23%) and other DMARDs (21%).
Respondents expressed their ongoing unmet need to manage symptoms and side
effects with current treatments.</p>

<p class=MsoNormal>Two respondents who had experience with guselkumab indicated
that the drug was effective in terms of improving psoriasis and arthritis and
slowing disease progression. Both stated that they did not experience side
effects.</p>

<p class=MsoNormal>Respondents expected new treatments to improve the following
key outcomes: management of symptoms (i.e., reducing pain and fatigue,
increasing mobility); tolerability of side effects; ease of drug
administration; improved ability to work and carry out tasks and daily
activities; and quality of life.</p>

<p class=MsoNormal><b>Clinician Input</b></p>

<p class=MsoNormal><b>Input From the Clinical Expert Consulted by CADTH</b></p>

<p class=MsoNormal>All CADTH review teams include at least 1 clinical
specialist with expertise regarding the diagnosis and management of the
condition for which the drug is indicated. Clinical experts are a critical part
of the review team and are involved in all phases of the review process (e.g.,
providing guidance on the development of the review protocol; assisting in the
critical appraisal of clinical evidence; interpreting the clinical relevance of
the results; and providing guidance on the potential place in therapy). The
following input was provided by 1 clinical specialist with expertise in the
diagnosis and management of PsA.</p>

<p class=MsoNormal><i>Unmet Needs</i></p>

<p class=MsoNormal>The goals of therapy are to control the symptoms of PsA
(i.e., pain stiffness, swelling, fatigue), reduce impacts on patients’ quality
of life and function, and prevent the progression of joint damage. A
substantial proportion of patients do not achieve a minimal response with their
first therapy or lose their response over time. In addition, some treatments
have more adverse effects than others. Thus, there is a need for medications
with new mechanisms of action or a different safety profile to offer alternate
treatment options. There also needs to be a choice for patients in terms of
preference with regards to the frequency of injections, injection versus
infusion, and oral administration versus injection.</p>

<p class=MsoNormal><i>Place in Therapy</i></p>

<p class=MsoNormal>According to the clinical expert, guselkumab may be used as
first- or second-line biologic therapy. It may be a preferred first-line
treatment for patients with moderate psoriasis in addition to musculoskeletal
disease. Guselkumab may be used in combination with methotrexate or
leflunomide. There is no evidence to support its use in combination with other
biologics. The expert stated that it would not be appropriate to recommend that
patients try other biologics before receiving guselkumab.</p>

<p class=MsoNormal><i>Patient Population</i></p>

<p class=MsoNormal>There are currently no biomarkers that may be used to
identify the patients who will be most suited for a particular drug. Clinicians
make these decisions based on patient history, physical examination, imaging,
and discussion.</p>

<p class=MsoNormal>There is currently no diagnostic test for PsA.
Rheumatologists can usually diagnose PsA after evaluating the patient and may
seek confirmation of the psoriasis diagnosis from a dermatologist. The expert
stated that 30% to 80% of psoriasis patients had a missed PsA diagnosis.</p>

<p class=MsoNormal><i>Assessing Response to Treatment</i></p>

<p class=MsoNormal>Response to therapy is based on a reduction in the number of
inflamed joints, improvement in the skin, and patient-reported outcomes.
According to the clinical expert, a major improvement would be considered an
improvement of at least 50%, but may also include achievement of MDA and
remission as measured by specific instruments. Assessment of response requires
the physician to perform a physical examination, including a joint count and
skin evaluation, and also includes patient-reported outcomes (i.e., assessment
of pain, function, fatigue). Less frequently, structural damage may be assessed
using X-rays.</p>

<p class=MsoNormal>An initial response may be expected within 3 months, with
more significant improvement by 6 months after initiating therapy. The expert
indicated that if a patient shows no change within 3 months to 6 months, they
would be considered a nonresponder and may be switched to another medication.</p>

<p class=MsoNormal><i>Discontinuing Treatment</i></p>

<p class=MsoNormal>Patients may be switched to another medication if no
improvement is observed within 3 months to 6 months or if the patient
experiences intolerable or serious adverse effects. If a patient has responded
in some but not all manifestations, another medication may be added to address
the area that has not responded.</p>

<p class=MsoNormal><i>Prescribing Conditions</i></p>

<p class=MsoNormal>Ideally, guselkumab would be prescribed by specialists who
are familiar with the drug and its uses, or at least in consultation with a
dermatologist or rheumatologist. The administration of guselkumab may take
place in any setting, including self-administration by the patient in their
home.</p>

<p class=MsoNormal><b>Clinician Group Input</b></p>

<p class=MsoNormal>This section was prepared by CADTH staff based on the input
provided by clinician groups. The full original clinician group input(s)
received by CADTH have been included in the stakeholder section at the end of
this report.</p>

<p class=MsoNormal>CADTH received 1 submission from Canadian
Rheumatologist&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Interest Group, based on
responses from 6 clinicians practising in academic and community settings. The
Canadian Rheumatologist&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Interest Group
consists of a group of clinical rheumatologists across Canada who have
extensive experience managing inflammatory arthritis, including PsA. No major
views contrary to those provided by the clinical experts consulted by CADTH for
this review were presented.</p>

<p class=MsoNormal>The clinician group stated that PsA is a complex disease
with varied manifestations. The current treatment options include
nonpharmacological treatments and pharmaceutical interventions, such as cDMARDs
and biologic therapies (i.e., TNF alpha inhibitors and IL-17A inhibitors) as
first-line therapies and IL-12/23 inhibitors and JAK inhibitors as second-line
therapies. The clinician group highlighted that not all patients achieve a good
response (defined as ACR 20 or MDA) to current treatments. In addition, the
adverse effects of TNF inhibitors (lupus-like syndromes or multiple sclerosis)
and IL-17A (inflammatory bowel disease) limit the use of the 2 most common
classes of biologics used to manage PsA. Moreover, biologic therapies are
associated with increased risk of serious infections. Thus, the clinician group
identified significant unmet need in the management of PsA.</p>

<p class=MsoNormal>According to the clinician group, the goals of treatment are
to improve quality of life and physical function by controlling symptoms (i.e.,
joint pain and stiffness, concomitant psoriasis, and extra-articular
manifestations) and to limit structural damage and minimize long-term
complications arising from inadequately controlled inflammation related to PsA.
The clinician group expressed that guselkumab may be used alone or in
combination with cDMARDs as a first-line biologic therapy or as a second-line treatment
after failure to respond to a TNF inhibitor. The clinician group stated that
rheumatologists can identify patients who are suitable for treatment with
guselkumab based on inflammatory arthritis in the presence of psoriasis; the
clinicians did not identify any potential challenges associated with the
diagnosis.</p>

<p class=MsoNormal>According to the clinician group, patients with early
disease and moderate to severe skin and joint involvement are most likely to
respond to guselkumab. Those who are refractory to current therapeutic drugs or
unable to take current classes of biologic drugs have the greatest need for an
intervention such as guselkumab. The clinicians noted that improvement in
tender and swollen joint counts, psoriasis, enthesitis, patient global
impression, and ACR 20 are commonly used to determine whether a patient is responding
to guselkumab. They also noted that composite measures — including MDA, Disease
Activity Index for PsA, and PsA Disease Activity Score — would be considered as
well. With regards to discontinuation, the clinician group noted several
factors that would be considered when deciding to stop guselkumab treatment,
such as inflammatory pain and stiffness, swollen or tender joint count,
worsening psoriasis, poor function, intolerability due to adverse effects, or
the development of severe extra-articular manifestations. The clinician group
indicated that rheumatologists or experienced nurse practitioners with
extensive rheumatology experience are required to diagnose and manage PsA. In
addition, the clinician group mentioned that guselkumab has shown effectiveness
in the treatment of joints in both biologic naive patients and patients with an
inadequate response to TNF, and has been shown to improve pain and fatigue in
clinical trials.</p>

<p class=MsoNormal><b>Drug Program Input</b></p>

<p class=MsoNormal>The drug programs provide input on each drug being reviewed
through CADTH’s reimbursement review processes by identifying issues that may
affect their ability to implement a recommendation. The implementation
questions and corresponding responses from the clinical experts consulted by
CADTH are summarized in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t05/?report=objectonly"
target=object>Table 5</a>.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t05/?report=objectonly"
title="&quot;Table 5&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 110"
src="psoriasis%20test_files/image005.png"
alt="Table 5. Summary of Drug Plan Input and Clinical Expert Response."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t05/?report=objectonly"
target=object>Table 5</a></b></p>

<p class=MsoNormal>Summary of Drug Plan Input and Clinical Expert Response.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Clinical Evidence</b></p>

<p class=MsoNormal>The clinical evidence included in the review of guselkumab
is presented in 3 sections. The first section, the Systematic Review, includes
pivotal studies provided in the sponsor’s submission to CADTH and Health
Canada, as well as those studies that were selected according to an a priori
protocol. The second section includes indirect evidence from the sponsor and
indirect evidence selected from the literature that met the selection criteria
specified in the review. The third section includes sponsor-submitted long-term
extension studies and additional relevant studies that were considered to
address important gaps in the evidence included in the systematic review.</p>

<p class=MsoNormal><b>Systematic Review (Pivotal and Protocol Selected Studies)</b></p>

<p class=MsoNormal><b>Objectives</b></p>

<p class=MsoNormal>To perform a systematic review of the beneficial and harmful
effects of guselkumab 100 mg/mL administered through a 1 mL pre-filled syringe
or patient-controlled injector for SC injection for the treatment of active PsA
in adults.</p>

<p class=MsoNormal><b>Methods</b></p>

<p class=MsoNormal>Studies selected for inclusion in the systematic review
included pivotal studies provided in the sponsor’s submission to CADTH and
Health Canada as well as those meeting the selection criteria presented
in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t06/?report=objectonly"
target=object>Table 6</a>. Outcomes included in the CADTH review protocol
reflect outcomes considered to be important to patients, clinicians, and drug
plans.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t06/?report=objectonly"
title="&quot;Table 6&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 109"
src="psoriasis%20test_files/image006.png"
alt="Table 6. Inclusion Criteria for the Systematic Review."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t06/?report=objectonly"
target=object>Table 6</a></b></p>

<p class=MsoNormal>Inclusion Criteria for the Systematic Review.</p>

<p class=MsoNormal>The literature search for clinical studies was performed by
an information specialist using a peer-reviewed search strategy according to
the&nbsp;<a href="https://www.cadth.ca/resources/finding-evidence/press"><i>PRESS
Peer Review of Electronic Search Strategies</i>&nbsp;checklist</a>.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>35</sup></a></p>

<p class=MsoNormal>Published literature was identified by searching the
following bibliographic databases: MEDLINE All (1946—) through Ovid and Embase
(1974—) through Ovid. All Ovid searches were run simultaneously as a multi-file
search. Duplicates were removed using Ovid deduplication for multi-file
searches, followed by manual deduplication in Endnote. The search strategy
comprised both controlled vocabulary, such as the National Library of
Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concept
was Tremfya (guselkumab). Clinical trial registries were searched: the US
National Institutes of Health’s clinicaltrials.gov, WHO’s International
Clinical Trials Registry Platform search portal, Health Canada’s Clinical
Trials Database, and the European Union Clinical Trials Register.</p>

<p class=MsoNormal>No filters were applied to limit retrieval by study type.
Retrieval was not limited by publication date or by language. Conference
abstracts were excluded from the search results. Refer to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a1">Appendix
1</a>&nbsp;for the detailed search strategies.</p>

<p class=MsoNormal>The initial search was completed on May 31, 2022. Regular
alerts updated the search until the meeting of the CADTH CDEC on September 28,
2022.</p>

<p class=MsoNormal>Grey literature (literature that is not commercially
published) was identified by searching relevant websites from the CADTH&nbsp;<a
href="https://www.cadth.ca/grey-matters"><i>Grey Matters: A Practical Tool For
Searching Health-Related Grey Literature</i>&nbsp;checklist</a>.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>36</sup></a>&nbsp;Included
in this search were the websites of regulatory agencies (FDA and the European
Medicines Agency). Google was used to search for additional internet-based
materials. Refer to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a1">Appendix
1</a>&nbsp;for more information on the grey literature search strategy.</p>

<p class=MsoNormal>In addition to the literature search, the manufacturer of
the drug was contacted for information regarding unpublished studies.</p>

<p class=MsoNormal>Two CADTH clinical reviewers independently selected studies
for inclusion in the review based on titles and abstracts, according to the
predetermined protocol. Full-text articles of all citations considered
potentially relevant by at least 1 reviewer were acquired. Reviewers
independently made the final selection of studies to be included in the review,
and differences were resolved through discussion.</p>

<p class=MsoNormal><b>Findings From the Literature</b></p>

<p class=MsoNormal>A total of 3 studies were identified from the literature for
inclusion in the systematic review (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig02/?report=objectonly"
target=object>Figure 2</a>). The included studies are summarized in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t07/?report=objectonly"
target=object>Table 7</a>. A list of excluded studies is presented in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a2">Appendix
2</a>.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig02/?report=objectonly"
title="&quot;Figure 2&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=100 height=114 id="Picture 108"
src="psoriasis%20test_files/image007.gif"
alt="Of the 510 citations identified in the database search, 497 were excluded. Thirteen electronic literature and 8 grey literature potentially relevant full-text reports were retrieved for scrutiny. In total, 9 reports are included in the review."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig02/?report=objectonly"
target=object>Figure 2</a></b></p>

<p class=MsoNormal>Flow Diagram for Inclusion and Exclusion of Studies.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t07/?report=objectonly"
title="&quot;Table 7&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 107"
src="psoriasis%20test_files/image008.png"
alt="Table 7. Details of Included Studies."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t07/?report=objectonly"
target=object>Table 7</a></b></p>

<p class=MsoNormal>Details of Included Studies.</p>

<p class=MsoNormal><b>Description of Studies</b></p>

<p class=MsoNormal>Three double-blind, randomized, placebo-controlled trials
met the inclusion criteria for the systematic review.</p>

<p class=MsoNormal>The objective of the DISCOVER-1 study was to evaluate the
efficacy of guselkumab in patients with active PsA who had inadequate response
to standard therapies (e.g., non-biologic DMARDs, apremilast, and/or NSAIDs).
Up to 30% of patients enrolled had received prior treatment with 1 or 2 TNF
alpha inhibitors. Patients were randomized (1:1:1) to guselkumab 100 mg SC
every 4 weeks for 48 weeks; guselkumab 100 mg SC at week 0, week 4, and every 8
weeks thereafter (with placebo injections at other time points); or placebo
every 4 weeks until week 20, crossing over to guselkumab 100 mg SC at week 24
and then every 4 weeks thereafter until week 48 (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig03/?report=objectonly"
target=object>Figure 3</a>). Patients were randomized centrally through an
interactive web response system using permuted block randomization, stratified
by non-biologic DMARD use at baseline (yes, no) and by prior exposure to TNF
alpha inhibitors (yes, no) (N&nbsp;= 381). The trial was conducted at a total
of 6 sites in Asia, Europe, the US, and Canada.</p>

<p class=MsoNormal>The objective of the DISCOVER-2 study was to evaluate the
efficacy of guselkumab in patients with active PsA who were biologic-naive and
had an inadequate response to standard therapies (e.g., non-biologic DMARDs,
apremilast, and/or NSAIDs). Patients were randomized (1:1:1) to guselkumab 100
mg SC every 4 weeks for 100 weeks; guselkumab 100 mg SC at week 0, week 4, and
every 8 weeks thereafter (with placebo injections at other time points); or
placebo every 4 weeks until week 20, crossing over at week 24 to guselkumab 100
mg SC every 4 weeks to week 100 (similar to the design shown in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig03/?report=objectonly"
target=object>Figure 3</a>). Permuted block randomization was used in the
trial, with randomization stratified by non-biologic DMARD use at baseline
(yes, no) and most recent CRP value (&lt;&nbsp;2.0 mg/dL versus
&#8805;&nbsp;2.0 mg/dL) (N&nbsp;= 741). The trial was conducted in Europe,
Asia, and the US.</p>

<p class=MsoNormal>The objective of the COSMOS study was to evaluate the
efficacy of guselkumab in patients with active PsA who had an inadequate
response or intolerance to 1 or 2 prior TNF alpha inhibitors. Patients were
randomized (1:1) to guselkumab 100 mg SC at week 0, week 4, and every 8 weeks
thereafter (with placebo injections at other time points) or to placebo until
week 20 before crossing over to guselkumab 100 mg SC at weeks 24, 28, 36, and
44 (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig04/?report=objectonly"
target=object>Figure 4</a>). Patients were randomized through an interactive
web response system (N&nbsp;= 285). Central permuted block randomization was
used, with randomization stratified by non-biologic DMARD use at baseline (yes,
no) and number of prior TNF alpha inhibitors (1 or 2). The trial was conducted
in Europe and Israel.</p>

<p class=MsoNormal>Data for the placebo-controlled portion of the 3 studies
(i.e., first 24 weeks) have been summarized as part of the systematic review,
including data from the interim database lock on March 2019 for the DISCOVER-1
and DISCOVER-2 studies and August 2020 for the COSMOS study. The study results
after placebo patients crossed over to guselkumab have been summarized in the
Other Relevant Evidence section, given that these uncontrolled follow-up
periods did not meet the study design criteria for the systematic review.</p>

<p class=MsoNormal>Data from the groups receiving guselkumab every 4 weeks in
the DISCOVER-1 and DISCOVER-2 studies have not been summarized in this report
because this dose is not consistent with the Health Canada–recommended dose and
dose adjustment.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>5</sup></a></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig03/?report=objectonly"
title="&quot;Figure 3&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=106 height=80 id="Picture 106"
src="psoriasis%20test_files/image009.gif"
alt="Patients were randomized to 3 treatment groups (guselkumab every 4 weeks, guselkumab every 8 weeks, or placebo), with the last dosing visit at 48 weeks. Patients were assessed for escape therapy at week 16."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig03/?report=objectonly"
target=object>Figure 3</a></b></p>

<p class=MsoNormal>DISCOVER-1 Study Schematic.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig04/?report=objectonly"
title="&quot;Figure 4&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=39 id="Picture 105"
src="psoriasis%20test_files/image003.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig04/?report=objectonly"
target=object>Figure 4</a></b></p>

<p class=MsoNormal>COSMOS Study Schematic — Redacted.</p>

<p class=MsoNormal><b>Populations</b></p>

<p class=MsoNormal><i>Inclusion and Exclusion Criteria</i></p>

<p class=MsoNormal>All 3 included studies enrolled adults greater than or equal
to 18 years of age with active PsA diagnosed at least 6 months prior who met
the Classification Criteria for&nbsp;<b>Psoriatic</b>&nbsp;Arthritis (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t07/?report=objectonly"
target=object>Table 7</a>). In the DISCOVER-1 and COSMOS studies, patients were
required to have least 3 tender and swollen joints — and in DISCOVER-2, at
least 5 tender and swollen joints — to qualify. Key inclusion criteria
differences were as follows:</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>In the DISCOVER studies, patients had to have documented
     evidence of inadequate response or intolerance to standard PsA therapies,
     including non-biologic DMARDs (&#8805;&nbsp;3 months), apremilast
     (&#8805;&nbsp;4 months), and/or NSAID therapy (&#8805;&nbsp;4 weeks). In
     DISCOVER-1, up to 30% of patients enrolled in had previously received 1 or
     2 TNF alpha inhibitors. DISCOVER-2 enrolled patients with no prior
     exposure to bDMARDs.</li>
 <li class=MsoNormal>COSMOS enrolled patients with an inadequate response or
     intolerance to 1 or 2 TNF alpha inhibitors.</li>
</ul>

<p class=MsoNormal>In all trials, the patients enrolled were required to have
at least 1 PsA subset: distal interphalangeal joint involvement, polyarticular
arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric
peripheral arthritis, or spondylitis with peripheral arthritis. Patients were
also required to have active plaque psoriasis with 1 or more lesions at least 2
cm in diameter, nail changes of psoriasis, or documented history of plaque
psoriasis.</p>

<p class=MsoNormal>Key exclusion criteria were the presence of other
inflammatory diseases, a nonplaque form of psoriasis or drug-induced psoriasis,
significant risk of suicide, recent serious infection, or herpes zoster,
tuberculosis, HIV, hepatitis B, or hepatitis C. Those with prior treatment with
JAK inhibitors or recent exposure to a prohibited medication without an
adequate washout period were also excluded.</p>

<p class=MsoNormal><i>Baseline Characteristics</i></p>

<p class=MsoNormal>The demographics of patients were generally similar within
and across trials (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t08/?report=objectonly"
target=object>Table 8</a>). The mean age of patients enrolled ranged from 44.9
years (SD&nbsp;= 11.9 years) to 49.1 years (SD&nbsp;= 12.3 years) across
treatment groups. The proportion of female patients ranged from 46% to 55%, and
most patients were White (89% to 98% in the DISCOVER studies; not reported for
the COSMOS study). The mean number of swollen joints ranged from 9.0 (SD&nbsp;=
5.7) to 12.3 (SD&nbsp;= 6.9), and the mean number of tender joints ranged from
18.2 (SD&nbsp;= 10.7) to 21.6 (SD&nbsp;= 13.1). Approximately 2-thirds of
patients had&nbsp;<b>psoriatic</b>&nbsp;involvement affecting at least 3% of
their BSA. Two-thirds of patients reported enthesitis, while approximately 40%
had dactylitis at baseline. Some potential imbalances were noted in the COSMOS
study in the proportion of female patients (55% versus 46%) and psoriasis at
baseline (70% versus 55%), and in the DISCOVER-2 study in the proportion with
enthesitis at baseline (64% versus 73%) in the groups receiving guselkumab
every 8 weeks versus placebo, respectively.</p>

<p class=MsoNormal>Across the studies, 89% to 95% of patients per treatment
group had received a prior non-biologic DMARD, of which methotrexate was the
most commonly received drug (80% to 92%). Prior use of any immunosuppressive or
apremilast was less common, and was reported by 2% to 6% of patients. In the
DISCOVER-1 and DISCOVER-2 studies, 39% to 48% of patients had previously
received systemic corticosteroids, while 87% to 92% had received NSAIDs (data
not reported for COSMOS).</p>

<p class=MsoNormal>In the DISCOVER-1 study, 41 patients (32%) and 39 patients
(31%) in the guselkumab and placebo groups, respectively, had received prior
TNF alpha inhibitors, including 7 and 4 patients, respectively, who had
received 2 prior drugs from this class. The reasons for stopping TNF alpha
inhibitor therapy in the guselkumab and placebo groups, respectively, were
financial (42% and 41%), inadequate response (37% and 31%), adverse events (2%
and 8%), contraindications (5% and 3%), or unspecified (22% and 23%). In the
COSMOS studies, all patients had received TNF alpha inhibitors. Among them, 88%
had received 1 prior drug and 12% had received 2 prior TNF inhibitors. As per
the inclusion criteria, no patients in DISCOVER-2 had prior exposure to TNF
inhibitors.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t08/?report=objectonly"
title="&quot;Table 8&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 104"
src="psoriasis%20test_files/image010.png"
alt="Table 8. Summary of Baseline Characteristics."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t08/?report=objectonly"
target=object>Table 8</a></b></p>

<p class=MsoNormal>Summary of Baseline Characteristics.</p>

<p class=MsoNormal><b>Interventions</b></p>

<p class=MsoNormal>In all trials, the study drug was supplied as 1 mL
pre-filled syringes that contained either placebo solution or guselkumab 100
mg. In the DISCOVER-1 and DISCOVER-2 trials, the study drugs were described as
identical in appearance and packaging. Patients and site investigators remained
blinded to treatment allocation until the ends of the studies (i.e., 60 weeks
for DISCOVER-1, 112 weeks for DISCOVER-2, and 56 weeks for COSMOS). An interim
database lock was planned for 24 weeks in all studies, and the sponsor’s
personnel were unblinded to patient-level data at that time to conduct the
primary data analysis. In the trials, the study drug was administered by health
care workers at week 0 and week 4, but patients had the option to
self-administer at later visits under the supervision of a health care
professional at the study site.</p>

<p class=MsoNormal>In DISCOVER-1 and DISCOVER-2, patients were randomized
(1:1:1) to guselkumab 100 mg SC every 4 weeks; guselkumab 100 mg SC at week 0,
week 4, and every 8 weeks thereafter (with placebo injections at other time
points); or placebo every 4 weeks until week 20, crossing over at week 24 to
guselkumab 100 mg SC and continuing every 4 weeks until the end of the study.
The double-blind treatment durations were 48 weeks for DISCOVER-1 and 100 weeks
for DISCOVER-2. At week 16, patients were assessed to determine if they met the
early escape criteria. Patients with less than 5% improvement from baseline in
tender and swollen joint counts were considered to have met the early escape
criteria and were allowed to start therapy or increase the dose of 1 of the
permitted concomitant&nbsp;<b>psoriatic</b>&nbsp;medications (up to the daily
maximum dose outlined in the study’s protocol). Titration to a stable dose was
to be completed by week 24.</p>

<p class=MsoNormal>In the DISCOVER-1 and DISCOVER-2 studies, stable use of
NSAIDs or other analgesics, oral corticosteroids (&#8804;&nbsp;10 mg of
prednisone per day or equivalent), and 1 of either methotrexate
[&#8804;&nbsp;25 mg/week], sulfasalazine [&#8804;&nbsp;3 g/day],
hydroxychloroquine [&#8804;&nbsp;400 mg/day], or leflunomide [&#8804;&nbsp;20
mg/day]) was allowed during the trial. A washout period was required for
patients who had recently stopped treatment with 1 of these medications (2
weeks for NSAIDs or corticosteroids, 12 weeks for leflunomide, and 4 weeks for
the other 3 DMARDs). Other psoriasis or PsA treatments had to be stopped 2
weeks to 4 weeks before the start of the study drug. Medications prohibited
during the trial included other biologic or non-biologic DMARDs, systemic
immunosuppressants, apremilast, JAK inhibitors, and cytotoxic drugs. Injectable
systemic corticosteroids or topical psoriasis treatments (except salicylic acid
or coal tar shampoo) were prohibited until after week 24. Low- and mid-potency
topical or intralesional corticosteroids were allowed after week 24. In
DISCOVER-2, high-potency topical corticosteroids, phototherapy, and systemic
treatments for psoriasis were prohibited until week 24, whereas DISCOVER-1
prohibited these therapies for the entire study duration. In both trials,
patients were allowed to have up to 2 intra-articular, tendon sheath, or bursal
corticosteroid injections in no more than 2 sites within any 24-week period of
the study.</p>

<p class=MsoNormal>In the COSMOS study, patients were randomized 2:1 to
guselkumab 100 mg SC at week 0, week 4, and every 8 weeks thereafter (with
placebo injections at other time points), or to placebo at week 0, week 4, week
12, and week 20 before crossing over to guselkumab 100 mg SC at week 24 and
continuing with it at week 28, week 36, and week 44. The double-blind treatment
duration was 48 weeks.</p>

<p class=MsoNormal>The same early escape criteria used in the DISCOVER trials
were applied in the COSMOS study. Patients who met the early escape criteria
could initiate or increase the dose of permitted concomitant medications, as
described previously. In addition, patients randomized to placebo who met the
escape criteria received guselkumab 100 mg SC at week 16, week 20, and every 8
weeks thereafter.</p>

<p class=MsoNormal>Stable doses of NSAIDs, oral corticosteroids, and select
cDMARDs (i.e., 1 of methotrexate [&#8804;&nbsp;25 mg/week], sulfasalazine
[&#8804;&nbsp;3 g/day], hydroxychloroquine [&#8804;&nbsp;400 mg/day], or
leflunomide [&#8804;&nbsp;20 mg/day]) were allowed during the study. A washout
period was required for patients who had recently stopped treatment with 1 of
these medications (2 weeks for NSAIDs or corticosteroids, 12 weeks for
leflunomide, and 4 weeks for the other 3 DMARDs).</p>

<p class=MsoNormal>Medications prohibited during the COSMOS study included
other biologic or non-biologic DMARDs, systemic immunosuppressants, apremilast,
JAK inhibitors, and lithium. Phototherapy, injectable systemic corticosteroids,
and topical psoriasis treatments that could affect psoriasis assessments were
also prohibited.</p>

<p class=MsoNormal><b>Outcomes</b></p>

<p class=MsoNormal>A list of efficacy end points identified in the CADTH review
protocol that were assessed in the clinical trials included in this review is
provided in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t09/?report=objectonly"
target=object>Table 9</a>. These end points are further summarized here. A
detailed discussion and critical appraisal of the outcome measures is provided
in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a4">Appendix
4</a>.</p>

<p class=MsoNormal>After reviewing the outcomes reported, some exploratory or
other end points were not summarized in this report if there were data for a
similar end point that was listed as a secondary outcome or was part of the
statistical testing hierarchy. Examples include the EQ-5D and some composite
measures related to PsA symptoms (i.e., the&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
Disease Activity Score, GRAPPA Composite Score, and Disease Activity Index
for&nbsp;<b>Psoriatic</b>&nbsp;Arthritis [DAPSA]).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t09/?report=objectonly"
title="&quot;Table 9&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 103"
src="psoriasis%20test_files/image011.png"
alt="Table 9. Summary of Outcomes of Interest Identified in the CADTH Review Protocol."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t09/?report=objectonly"
target=object>Table 9</a></b></p>

<p class=MsoNormal>Summary of Outcomes of Interest Identified in the CADTH
Review Protocol.</p>

<p class=MsoNormal><i>Clinical Response in PsA Symptoms</i></p>

<p class=MsoNormal>In all studies, a trained, independent joint assessor who
was not otherwise involved in the conduct of the trial evaluated each of 68
joints for tenderness and each of 66 joints for swelling (hips were excluded
for swelling). This assessor also conducted enthesitis and dactylitis
assessments.</p>

<p class=MsoNormal>ACR 20, ACR 50, and ACR 70 are measurements of improvement
in multiple disease assessment criteria. The ACR 20 is defined as a greater
than or equal to 20% improvement from baseline in both swollen joint count (66
joints) and tender joint count (68 joints), and a greater than or equal to 20%
improvement from baseline in 3 of the following 5 assessments: the patient’s
assessment of pain (visual analogue scale [VAS]), the patient’s global
assessment of disease activity (arthritis, VAS), the physician’s global
assessment of disease activity (VAS), the HAQ-DI, and CRP. ACR 50 and ACR 70
response criteria require changes from baseline of 50% and 70%, respectively.
The ACR 20 is generally accepted as the MID, indicating a response to
treatment, while the ACR 50 and ACR 70 more likely reflect truly important
change for the long-term management of arthropathy.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>44</sup></a></p>

<p class=MsoNormal>The MDA is a composite measure that encompasses different
aspects of PsA disease.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>45</sup></a>&nbsp;To
meet the MDA criteria, patients had to achieve at least 5 out of the following
7 items: tender joint count less than or equal to 1, swollen joint count less
than or equal to 1, PASI score less than or equal to 1, patient’s assessment of
pain less than or equal to 15 (VAS), patient’s global assessment of disease
activity less than or equal to 20 (arthritis and psoriasis, VAS), HAQ-DI score
less than or equal to 0.5, and tender entheseal points less than or equal to 1.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>45</sup></a></p>

<p class=MsoNormal>The Disease Activity Score 28 (DAS 28) using CRP (DAS 28
CRP) is composite measure of disease activity developed for patients with
rheumatoid arthritis. It combines tender joints (28 joints) and swollen joints
(28 joints) of the arms, shoulders, and knees with the CRP and the patient’s
global assessment of disease activity.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>46</sup></a>&nbsp;The
range of the DAS 28 is 0 to 9.4, with higher scores indicating more active
disease.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>47</sup></a>&nbsp;No
evidence was found to support the validity, reliability, or responsiveness in
patients with PsA. According to the clinical expert consulted by CADTH, the
relevance of this outcome measure in patients with PsA has been questioned
because the DAS 28 does not include an assessment of inflammation in the feet,
which is more common in patients with PsA than in those with rheumatoid
arthritis. Assessment of 66 and 68 swollen and tender joints over the 28-joint
count in patients with PsA has been endorsed by GRAPPA and the Outcome Measures
in Rheumatology working group.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>48</sup></a></p>

<p class=MsoNormal><i>Functioning or Disability</i></p>

<p class=MsoNormal>The HAQ-DI is a patient-reported, 20-question instrument
that assesses the degree of difficulty a patient has in accomplishing tasks in
8 functional areas (dressing, arising, eating, walking, hygiene, reaching,
gripping, and activities of daily living). Each functional area is scored from
0 (indicating no difficulty) to 3 (indicating inability to perform a task in
that area). The overall score is the average of 8 domains, ranging from 0 (no
disability) to 3 (completely disabled). The Clinical Study Report (CSR) states
that in PsA, a decrease in score of 0.35 has been determined to indicate a
clinically meaningful improvement.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>6</sup></a>&nbsp;Other
sources have reported MIDs of 0.131 and 0.16 in patients with PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>49</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a></p>

<p class=MsoNormal><i>Health-Related Quality of Life</i></p>

<p class=MsoNormal>The SF-36 is a 36-item general health status instrument that
consists of 8 health domains: physical functioning, role physical, bodily pain,
general health, vitality, social functioning, role emotional, and mental
health. The SF-36 also provides 2 component summaries, the PCS and the MCS,
which are derived by aggregating the 8 domains according to a scoring
algorithm. All domain and component scores are based on a scale of 0 to 100,
with higher scores indicating higher health status. Scores were standardized
with a mean of 50 points and an SD of 10 points in the general US population.
The CSR defined a change of greater than or equal to 5 points in the PCS and
MCS as a clinically meaningful improvement; however, this threshold was not
specific to patients with PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>11</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>51</sup></a>&nbsp;MIDs
of 3.74 points for the PCS and 1.77 points for the MCS have been reported for
patients with PsA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>7</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a></p>

<p class=MsoNormal><i>Psoriasis-Specific Measures</i></p>

<p class=MsoNormal>Psoriasis-specific end points were evaluated in the subgroup
of patients with&nbsp;<b>psoriatic</b>&nbsp;involvement affecting at least 3%
of their BSA and an IGA score of 2 (mild) or higher at baseline.</p>

<p class=MsoNormal>The IGA is a composite score of physician assessment of the
overall severity of the patient’s&nbsp;<b>psoriatic</b>&nbsp;lesions. The
static version of the IGA was used in all included studies, and is a
measurement of disease severity at a given time point. The investigator
assessed the overall severity of induration, erythema, and scaling of lesions
based on a 5-point scale scored as 0 (no evidence), 1 (minimal), 2 (mild), 3
(moderate), and 4 (severe). The IGA score was the average of the induration,
erythema, and scaling scores. The patient’s psoriasis was assessed as cleared
(0), minimal (1), mild (2), moderate (3), or severe (4).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>53</sup></a>&nbsp;IGA
response was defined as a score of 0 or 1 and at least a 2-point decrease from
baseline.</p>

<p class=MsoNormal>The PASI is a widely used instrument in psoriasis trials
that grades the extent and severity of&nbsp;<b>psoriatic</b>&nbsp;lesions. It
combines an assessment of the BSA affected in 4 anatomic regions (head, trunk,
arms, and legs) and the severity of desquamation, erythema, and plaque
induration or infiltration (thickness) in each region. Scores range from 0
points to 72 points, with a PASI score greater than 10 representing more severe
disease.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>54</sup></a>&nbsp;A
PASI 75, PASI 90, or PASI 100 response is defined, respectively, as a greater
than or equal to 75%, greater than or equal to 90%, or greater than or equal to
100% improvement in PASI score from baseline. No MID for the PASI has been
estimated among patients with PsA.</p>

<p class=MsoNormal><i>Other Musculoskeletal Outcomes</i></p>

<p class=MsoNormal>Dactylitis was assessed in both hands and feet using a
scoring system from 0 to 3 for each digit (where 0&nbsp;= no dactylitis,
1&nbsp;= mild dactylitis, 2&nbsp;= moderate dactylitis, and 3&nbsp;= severe
dactylitis). The results were summed to produce a final score ranging from 0 to
60. Enthesitis was assessed using the Leeds Enthesitis Index (LEI), which
counts the number of painful entheses among the left and right lateral
epicondyle humerus, left and right medial femoral condyle, and left and right Achilles
tendon insertion. The LEI index ranges from 0 to 6.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>55</sup></a>&nbsp;No
MID was identified for the LEI and dactylitis score. In all trials, only
patients with dactylitis or enthesitis at baseline were included in the
analysis of these end points.</p>

<p class=MsoNormal>The BASDAI is a patient-reported assessment for ankylosing
spondylitis. It consists of 6 questions relating to the 5 major symptoms of
ankylosing spondylitis (fatigue, spinal pain, peripheral joint pain, localized
tenderness, and morning stiffness). Each question is scored using a 10-unit VAS
to indicate the degree of symptoms over the past week. The total score ranges
from 0 to 10, with higher scores indicate greater disease severity.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>56</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>57</sup></a>&nbsp;According
to the CSR, a 50% decrease in the score is clinically meaningful.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>11</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>58</sup></a>&nbsp;The
MID in patients with PsA is unclear. In the clinical trials, only patients with
spondylitis with peripheral arthritis as the primary arthritic presentation of
PsA completed the BASDAI.</p>

<p class=MsoNormal><i>Symptoms</i></p>

<p class=MsoNormal>FACIT-Fatigue consists of 13 questions that assess a
patient’s level of fatigue and tiredness over the last 7 days. Each question
was graded on a 5-point scale (where 0&nbsp;= not at all, 1&nbsp;= a little
bit, 2&nbsp;= somewhat, 3&nbsp;= quite a bit, and 4&nbsp;= very much). The
score ranges from 0 to 52, with lower scores reflecting more severe fatigue.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;The
CSR states that in rheumatology, a change of 4 points is considered meaningful
and has been used in the PsA population.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;An
MID of 3.1 points has also been reported for patients with PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>9</sup></a></p>

<p class=MsoNormal><i>Radiologic End Points</i></p>

<p class=MsoNormal>For the assessment of radiographic changes, single
radiographs of the hands and feet were evaluated by central independent readers
and scored using the modified vdH-S score. The modified vdH-S score, which
ranges from 0 (best) to 528 (worst), is the sum of the joint erosion score and
the joint space narrowing score.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>10</sup></a>&nbsp;In
addition to reporting the change from baseline in the modified vdH-S score, the
DISCOVER-2 study also reported the number of patients with radiographic
progression based on the smallest detectable change. The smallest detectable
change is defined as the amount of change from baseline for which any smaller
change cannot be reliably distinguished from random error in the measurement.
The MID in patients with PsA is not known.</p>

<p class=MsoNormal><i>Safety</i></p>

<p class=MsoNormal>Treatment-emergent adverse events included any adverse
events that occurred after the start of study drug administration and any
adverse events that were present at baseline but worsened in severity after the
start of study drug administration. Serious adverse events included any event
that resulted in death, was life-threatening, required hospitalization or
prolongation of existing hospitalization, resulted in persistent or significant
disability, was a congenital anomaly, was the suspected transmission of an
infectious drug through a medicinal product, or was medically important (e.g.,
required intervention to prevent 1 of the other outcomes listed).</p>

<p class=MsoNormal><b>Statistical Analysis</b></p>

<p class=MsoNormal><i>Primary Analysis Methods</i></p>

<p class=MsoNormal>In all of the trials, the primary analysis of efficacy
outcomes was based on the composite estimand, which assessed the treatment
effects based on the outcome variable as well as events that met the treatment
failure criteria. Patients who met any of the treatment failure criteria up to
week 24 were considered nonresponders for the binary (responder) outcomes, or
were considered as no change from baseline for the continuous outcomes.
Treatment failure was defined as 1 of the following: discontinued study drug
injections due to any reason; terminated study participation due to any reason;
initiated or increased the dose of non-biologic DMARDs (methotrexate,
sulfasalazine, hydroxychloroquine, leflunomide) or oral corticosteroids over
baseline for PsA; initiated protocol-prohibited medications or therapies for
PsA; or met early escape criteria (COSMOS only). An alternate estimand, the
treatment policy strategy, was the primary estimand for radiologic outcomes in
DISCOVER-2 (refer to the Sensitivity and Subgroup Analyses section for
details).</p>

<p class=MsoNormal>The statistical methods used in the included studies have
been summarized in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t10/?report=objectonly"
target=object>Table 10</a>. The primary outcome (i.e., ACR 20 at week 24) and
other binary outcomes were tested using a CMH test (or Fisher’s exact test, if
CMH was not appropriate) stratified by baseline factors specific to each trial.
In DISCOVER-1, the stratification factors were the use of a non-biologic DMARD
at baseline (yes, no) and prior exposure to TNF alpha inhibitors (yes, no).
DISCOVER-2 patients were stratified by baseline use of non-biologic DMARDs
(yes, no) and most recent CRP value (&lt;&nbsp;2.0 mg/dL versus &#8805;&nbsp;2.0
mg/dL). In the COSMOS study, the stratification factors were non-biologic DMARD
use at baseline (yes, no) and number of prior TNF alpha inhibitors (1 or 2).
The differences in response rates and 95% CI between the guselkumab and placebo
groups were calculated based on the Wald statistic. Patients who met any of the
treatment failure criteria were considered nonresponders at week 24, regardless
of their ACR 20 response status. In addition, any patients with missing data
were imputed as not achieving the response.</p>

<p class=MsoNormal>In the DISCOVER trials, major secondary continuous outcomes
were analyzed using an ANCOVA model based on multiple imputation data, with
missing data imputed under the missing-at-random assumption (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t10/?report=objectonly"
target=object>Table 10</a>). The model included covariates for baseline score
and each studies’ stratification factors. Other continuous outcomes (e.g.,
FACIT-Fatigue, BASDAI) were analyzed using an MMRM with no imputation for
missing data in the DISCOVER trials. In the COSMOS study, continuous outcomes
were analyzed using an MMRM with no imputation for missing data. Any patients
who met the treatment failure criteria were imputed as no change (i.e., no
improvement) from baseline in the model.</p>

<p class=MsoNormal><i>Sensitivity and Subgroup Analyses</i></p>

<p class=MsoNormal>Several sensitivity analyses were planned for the primary
outcome in the DISCOVER-1 and DISCOVER-2 studies. These included the following:
a tipping point analysis where all combinations of missing data, imputed as
responders and nonresponders, were analyzed; a treatment policy analysis, which
was based on observed ACR 20 response data for all patients regardless of
whether treatment failure criteria were met before week 24 and using multiple
imputation methods for missing data (missing-at-random assumption); a tipping
point analysis based on multiple imputation methods for missing data for the
treatment policy estimand; an alternate composite analysis where patients who
stopped treatment for reasons other than lack of efficacy were not considered
as nonresponders; and a per-protocol analysis that was based on the last
non-missing data before stopping therapy or meeting treatment failure criteria
in patients who did not have any major protocol violations.</p>

<p class=MsoNormal>In the DISCOVER trials, subgroup analyses based on treatment
history and concomitant DMARD use were of interest to this review. These
preplanned analyses for the ACR 20 end point were based on a logistic
regression model and reported as odds ratios and 95% CIs. P values for the
treatment by subgroup interaction terms were reported.</p>

<p class=MsoNormal>In the COSMOS study, a supplementary analysis was conducted
based on the treatment policy estimand, which evaluated treatment effects using
all observed data, regardless of the intercurrent events that met the treatment
failure criteria, with imputation for missing data. In this trial, this
estimand ignored the week 16 crossover of placebo patients who met the early
escape criteria and received guselkumab. The sponsor stated that this analysis
biases the results against guselkumab because it does not consider any benefit
that patients in the placebo group may have received from switching to active
treatment. A second supplementary analysis was conducted where discontinuation
of the study drug due to reasons other than lack of efficacy was not considered
as treatment failure.</p>

<p class=MsoNormal>A total of 20 patients in the COSMOS study (8 patients [8%]
in the placebo group and 12 patients [6%] in the guselkumab group) were
incorrectly assigned to early escape. Patients in the placebo group were
incorrectly switched to guselkumab, and there was no change to the study drug
received by the patients who had been incorrectly assigned to early escape in
the guselkumab group. Two sensitivity analyses were conducted for these
patients. The first ignored the early escape criterion, which meant that the 12
patients on guselkumab were not considered to have experienced treatment
failure (i.e., no change in therapy); however, the 8 placebo patients were
analyzed as a treatment failure because they had received a prohibited
medication. The second analysis set the week 16 to week 24 end point values as
missing. These were imputed using multiple imputation methods for binary
outcomes or MMRM for continuous end points.</p>

<p class=MsoNormal>The preplanned subgroup analyses based on patient
demographics were not of interest to this review and have not been summarized
in this report.</p>

<p class=MsoNormal><i>Statistical Power</i></p>

<p class=MsoNormal>The DISCOVER-1 study was estimated to have greater than 90%
power at a 2-sided alpha level of 0.05 for the primary outcome of ACR 20
response. This estimate was based on enrolling a total of 360 patients and
assuming a 40% ACR 20 response rate in the guselkumab group and a 20% ACR 20
response in the placebo group at week 24.</p>

<p class=MsoNormal>For the DISCOVER-2 study, assuming ACR 20 response rates of
45% and 20% in the guselkumab and placebo groups, respectively, a sample size
of 228 patients per group would have 99% power to detect a significant
treatment effect at a 2-sided significance level of 0.05. With a sample size of
228 patients per group, the trial would have 90% power to detect a difference
in the mean change from baseline in the vdH-S score, assuming a mean change of
0.9 in the placebo group and 0.3 in the guselkumab group, with an SD of 2.5. No
references were listed to support the assumptions used in the calculations.</p>

<p class=MsoNormal>The COSMOS study was planned to have 90% power to detect a
difference in the primary outcome (i.e., ACR 20) at a 2-sided significance
level of 0.05 based on a sample size of 163 patients in the guselkumab group
and 82 patients in the placebo group, assuming a response rate of 41% versus
20% for guselkumab and placebo, respectively. The estimated ACR 20 response
rates were based on data from an ustekinumab trial in patients previously
treated with TNF alpha inhibitors.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>59</sup></a></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t10/?report=objectonly"
title="&quot;Table 10&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 102"
src="psoriasis%20test_files/image012.png"
alt="Table 10. Statistical Analysis of Efficacy End Points."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t10/?report=objectonly"
target=object>Table 10</a></b></p>

<p class=MsoNormal>Statistical Analysis of Efficacy End Points.</p>

<p class=MsoNormal><i>Control of Type I Error Rate</i></p>

<p class=MsoNormal>In the DISCOVER trials, the overall type I error was
controlled at a significance level of less than or equal to 0.05 for the
primary outcome (i.e., ACR 20) and select major secondary outcomes. Due to
regulatory requirements, there were 2 pre-specified multiplicity adjustment
procedures used: 1 for the US and 1 for countries except the US (global). In
both procedures, the primary outcome was tested first for the group receiving
guselkumab every 4 weeks versus the placebo group, and then for the group receiving
guselkumab every 8 weeks versus the placebo group. Testing of select major
secondary outcomes proceeded if the primary outcome was statistically
significant. In the DISCOVER-1 study, the global testing procedure included 8
major secondary outcomes that were tested for each guselkumab dose group
independently in the order specified in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t11/?report=objectonly"
target=object>Table 11</a>. In the US testing procedure, the 2 dosage groups
were tested in parallel, as shown in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig05/?report=objectonly"
target=object>Figure 5</a>. The overall significance level of less than or
equal to 0.05 was controlled for the 24-week IGA response and the HAQ-DI and
SF-36 PCS outcomes. Other secondary outcomes were not controlled for type I
error rate. The testing procedures stated that ACR 20 at week 16, ACR 50 at
week 16, ACR 50 at week 24, ACR 70 at week 24, and change from baseline DAS 28
at week 24 were tested (with a nominal P value) only if the primary outcome for
the corresponding guselkumab dosage group was statistically significant.</p>

<p class=MsoNormal>In the DISCOVER-2 study, the US-based testing procedure
controlled the type I error at an overall significance level of less than or
equal to 0.05 for the primary outcome (i.e., ACR 20) and for 3 major secondary
end points that were not highly correlated with each other (IGA response,
HAQ-DI, and SF-36 PCS at week 24). Figure 6 shows the testing procedure for
these 4 outcomes in the 2 dosage groups. The global testing procedure
controlled the type I error rate for 12 outcomes, as shown in Figure 7, and included
a pooled analysis of the resolution of enthesitis or dactylitis based on data
from DISCOVER-1 and DISCOVER-2. Five other outcomes highly correlated with ACR
20 were tested (with nominal P values) only if statistical significance was
achieved for ACR 20 response at week 24 for the corresponding guselkumab dose
group. These outcomes included ACR 20 and ACR 50 response at week 16, ACR 50
and ACR 70 response at week 24, and change from baseline in DAS 28 at week 24.
Other secondary outcomes were not formally tested, and nominal P values were
reported. Of note: the Health Canada reviewer’s report stated that the US
analyses were deemed the preferred method.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>40</sup></a></p>

<p class=MsoNormal>For the COSMOS study, the type I error rate was controlled
for the primary outcome and 4 major secondary outcomes. These were tested in a
fixed sequence (week 24 HAQ-DI, ACR 50, SF-36 PCS, PASI 100 response).
Statistical testing was performed sequentially only if the previous outcome
reported a P value of less than 0.05. The P values for the other outcomes
reported were not controlled for multiple testing, and the sponsor stated that
these were descriptive and not to be used to determine statistical significance.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t11/?report=objectonly"
title="&quot;Table 11&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 101"
src="psoriasis%20test_files/image013.png"
alt="Table 11. Hierarchical Sequence for Testing Secondary Outcomes."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t11/?report=objectonly"
target=object>Table 11</a></b></p>

<p class=MsoNormal>Hierarchical Sequence for Testing Secondary Outcomes.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig05/?report=objectonly"
title="&quot;Figure 5&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=39 id="Picture 100"
src="psoriasis%20test_files/image003.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig05/?report=objectonly"
target=object>Figure 5</a></b></p>

<p class=MsoNormal>US-Specific Multiplicity Testing Procedure — DISCOVER-1 —
Redacted.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig06/?report=objectonly"
title="&quot;Figure 6&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=39 id="Picture 99"
src="psoriasis%20test_files/image003.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig06/?report=objectonly"
target=object>Figure 6</a></b></p>

<p class=MsoNormal>US-Specific Multiplicity Testing Procedure — DISCOVER-2 —
Redacted.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig07/?report=objectonly"
title="&quot;Figure 7&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=39 id="Picture 98"
src="psoriasis%20test_files/image003.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig07/?report=objectonly"
target=object>Figure 7</a></b></p>

<p class=MsoNormal>Global Multiplicity Testing Procedure — DISCOVER-2 —
Redacted.</p>

<p class=MsoNormal><i>Analysis Populations</i></p>

<p class=MsoNormal>In all studies, most efficacy outcomes were analyzed based
on the FAS, which included all randomized patients who received at least 1 dose
of the study drug according to their randomized group. Psoriasis-specific
outcomes (i.e., IGA or PASI response) were analyzed in specific FAS
subpopulations that had greater than or equal to 3% BSA&nbsp;<b>psoriatic</b>&nbsp;involvement
and an IGA score of greater than or equal to 2 at baseline. Patients included
in the enthesitis analyses had to have at least 1 tender enthesis among the 6
sites included in the LEI at baseline. The dactylitis outcomes were analyzed in
patients with dactylitis at baseline, and the BASDAI was analyzed in the subset
of patients with spondylitis and peripheral joint PsA as their primary
presentation. DISCOVER-2 also included a preplanned, pooled analysis of
enthesitis and dactylitis outcomes that were based on relevant subgroup data
from the DISCOVER-1 and DISCOVER-2 trials.</p>

<p class=MsoNormal>The safety population included all randomized patients who
received at least 1 dose of the study drug and were analyzed according to the
actual treatment received.</p>

<p class=MsoNormal><b>Results</b></p>

<p class=MsoNormal><b>Patient Disposition</b></p>

<p class=MsoNormal>In the DISCOVER-1 study, 624 patients were screened, and 381
patients (61%) were randomized to 1 of 3 treatment groups. By week 24, 7%
versus 2% of patients in the placebo group and the group receiving guselkumab
every 8 weeks, respectively, had discontinued from the study, and 10% versus 3%
stopped treatment early.&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t12/?report=objectonly"
target=object>Table 12</a>&nbsp;describes the reasons for discontinuation. More
patients met the treatment failure criteria (17% versus 6%) and qualified for
early escape (19% and 3%) in the placebo group than in the guselkumab group.</p>

<p class=MsoNormal>Of the 1,153 patients screened in the DISCOVER-2 study, 741
patients were randomized, and 739 patients were treated (64%). The proportion
of patients who discontinued the study was low (1% and 2%), as were the
proportions who discontinued the study drug (2% and 3% in both the placebo and
guselkumab groups, respectively). The treatment failure criteria were met by 7%
and 5% of patients — and the early escape criteria were met by 15% and 5% of
patients — in the placebo group and the group receiving guselkumab every 8
weeks, respectively.</p>

<p class=MsoNormal>In the COSMOS study, 328 patients were screened, of whom 285
patients (87%) were randomized. By week 24, 2% of patients in each group had
discontinued the study, and 10% and 8% in the placebo and guselkumab groups,
respectively, had discontinued the study drug. Approximately half of the
patients in the placebo group met the treatment failure criteria or early
escape criteria (54% and 47%, respectively), compared with 27% and 21% of
patients in the guselkumab group. The CSR reported that a total of 20 patients
were incorrectly assigned to early escape without having met the escape
criteria. This affected 8 patients in the placebo group (8%) and 12 patients
(6%) in the guselkumab group (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t12/?report=objectonly"
target=object>Table 12</a>).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t12/?report=objectonly"
title="&quot;Table 12&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 97"
src="psoriasis%20test_files/image014.png" alt="Table 12. Patient Disposition."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t12/?report=objectonly"
target=object>Table 12</a></b></p>

<p class=MsoNormal>Patient Disposition.</p>

<p class=MsoNormal><b>Exposure to Study Treatments</b></p>

<p class=MsoNormal>The durations of study follow-up were similar across the
studies (mean&nbsp;= 23.7 weeks [SD&nbsp;= 2.4 weeks] to 24.0 weeks [SD&nbsp;=
0.5 weeks]). In the DISCOVER studies, the mean number of study drug
administrations ranged from 5.8 weeks (SD&nbsp;= 0.8 weeks) to 5.9 weeks
(SD&nbsp;= 0.5 weeks). In the COSMOS study, these numbers were 4.1 weeks
(SD&nbsp;= 0.6 weeks) in the group receiving guselkumab every 8 weeks and 4.3
weeks (SD&nbsp;= 0.9 weeks) in the placebo group (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t13/?report=objectonly"
target=object>Table 13</a>).</p>

<p class=MsoNormal>In general, the proportions of patients receiving permitted
concomitant therapies for PsA were similar between groups in the trials. In the
DISCOVER trials, at baseline, 54% to 63% of patients per group were receiving
methotrexate, || || || were receiving sulfasalazine, || || || were receiving
leflunomide, and 14% to 20% were receiving oral corticosteroids. Mean daily or
weekly doses of permitted concomitant therapies are listed in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t13/?report=objectonly"
target=object>Table 13</a>. In the COSMOS study, 58% and 61% of patients were
receiving methotrexate at baseline.</p>

<p class=MsoNormal>In the DISCOVER-1 study, 3% of patients in the group
receiving guselkumab every 8 weeks met the early escape criteria compared with
19% of patients in the placebo group. Similarly, 5% and 15% in the guselkumab
and placebo groups of the DISCOVER-2 study met the early escape criteria. In
the COSMOS study, 39 patients (21%) in the group receiving guselkumab every 8
weeks versus 45 patients (47%) in the placebo group were assigned to early
escape. However, 20 patients were erroneously assigned to receive early escape
therapy without having met the criteria. This error affected 12 patients (6.3%)
in the guselkumab and 8 patients (8.3%) in the placebo group.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t13/?report=objectonly"
title="&quot;Table 13&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 96"
src="psoriasis%20test_files/image015.png"
alt="Table 13. Exposure to Study Treatments and Permitted Concomitant Therapies."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t13/?report=objectonly"
target=object>Table 13</a></b></p>

<p class=MsoNormal>Exposure to Study Treatments and Permitted Concomitant
Therapies.</p>

<p class=MsoNormal><b>Efficacy</b></p>

<p class=MsoNormal>Only those efficacy outcomes and analyses of subgroups
identified in the review protocol are reported. Refer to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a3">Appendix
3</a>&nbsp;for detailed efficacy data.</p>

<p class=MsoNormal>The systematic review protocol identified pain as an outcome
of interest. None of the trials included pain as a secondary or exploratory
outcome; however, patient-reported pain severity was included as part of the
ACR and MDA response criteria and the SF-36.</p>

<p class=MsoNormal><i>Clinical Response in PsA Symptoms</i></p>

<p class=MsoNormal>In the DISCOVER-1 study, which enrolled both biologic-naive
and biologic-experienced patients, 52.0% of patients in the group receiving
guselkumab every 8 weeks achieved ACR 20 at 24 weeks compared with 22.2% of
patients in the placebo group. The absolute difference was 29.8% (95% CI, 18.6%
to 41.1%; P&nbsp;&lt;&nbsp;0.001) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
target=object>Table 14</a>) favouring guselkumab versus placebo. At week 24,
29.9% of patients versus 8.7% of patients in the guselkumab versus placebo
groups, respectively, achieved ACR 50 (absolute difference&nbsp;= 21.4%; 95%
CI, 12.1% to 30.7%; P&nbsp;&lt;&nbsp;0.001), and 11.8% versus 5.6% achieved ACR
70 (6.4%; 95% CI, &#8722;0.3% to 13.1%; P&nbsp;=&nbsp;0.086). ACR 50 and ACR 70
outcomes were controlled for multiple testing based on the global testing
procedure rather than the US-specific testing procedure. The US-specific
procedure was preferred by Health Canada.</p>

<p class=MsoNormal>Among patients who were biologic-naive (in DISCOVER-2),
64.1% and 32.9% of patients achieved ACR 20 in the group receiving guselkumab
every 8 weeks and the placebo group, respectively, with an absolute difference
of 31.2% (95% CI, 22.9% to 39.5%; P&nbsp;&lt;&nbsp;0.001) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
target=object>Table 14</a>). The difference between guselkumab and placebo in
the proportion of patients who achieved ACR 50 was 17.2% (95% CI, 10.0% to
24.4%), and the proportion of patients who achieved ACR 70 was 14.5% (95% CI,
9.1% to 19.9%). However, neither outcome was statistically tested according to
the global testing procedure due to failure of a prior outcome in the
hierarchy. ACR 50 and ACR 70 were not controlled for multiple testing in the
US-specific procedure.</p>

<p class=MsoNormal>Among biologic-experienced patients in the COSMOS study,
44.4% and 19.8% achieved ACR 20 at week 24 in the guselkumab and placebo
groups, respectively. The absolute difference between groups (24.6%) favoured
guselkumab (95% CI, 14.1% to 35.2%; P&nbsp;&lt;&nbsp;0.001) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
target=object>Table 14</a>). The difference for guselkumab versus placebo for
the proportion who achieved ACR 50 was 19.6% versus 5.2%; the absolute
difference was 14.3% (95% CI, 7.2% to 21.4%; P&nbsp;&lt;&nbsp;0.001). ACR 70
response was achieved by 7.9% versus 1.0% of patients in the guselkumab versus
placebo groups, with an absolute difference of 6.8% (95% CI, 2.6% to 11.1%).
ACR 70 was not controlled for multiple testing and should be interpreted
considering the inflated risk of type I error rate.</p>

<p class=MsoNormal>In the DISCOVER-1 and 2 studies, the results of the
sensitivity analyses for ACR 20 were generally consistent with the results of
the primary analysis. In the COSMOS study, the analysis that was based on
observed case data regardless of meeting treatment failure criteria reported an
absolute difference of 10.9% (95% CI, &#8722;1.3% to 23.2%), which the
investigators stated was due to the doubled ACR 20 response rate in the placebo
group, noting that almost half of patients in the placebo group received early
escape therapies starting at week 16. Other sensitivity analyses (per-protocol
population and analyses adjusting for errors in early escape assignment) showed
results that were consistent with the primary analysis.</p>

<p class=MsoNormal>The proportion of patients who achieved MDA at week 24 was
higher in the group receiving guselkumab every 8 weeks versus the placebo group
in all 3 studies. However, this outcome was not controlled for multiple testing
and should be interpreted with caution because of the potential for inflated
type I error rate. The absolute differences between guselkumab and placebo were
11.9% (95% CI, 2.9% to 20.9%) for DISCOVER-1, 18.9% (95% CI, 12.8% to 25.0%)
for DISCOVER-2, and 11.7% (95% CI, 5.6% to 17.7%) for the COSMOS study (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
target=object>Table 14</a>).</p>

<p class=MsoNormal>Subgroup analyses of interest to this review for the
DISCOVER studies are shown in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig11/?report=objectonly"
target=object>figures 11</a>&nbsp;to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig14/?report=objectonly"
target=object>14</a>&nbsp;in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a3">Appendix
3</a>. The odds ratios for ACR 20 response were generally consistent across
subgroups based on prior use of TNF alpha inhibitors, non-biologic DMARDs, oral
corticosteroids, or NSAIDs at baseline. The COSMOS study did not report data
for any subgroups of interest.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
title="&quot;Table 14&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 95"
src="psoriasis%20test_files/image016.png"
alt="Table 14. ACR and MDA Response at Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t14/?report=objectonly"
target=object>Table 14</a></b></p>

<p class=MsoNormal>ACR and MDA Response at Week 24.</p>

<p class=MsoNormal>Additional data on the ACR 20 and ACR 50 response rates at
week 16 are summarized in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a3">Appendix
3</a>,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t42/?report=objectonly"
target=object>Table 42</a>. These findings were generally consistent with the
ACR 20 results at week 24; however, the ability to draw statistical inferences
from the data may be limited, whether because no statistical testing was
performed (DISCOVER-2), there was no control for multiple testing (COSMOS), or
control of the type I error rate was based on global rather than US-specific
testing procedures (DISCOVER-1). For ACR 50, the DISCOVER-1 study failed to
detect a statistically significant difference between guselkumab every 8 weeks
and placebo at week 16 (based on global testing procedure). No statistical
testing was performed in DISCOVER-2 (due to failure of a prior outcome). The
response rates were nominally higher for the guselkumab versus placebo groups
in the COSMOS study, but there was no control of the type I error rate.</p>

<p class=MsoNormal>Data on the changes from baseline in DAS 28 CRP scores are
summarized in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/#tr8269861151140733_ch01_a3">Appendix
3</a>,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t43/?report=objectonly"
target=object>Table 43</a>. The point estimates for the LS mean differences
ranged from &#8722;0.61 to &#8722;0.73, suggesting an improvement with
guselkumab every 8 weeks versus placebo in all trials; however, in the COSMOS
study, this outcome was not controlled for multiple testing, and in the
DISCOVER studies, it was controlled for multiple testing based on the global
testing procedure rather than the US-specific procedure.</p>

<p class=MsoNormal><i>Function or Disability</i></p>

<p class=MsoNormal>Changes from baseline to week 24 in the HAQ-DI favoured
guselkumab every 8 weeks versus placebo in all trials. The LS mean differences
reported were &#8722;0.25 (95% CI, &#8722;0.36 to &#8722;0.13;
P&nbsp;&lt;&nbsp;0.001) in the DISCOVER-1 study, &#8722;0.24 (95% CI,
&#8722;0.32 to &#8722;0.15; P&nbsp;&lt;&nbsp;0.001) in the DISCOVER-2 study,
and &#8722;0.17 (95% CI, &#8722;0.28 to &#8722;0.06; P&nbsp;=&nbsp;0.003) in
the COSMOS study. Across the trials, only the group receiving guselkumab every
8 weeks in the DISCOVER-2 study achieved a change from baseline that exceeded
the 0.35 MID cited in the study’s protocol.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>6</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>7</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>51</sup></a></p>

<p class=MsoNormal>The proportion of HAQ-DI responders was reported as another
secondary outcome in the DISCOVER trials (i.e., no control for type I error
rate). Response was defined achieving a point improvement of greater than or
equal to a 0.35 in the HAQ-DI score from baseline (among the subset of patients
who had a HAQ-DI score &#8805;&nbsp;0.35 points at baseline). At 24 weeks in
the DISCOVER-1 study, 50.9% of patients (57 of 112) in the guselkumab group and
29.1% of patients (32 of 110) in the placebo group achieved HAQ-DI responses
(absolute difference&nbsp;= 21.8%; 95% CI, 9.3% to 34.2%). In DISCOVER-2, 50.0%
of patients (114 of 228) and 31.4% of patients (74 of 236) in the guselkumab
versus placebo groups, respectively, achieved HAQ-DI responses (absolute
difference&nbsp;= 18.7%; 95% CI, 10.0% to 27.3%).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t15/?report=objectonly"
title="&quot;Table 15&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 94"
src="psoriasis%20test_files/image017.png"
alt="Table 15. Change From Baseline in HAQ-DI to Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t15/?report=objectonly"
target=object>Table 15</a></b></p>

<p class=MsoNormal>Change From Baseline in HAQ-DI to Week 24.</p>

<p class=MsoNormal><i>Health-Related Quality of Life</i></p>

<p class=MsoNormal>The change from baseline in the SF-36 PCS was a secondary
outcome in all studies. Most treatment groups reported an improvement at week
24, with a difference that favoured guselkumab every 8 weeks versus placebo in
all studies (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t16/?report=objectonly"
target=object>Table 16</a>). The LS mean difference was 4.1 (95% CI, 2.4 to
5.9; P&nbsp;&lt;&nbsp;0.001) in the DISCOVER-1 study, 4.0 (95% CI, 2.7 to 5.2;
P&nbsp;=&nbsp;0.011) in the DISCOVER-2 study, and 3.9 (95% CI, 2.5 to 5.4;
P&nbsp;&lt;&nbsp;0.001) in the COSMOS study. The CSR defined an increase of at
least 5 points as clinically meaningful, but a MID of 3.74 has also been
reported in the literature.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>7</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>51</sup></a></p>

<p class=MsoNormal>All trials failed to detect a statistically significant
difference between guselkumab every 8 weeks and placebo in the change from
baseline to week 24 in the SF-36 MCS (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t16/?report=objectonly"
target=object>Table 16</a>).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t16/?report=objectonly"
title="&quot;Table 16&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 93"
src="psoriasis%20test_files/image018.png"
alt="Table 16. Change From Baseline in the SF-36 PCS and MCS to Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t16/?report=objectonly"
target=object>Table 16</a></b></p>

<p class=MsoNormal>Change From Baseline in the SF-36 PCS and MCS to Week 24.</p>

<p class=MsoNormal><i>Psoriasis Skin Disease</i></p>

<p class=MsoNormal>In all trials, psoriasis skin disease outcome measures were
analyzed in the subgroup of patients who had psoriasis affecting greater than
or equal to 3% of their BSA and an IGA score of greater than or equal to 2 at
baseline (55% to 74% of patients per treatment group). Randomization was not
stratified by the presence of skin disease at baseline.</p>

<p class=MsoNormal>The proportion of patients who achieved an IGA response at
week 24 was higher in the group receiving guselkumab every 8 weeks than in the
placebo group in the DISCOVER-1 study (57.3% versus 15.4%; absolute
difference&nbsp;= 42.0% [95% CI, 28.9% to 55.1%; P&nbsp;&lt;&nbsp;0.001]) and
the DISCOVER-2 study (70.5% versus 19.1%; absolute difference&nbsp;= 50.9% [95%
CI, 42.2% to 59.7%; P&nbsp;&lt;&nbsp;0.001]). In the COSMOS study, 48.1% versus
9.4% of patients achieved an IGA response in the guselkumab and placebo groups;
the absolute difference was 38.8% (95% CI, 27.3% to 50.4%). However, the P
value was not adjusted to control for multiple testing; it should be
interpreted with caution because of the potential for inflated type I error
rate.</p>

<p class=MsoNormal>PASI 100 response at week 24 was a secondary outcome in the
COSMOS study. In the group receiving guselkumab every 8 weeks, 30.8% of
patients achieved a PASI 100 response compared with 3.8% of patients in the
placebo group (absolute difference&nbsp;= 27.4%; 95% CI, 17.9% to 36.8%;
P&nbsp;&lt;&nbsp;0.001]). The PASI 90 and PASI 75 results in the COSMOS study
were nominally higher in the guselkumab versus placebo groups, but the type I
error rate was not controlled for these outcomes. The PASI 100, PASI 90, and
PASI 75 response rates in the DISCOVER trials were nominally higher for
guselkumab versus placebo, but these outcomes were not part of the statistical
testing procedure and should be interpreted with caution, considering the
potential for inflated type I error rate (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t17/?report=objectonly"
target=object>Table 17</a>).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t17/?report=objectonly"
title="&quot;Table 17&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 92"
src="psoriasis%20test_files/image019.png"
alt="Table 17. IGA and PASI Response at Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t17/?report=objectonly"
target=object>Table 17</a></b></p>

<p class=MsoNormal>IGA and PASI Response at Week 24.</p>

<p class=MsoNormal><i>Other Musculoskeletal Disease</i></p>

<p class=MsoNormal>Outcomes related to enthesitis and dactylitis were analyzed
for patients reporting these symptoms at baseline. Approximately 2-thirds of
patients reported enthesitis at baseline (57% to 72%), whereas 35% to 45% of
patients reported dactylitis across treatment groups in the 3 trials.
Randomization was not stratified by the presence of enthesitis or dactylitis at
baseline. These outcomes were not controlled for multiple testing; thus, P
values of less than 0.05 should be interpreted with caution, considering the
potential for inflated type I error rate. The results for these outcomes in
each trial are shown in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t18/?report=objectonly"
target=object>Table 18</a>.</p>

<p class=MsoNormal>The DISCOVER-2 study planned a prior pooled analysis of the
resolution of enthesitis and dactylitis end points using combined data from the
DISCOVER-1 and DISCOVER-2 trials. Based on the pooled analysis, 49.6% and 29.4%
of patients in the group receiving guselkumab every 8 weeks and the placebo
group had resolution of enthesitis at week 24, with a between-group difference
of 20.1% (95% CI, 11.8% to 28.5%; P&nbsp;=&nbsp;0.03 [based on the US-specific
testing procedure]). The proportion of patients whose dactylitis resolved at
week 24 was 59.4% versus 42.2% in the guselkumab versus placebo group; the
between-group difference was 18.0% (95% CI, 7.4% to 28.6%; P&nbsp;=&nbsp;0.03
[based on the US-specific testing procedure]). In accordance with the global
testing procedure, these outcomes were not formally tested due to the failure
of a prior outcome in the testing hierarchy.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t18/?report=objectonly"
title="&quot;Table 18&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 91"
src="psoriasis%20test_files/image020.png"
alt="Table 18. Enthesitis and Dactylitis Outcomes at 24 Weeks."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t18/?report=objectonly"
target=object>Table 18</a></b></p>

<p class=MsoNormal>Enthesitis and Dactylitis Outcomes at 24 Weeks.</p>

<p class=MsoNormal>The change in the BASDAI score was analyzed for the subgroup
of patients with spondylitis and peripheral joint PsA as their primary
presentation at baseline (18% to 37% of patients per treatment group across the
studies). Randomization was not stratified by the presence of axial disease at
baseline. The sponsor stated that a 50% improvement in the BASDAI represents a
clinically important change.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>58</sup></a></p>

<p class=MsoNormal>Among biologic-naive patients (DISCOVER-2), 39% and 22% in
the guselkumab and placebo groups, respectively, achieved at least a 50%
improvement in the BASDAI score at week 24 (absolute difference&nbsp;= 15%)
(95% CI, 0.4% to 30%; not controlled for type I error rate) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t19/?report=objectonly"
target=object>Table 19</a>). The proportion of patients with an improvement of
greater than or equal to 50% was the same in both treatment groups (19%) among
patients who were biologic-experienced in the COSMOS study. In the mixed
population enrolled in the DISCOVER-1 study, 42% and 13% of patients in the
guselkumab and placebo groups achieved at least a 50% improvement,
respectively, with an absolute difference of 24% (95% CI, &#8722;1% to 49%).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t19/?report=objectonly"
title="&quot;Table 19&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 90"
src="psoriasis%20test_files/image021.png"
alt="Table 19. Improvement in BASDAI Score at Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t19/?report=objectonly"
target=object>Table 19</a></b></p>

<p class=MsoNormal>Improvement in BASDAI Score at Week 24.</p>

<p class=MsoNormal><i>PsA Symptoms</i></p>

<p class=MsoNormal>FACIT-Fatigue scores range from 0 to 52, with higher scores
indicating less fatigue. This outcome was not controlled for multiple testing;
thus, P values of less than 0.05 should be interpreted with caution,
considering the potential for inflated type I error rate. MIDs of 3.1 to 4
points have been reported in the literature.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>9</sup></a></p>

<p class=MsoNormal>The FACIT-Fatigue scores suggest improvement in fatigue,
with point estimates for the within-group change from baseline to week 24 that
exceeded the MID for all groups receiving guselkumab every 8 weeks and for the
placebo group in the DISCOVER-2 study (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t20/?report=objectonly"
target=object>Table 20</a>). The DISCOVER-1 study reported an LS mean
difference of 3.4 points (95% CI, 1.4 to 5.4); the DISCOVER-2 study reported an
LS mean difference of 4.0 (95% CI, 2.5 to 5.5); and the COSMOS study reported
an LS mean difference of 3.6 (95% CI, 1.7 to 5.4) for guselkumab every 8 weeks
versus placebo. In all studies, the between-group difference exceeded the MID
of 3.1, while only the DISCOVER-2 study met the 4-point threshold.</p>

<p class=MsoNormal><i>Radiologic Outcomes</i></p>

<p class=MsoNormal>The change from baseline to week 24 in the modified vdH-S
score was a major secondary outcome in the DISCOVER-2 study. At 24 weeks, the
LS mean difference observed for guselkumab versus placebo was &#8722;0.43 (95%
CI, &#8722;0.90 to 0.03) (P&nbsp;=&nbsp;0.068) (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t21/?report=objectonly"
target=object>Table 21</a>).</p>

<p class=MsoNormal>The proportions of patients with no progression (defined as
a change from baseline that was less than or equal to the smallest detectable
change for the modified vdH-S total score) were 89.0% in the group receiving
guselkumab every 8 weeks and 84.0% in the placebo group (absolute
difference&nbsp;= 5.0%; 95% CI, –1.0% to 10.9%).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t20/?report=objectonly"
title="&quot;Table 20&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 89"
src="psoriasis%20test_files/image022.png"
alt="Table 20. Change From Baseline in FACIT-Fatigue Score to Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t20/?report=objectonly"
target=object>Table 20</a></b></p>

<p class=MsoNormal>Change From Baseline in FACIT-Fatigue Score to Week 24.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t21/?report=objectonly"
title="&quot;Table 21&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 88"
src="psoriasis%20test_files/image023.png"
alt="Table 21. Change From Baseline in Modified vdH-S of PsA to 24 Weeks."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t21/?report=objectonly"
target=object>Table 21</a></b></p>

<p class=MsoNormal>Change From Baseline in Modified vdH-S of PsA to 24 Weeks.</p>

<p class=MsoNormal><b>Harms</b></p>

<p class=MsoNormal>Only those harms identified in the review protocol are
reported in this section. Refer to&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a>&nbsp;for detailed harms data.</p>

<p class=MsoNormal><i>Adverse Events</i></p>

<p class=MsoNormal>The frequency of adverse events was generally similar
between groups, with 42% to 54% of patients in the groups receiving guselkumab
every 8 weeks and 41% to 60% of patients in the placebo groups reporting 1 or
more adverse events during the 24-week treatment period (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a>). Nasopharyngitis (4% to 13%), upper respiratory
tract infection (2% to 5%), and increased alanine aminotransferase (2% to 6%)
were the most commonly reported adverse events in the guselkumab groups. The
corresponding proportions of patients experiencing these adverse events in the
placebo groups were 4% to 6% for nasopharyngitis, 3% to 7% for upper
respiratory tract infections, and 3% to 6% for increased alanine
aminotransferase.</p>

<p class=MsoNormal>In the COSMOS study, adverse event data were reported
separately for 45 patients who switched from placebo to guselkumab every 8
weeks before week 24. Six patients (13%) experienced an adverse event,
including 1 patient with a serious adverse event (a buttock injury) and 2
patients with infections (4%).</p>

<p class=MsoNormal><i>Serious Adverse Events</i></p>

<p class=MsoNormal>The frequency of serious adverse events ranged from 1% to 4%
in the groups receiving guselkumab every 8 weeks and from 3% to 4% in the
placebo groups (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a>). No specific serious adverse events were reported
in more than 1 patient per treatment group (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t23/?report=objectonly"
target=object>Table 23</a>). In the DISCOVER-1 study, only 1 of the serious
adverse events (plasma cell myeloma in the guselkumab group) resulted in
treatment discontinuation. One patient in the guselkumab group of the COSMOS
study experienced increased alanine aminotransferase that was categorized as a
serious adverse event. This patient was subsequently diagnosed with autoimmune
hepatitis and the study drug was stopped.</p>

<p class=MsoNormal><i>Treatment Discontinuation Due to Adverse Events</i></p>

<p class=MsoNormal>Adverse events that resulted in treatment discontinuation
were generally low (1% to 3%) and similar between groups (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a>). Other than 2 patients in the placebo group of the
DISCOVER-1 study, who stopped treatment due to psoriasis, all other events were
reported in 1 patient (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t23/?report=objectonly"
target=object>Table 23</a>).</p>

<p class=MsoNormal><i>Mortality</i></p>

<p class=MsoNormal>In the DISCOVER-1 study, 1 patient in the placebo group died
due to cardiac failure. No other deaths were reported in the guselkumab groups
or placebo groups during the first 24 weeks of the 3 studies.</p>

<p class=MsoNormal><i>Notable Harms</i></p>

<p class=MsoNormal>Generally, the frequency of infections was similar in the
groups receiving guselkumab every 8 weeks (16% to 26%) and the placebo groups
(18% to 25%) across trials (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a>). In the DISCOVER-1 study, no patients in the
guselkumab group reported a serious infection. Two patients in the placebo
group experienced a serious infection, which included a serious upper
respiratory tract infection and an abscessed limb. In the DISCOVER-2 study, 1
patient in each group reported a serious infection, including pyrexia in the
guselkumab group and post-procedural fistula in the placebo group. In the
COSMOS study, 1 patient in the guselkumab group reported a serious
community-acquired pneumonia that required hospitalization. No serious
infections were reported among patients who received placebo. No cases of
tuberculosis or opportunistic infections were reported in the first 24 weeks of
all 3 trials.</p>

<p class=MsoNormal>The other notable harms identified in the systematic review
protocol were infrequently reported (i.e., injection-site reactions,
anaphylactic adverse events, and liver-related adverse events).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
title="&quot;Table 22&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 87"
src="psoriasis%20test_files/image024.png"
alt="Table 22. Summary of Harms Up to 24 Weeks (Safety Set)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t22/?report=objectonly"
target=object>Table 22</a></b></p>

<p class=MsoNormal>Summary of Harms Up to 24 Weeks (Safety Set).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t23/?report=objectonly"
title="&quot;Table 23&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 86"
src="psoriasis%20test_files/image025.png"
alt="Table 23. Description of SAEs or Adverse Events Leading to Treatment Discontinuation Up to 24 Weeks (Safety Set)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t23/?report=objectonly"
target=object>Table 23</a></b></p>

<p class=MsoNormal>Description of SAEs or Adverse Events Leading to Treatment
Discontinuation Up to 24 Weeks (Safety Set).</p>

<p class=MsoNormal><b>Critical Appraisal</b></p>

<p class=MsoNormal><i>Internal Validity</i></p>

<p class=MsoNormal>The risk of bias related to randomization and treatment
allocation concealment was rated as low for all studies, and, in general, the
patient characteristics and co-interventions appeared to be balanced between
groups at baseline. However, some differences were noted in the proportion of
female patients and patients with psoriasis at baseline in the COSMOS study and
in the proportion of patients with enthesitis at baseline in the DISCOVER-2
study. No issues were identified in the methods used to randomize patients and
conceal allocation. The trials were double blind and took steps to maintain
blinding of patients and investigators. In the DISCOVER studies, where the
frequency of dosing varied across treatment groups (i.e., every 4 weeks or
every 8 weeks), patients in the group receiving the study drug every 8 weeks
also received placebo injections at alternate visits to match the every-4-weeks
dosing schedule of the other guselkumab group. In all studies, an independent
joint assessor not otherwise involved in the conduct of the trial evaluated
patients’ joints for tenderness and swelling and the presence of enthesitis and
dactylitis. Central raters assessed radiographs in DISCOVER-2. Therefore, the
risk of bias in the measurement of the outcomes was low for all trials. In
general, the type and frequency of adverse events were similar across groups,
so there was low risk that adverse events led to substantial unblinding.</p>

<p class=MsoNormal>In all trials, the primary and other dichotomous end points
were analyzed using a CMH test that was stratified by randomization
stratification factors, with missing data imputed as nonresponders. The
DISCOVER trials used an adjusted ANCOVA model, while the COSMOS study used an
unadjusted MMRM model to analyze continuous outcomes. Missing data were imputed
under the missing-at-random assumption, which may not hold true; however, this
was not thought to be a major source of bias, given the low frequency of withdrawals
and the use of the composite estimand to conduct the analyses. The efficacy
analyses were based on the FAS (randomized and treated), which is not a true
intention-to-treat population; however, only 1 patient in the DISCOVER-2 study
was excluded. As a result, the analyses were appropriate for estimating the
effect of assignment to the intervention.</p>

<p class=MsoNormal>All efficacy analyses were based on the composite estimand,
where any patients who met the treatment failure criteria were considered
nonresponders for binary end points, or to have experienced no change from
baseline for continuous measures (e.g., HAQ-DI). Based on the composite
estimand, patients who discontinued the study or study drug, initiated or
increased the dose of cDMARDs or corticosteroids, initiated prohibited
medication, or, in the COSMOS study, met early escape criteria, were considered
treatment failures. This estimand, which considers any treatment failure end
points to be unfavourable outcomes, may be considered a more conservative
estimate of treatment effects, and was the estimand preferred by Health Canada.
Of note, the COSMOS study incorrectly assigned 20 patients to early escape even
though they had not met the escape criteria. As a result, 8 patients in the
placebo group (8.3%) were switched to guselkumab treatment at week 16, and 12
patients (6.3%) in the guselkumab group were analyzed as nonresponders in the
primary analysis. Although the sponsor conducted sensitivity analyses to
explore the impact of this error, these analyses cannot fully address the
potential bias.</p>

<p class=MsoNormal>The type I error rate was controlled for the primary and
selected secondary outcomes in all studies. Two different testing strategies
were used in the DISCOVER trials to meet US and other regulators’ requirements.
The Health Canada reviewer’s report indicated that the US-based strategy was
preferred.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>40</sup></a>&nbsp;Several
outcomes of interest to this review were tested, and nominal P values reported
(e.g., MDA, ACR 70, PASI response, resolution of enthesitis and dactylitis,
FACIT-Fatigue); however, any results with a P of less than 0.05 should be
interpreted with caution, considering the potentially inflated type I error
rate. Although the subgroup analyses were pre-specified, there is no evidence
that the studies were powered to detect subgroup differences, and the 95% CIs
for some subgroups were imprecise.</p>

<p class=MsoNormal>Of note, skin-related end points — as well as enthesitis,
dactylitis, and axial disease outcome measures — were tested in subgroups of
patients affected with these conditions at baseline. Randomization was not
stratified for the presence of these conditions; thus, the interpretation of
the results for these outcomes should consider the possibility of imbalances in
baseline demographic and disease characteristics between treatment groups in
these subpopulations. According to the expert consulted by CADTH, the DAS 28 is
not relevant for PsA because it assesses only 28 joints and excludes the lower
extremities (which may be important in PsA).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>48</sup></a>&nbsp;Moreover,
CADTH found limited data on the validity — and no data on the reliability and
responsiveness — of the DAS 28 in patients with PsA. Thus, although this end
point was a major secondary outcome in the DISCOVER trials, it should be
interpreted with caution. Based on CADTH’s review, there was also limited
evidence to support the validity or reliability of the BASDAI and the
enthesitis and dactylitis scales used in the clinical trials. In addition, the
MID for the change in vdH-S scores was unknown.</p>

<p class=MsoNormal>Although the trials were 48 weeks to 100 weeks in duration,
the comparative period was limited to 24 weeks for this chronic condition. For
outcomes such as radiologic changes, this duration of treatment may have been
insufficient to detect the impact of guselkumab every 8 weeks. Moreover, none
of the trials included an active control group (other than the group receiving
guselkumab every 4 weeks, which is not a Health Canada–approved dosage); thus,
direct evidence comparing guselkumab every 8 weeks to other biologics available
in Canada is not available.</p>

<p class=MsoNormal>The primary outcome was ACR 20 response, but according to
the clinical expert, this represents the minimum level of improvement that may
be relevant to patients. In practice, the goal of therapy is to achieve higher
levels of response, such as MDA or low disease activity as measured by the
DAPSA. The COSMOS study included ACR 50 in its statistical testing procedures
to control the type I error rate, but according to the US-based procedure in
the DISCOVER trials, ACR 50 and ACR 70 were not controlled for multiple
testing. The MDA end point was not controlled for multiple testing in any of
the trials, which limits the ability to draw statistical inference from these
data.</p>

<p class=MsoNormal><i>External Validity</i></p>

<p class=MsoNormal>The trials enrolled adults who, on average, were in their
mid to late forties and predominantly White. There were a roughly equal number
of male and female patients enrolled. Although patients with only 3 or 5 tender
or swollen joints could enrol, the mean number of tender joints was about 20
and the mean number of swollen joints was about 11. The mean PASI score was
generally less than 10, which the expert stated was consistent with scores seen
in rheumatology clinics, given that most patients had received DMARDs (which
may help to control psoriasis). Approximately 8% of patients in the trials had
not previously received a cDMARD before being enrolled. Of the patients
screened, 13%, 36%, and 39% were excluded. However, based on reporting in the
CSRs, there was limited information about the characteristics of these patients
and the reasons for their screening failures. Most of the trials were conducted
in Europe, with some sites in Asia, the US, Australia, and Israel. Only the
DISCOVER-1 study included sites in Canada, which enrolled 15 patients (4%).
Based on the inclusion and exclusion criteria and the characteristics of
patients, the clinical expert did not identify any substantial limits to the
generalizability of the results of the trials.</p>

<p class=MsoNormal>The guselkumab-every-8-weeks dosing regime used in the
trials was consistent with the Health Canada–recommended dose, and the clinical
expert stated that concomitant utilization of cDMARDs was similar to what may
be expected in practice. However, the clinical expert also noted that the use
of oral corticosteroids in the DISCOVER trials (14% to 20%) was higher than
would be expected in Canada, where chronic corticosteroid use is generally
avoided. The trials excluded patients who had previously been treated with
biologics other than TNF inhibitors; thus, the efficacy in patients with
intolerance or inadequate response to other biologics is not known.</p>

<p class=MsoNormal>The trials assessed several of the outcomes that patients
report as important. However, not all were part of the statistical testing
strategy; as a result, the ability to draw conclusions from these data may be
limited. The 24-week duration of the comparative part of the trials may be
considered short, given that PsA is a chronic condition. Moreover, the
comparator used in the trials (i.e., placebo plus cDMARD) may not reflect
current practice, given that most patients who show an inadequate response cDMARDs
or bDMARDs DMARDs would be offered biologic therapy.</p>

<p class=MsoNormal><b>Indirect Evidence</b></p>

<p class=MsoNormal><b>Objectives and Methods for the Summary of Indirect
Evidence</b></p>

<p class=MsoNormal>A review of indirect evidence was required because none of
the clinical trials included in the systematic review included an active
control group (other than guselkumab every 4 weeks, which is not a Health
Canada–approved dosage). In addition, an appraisal of the ITC submitted by the
sponsor was necessary, given that these data were used to inform the
pharmacoeconomic model.</p>

<p class=MsoNormal>A focused literature search for ITCs dealing with PsA was
run in MEDLINE All (1946–) on May 30, 2022. No limits were applied to the
search. The results were reviewed by&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/">1</a>&nbsp;researcher to
select any ITCs that met the patient, intervention, comparator, and outcome
criteria listed in the review protocol (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t06/?report=objectonly"
target=object>Table 6</a>).</p>

<p class=MsoNormal>Nine potentially relevant ITCs<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>60</sup></a><sup>-</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>67</sup></a>&nbsp;were
identified in the literature search. However, 4 of these trials did not include
guselkumab, and were excluded.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>60</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>63</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>64</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>67</sup></a></p>

<p class=MsoNormal>Another 4 ITCs were not summarized in this report. In 1 ITC,
the only guselkumab data available was from a phase II trial; thus, it was
missing key evidence to inform the indirect comparison.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>61</sup></a>&nbsp;Another
ITC was an earlier version of the sponsor’s ITC and was considered out of date,<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>62</sup></a>&nbsp;and
a third ITC had a limited scope (comparing guselkumab to secukinumab only) and
was missing many comparators that were relevant to the Canadian context.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>65</sup></a>&nbsp;The
ITC by Torres et al. (2020)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>66</sup></a>&nbsp;included
guselkumab PsA trials in the systematic review, but these studies were excluded
from the NMA. Thus, Torres et al. (2020) was excluded because it did not
provide any additional data to support the reimbursement decision.</p>

<p class=MsoNormal>This section provides a critical appraisal of the sponsor’s
ITC<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>20</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>68</sup></a>&nbsp;as
well as a brief summary of the published ITC by McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;that
was identified in the literature search conducted by CADTH.</p>

<p class=MsoNormal><b>Description of ITC</b></p>

<p class=MsoNormal>The sponsor conducted an NMA of RCTs that assessed the
comparative efficacy and safety of guselkumab and other bDMARDs for the
short-term treatment of acute PsA. The NMA by McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;evaluated
the efficacy and safety of licensed and unlicensed bDMARDs for patients with
active PsA.</p>

<p class=MsoNormal><b>Methods of the Sponsor-Submitted ITC</b></p>

<p class=MsoNormal><i>Objectives</i></p>

<p class=MsoNormal>The objective of the sponsor-submitted ITC was to assess the
relative efficacy and safety of guselkumab compared with other biologics after
12 weeks to 24 weeks of therapy in patients with active PsA.</p>

<p class=MsoNormal><i>Study Selection Methods</i></p>

<p class=MsoNormal>The ITC was based on a systematic literature review of RCTs
that evaluated biologic and non-biologic DMARDs in adults with active PsA. The
review was based on a protocol that was drafted a priori and published to
PROSPERO in April 2020. The systematic review was first conducted in 2018, was
updated in 2020 and 2021, and was published in 2021.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>62</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>68</sup></a>&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t24/?report=objectonly"
target=object>Table 24</a>&nbsp;outlines the patients, interventions,
comparators, outcomes, and study designs included in the current version of the
sponsor’s systematic review. The review included phase II and III RCTs in
adults with active PsA who were treated with 1 or more DMARD or placebo for at
least 12 weeks. The review included a broad scope of treatments for PsA;
however, the authors made no statement with regards to doses of treatments that
would be accepted in the systematic review. No limits were placed on the
outcomes of interest to the review.</p>

<p class=MsoNormal>The systematic review was based on a peer-reviewed
literature search of the Embase, MEDLINE, and Cochrane Central databases and a
search of ClinicalTrials.gov. Studies were selected based on the criteria
listed in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t24/?report=objectonly"
target=object>Table 24</a>, with screening conducted by 2 reviewers
independently. Data were extracted by 1 reviewer and verified by a second.
Trials were assessed for study quality by a single reviewer using the National
Institute for Health and Care Excellence clinical effectiveness quality
assessment checklist. Although not explicitly stated, it appears that no trials
were excluded based on study quality.</p>

<p class=MsoNormal>Additional criteria were applied to determine which studies
were included in the quantitative analysis; however, no rationale was provided
for these criteria, and it is unclear if these were determined a priori. Based
on the description of the excluded studies, the ITC was limited to phase III
RCTs of a biologic (including small-molecule inhibitors apremilast,
tofacitinib, and upadacitinib) at dosages approved by the FDA or European
Medicines Agency. It is not clear how outcomes were selected for analysis in
the ITC.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t24/?report=objectonly"
title="&quot;Table 24&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 85"
src="psoriasis%20test_files/image026.png"
alt="Table 24. Study Selection Criteria and Methods for Sponsor-Submitted ITC."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t24/?report=objectonly"
target=object>Table 24</a></b></p>

<p class=MsoNormal>Study Selection Criteria and Methods for Sponsor-Submitted
ITC.</p>

<p class=MsoNormal><i>ITC Analysis Methods</i></p>

<p class=MsoNormal>The authors conducted an NMA using Bayesian methods (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t25/?report=objectonly"
target=object>Table 25</a>). The authors stated that a random-effects model was
selected a priori as the primary analysis method due to the known clinical
heterogeneity in PsA trials. Unadjusted fixed-effects models would also be run,
but would be accepted only if there were compelling reasons, such as the
between-trial heterogeneity prior not being updated by the data, leading to
conclusions (based on overlap of the 95% CrIs) that are contrary to primary
trial results. Further, a baseline risk-adjusted model (adjusting for placebo response,
described by the authors as a proxy for measured and unmeasured patient
characteristics) was planned to adjust for known heterogeneity in patient and
study characteristics, as has been done in other NMAs for PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>69</sup></a>&nbsp;Model
fit was assessed based on 4 factors: estimated regression coefficient (beta)
and a 95% CrI that excludes the null for a meta-regression covariate; lower
between-study SD compared with the unadjusted model; lower deviance information
criterion (by &#8805;&nbsp;5 points) compared with the unadjusted model; and
posterior mean of the residual deviance approximately equal to the number of
treatment arms. The first 2 factors were given more weight when determining if
the baseline risk-adjusted model fit best.</p>

<p class=MsoNormal>An inconsistency model was used to identify loops with
inconsistency, although the authors stated that this method had low power to
detect a difference. Of note, the network had few closed loops; only 5 studies
had an active comparator. The authors stated that their interpretation of the
reliability of estimates was based on their quality assessment of the
transitivity assumption and evaluation of the estimated between-trial
heterogeneity.</p>

<p class=MsoNormal>The NMA included trials with outcomes assessed at 12 weeks
to 24 weeks. Although not explicitly stated, it appears that each dosage
regimen was a separate node. Outcomes assessed include ACR response, PASI
response, change from baseline in HAQ-DI,&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
Response Criteria response, SF-36 PCS and MCS, change from baseline in vdH-S,
adverse events, and serious adverse events. No rationale was provided for the
selection of these outcome measures.</p>

<p class=MsoNormal>The primary analysis included a mixed population of
biologic-naive and biologic-experienced patients. Subgroup analyses were run,
restricted to patients who were biologic-naive and biologic-experienced. For
the overall and biologic-experienced populations, sensitivity analyses were run
to test the impact of the early escape errors in the COSMOS study. The primary
analysis used the main findings from COSMOS, with a secondary analysis that
accounted for errors in early escape.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t25/?report=objectonly"
title="&quot;Table 25&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 84"
src="psoriasis%20test_files/image027.png" alt="Table 25. ITC Analysis Methods."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t25/?report=objectonly"
target=object>Table 25</a></b></p>

<p class=MsoNormal>ITC Analysis Methods.</p>

<p class=MsoNormal><b>Results of Sponsor-Submitted ITC</b></p>

<p class=MsoNormal><i>Summary of Included Studies</i></p>

<p class=MsoNormal>The systematic review included 169 citations of 80 RCTs. Of
these, 46 RCTs were excluded from the ITC because the trials included a
treatment or dose that was not approved by the European Medicines Agency or FDA
(17 studies), included only 1 relevant treatment (1 study), did not include a
biologic (21 studies), or were a phase II study (8 studies). A total of 34 RCTs
published between 2004 and 2021 were included in the ITCs.</p>

<p class=MsoNormal>Fourteen bDMARDs were included in the NMA: abatacept,
adalimumab, apremilast; certolizumab pegol, etanercept, golimumab, guselkumab,
infliximab, ixekizumab, risankizumab, secukinumab, tofacitinib, upadacitinib,
and ustekinumab. Most studies included a placebo group (32 trials). Of the 16
studies that compared active treatments, most included 2 dosing regimens of the
same drug. Four trials compared 2 different active treatments. The sample size
of the studies ranged from 100 patients to 1,281 patients.</p>

<p class=MsoNormal>The authors of the ITC acknowledged that there was
heterogeneity across studies and provided data tables describing the patient
and study characteristics of the included trials. The enrolment criteria of all
studies specified adults (&#8805;&nbsp;18 years) with active PsA; however, the
definition of active PsA varied across trials. Most trials required patients to
have at least 3 tender or swollen joints and a history or presence of plaque
psoriasis at enrolment. The mean age of patients enrolled ranged from 45.7 years
to 53.6 years. In terms of gender and race, 41.9% to 61% of patients enrolled
were male, and 76.5% to 99.7% were White (not reported in 2 studies). The mean
duration of PsA ranged from 3.1 years to 13.4 years across the studies. At
baseline, the mean number of swollen and tender joints ranged from 6.1 to 18.3
and 14 to 27.3, respectively. The proportion of patients with psoriasis
affecting more than 3% of their BSA ranged from 42% to 100% (not available in 6
studies). At baseline, the mean PASI score ranged from 5.9 to 12.2 (not
reported in 9 studies).</p>

<p class=MsoNormal>Eighteen trials involved patients who were biologic-naive, 4
trials involved patients who were biologic-experienced, and 12 trials involved
a mixed population. In the mixed-population studies, 14% to 61% of patients had
prior experience with a biologic treatment. Where reported, 21% to 100% of
patients had previously received cDMARDs (not reported in 16 studies). In most
studies, patients were receiving methotrexate at baseline (38% to 83% of those
enrolled). No information was provided about other co-interventions received
during the trials.</p>

<p class=MsoNormal>The primary time point in 9 trials was 12 weeks. Ten trials
had time points of 14 weeks to 16 weeks, and 15 trials lasted 24 weeks. In
general, the trials of TNF inhibitors, JAK inhibitors, and apremilast were 16
weeks or shorter, whereas the studies of abatacept and the IL-17, IL-12 to 23,
and IL-23 inhibitors were 24 weeks in duration. The exceptions were adalimumab
and secukinumab — for which there were data from both shorter- and
longer-duration trials — and etanercept, for which there were data from only a
24-week trial. Twelve of the 16 24-week studies (75%) had an early escape route
available before the primary efficacy end point, which is a potential source of
confounding. There were no details provided on how patients who received escape
therapy were handled in each study.</p>

<p class=MsoNormal>To explore clinical heterogeneity within and across the
studies, bar plots of the distribution of placebo responses and scatterplots of
the relationships between placebo response and the treatment effect from each
study were examined by the authors of the ITC (data not available). The authors
stated that the placebo response varied across trials and tended to be lower
for stricter ACR categories. Across the trials, the ACR 20 response rate in the
placebo groups ranged from 9% to 33% (median&nbsp;= 20%; N&nbsp;= 32). The
authors also noted that the trials evaluating guselkumab tended to have a
higher-than-average placebo response (i.e., ACR 20&nbsp;= 20% to 33%). The
authors stated that a strong, negative association between treatment effect and
placebo response was evident for all ACR response levels, with studies with
larger placebo responses appearing to have smaller treatment effects. The
authors of the ITC stated that failure to adjust for baseline risk could result
in biased estimates of comparative efficacy. A summary of the CADTH assessment
of clinical heterogeneity is provided in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t26/?report=objectonly"
target=object>Table 26</a>.</p>

<p class=MsoNormal>The authors of the ITC rated most of the included studies as
having a low overall risk of bias; however, 53% were rated as having an unclear
risk of bias, and 18% were rated as having a high risk of bias in at least 1
domain. Eight of 34 studies (24%) had unclear risk of bias related to
randomization and/or allocation concealment. Blinding of patients, care
providers, and/or outcome assessors was unclear in 6 studies (18%); and study
participants were unblinded in 1 study (3%). The authors of the ITC assessed
that the groups were balanced at the start of all studies, and that only 1
study had an unclear risk of bias related to imbalances in dropouts. Seventeen
studies (50%) had an unclear risk of bias and 1 study (3%) had a high risk of
bias related to the methods used to account for missing data. Three studies
(9%) had a high risk of reporting bias.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t26/?report=objectonly"
title="&quot;Table 26&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 83"
src="psoriasis%20test_files/image028.png"
alt="Table 26. Assessment of Homogeneity for Sponsor-Submitted ITC."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t26/?report=objectonly"
target=object>Table 26</a></b></p>

<p class=MsoNormal>Assessment of Homogeneity for Sponsor-Submitted ITC.</p>

<p class=MsoNormal><i>Results</i></p>

<p class=MsoNormal><i>ACR Response</i></p>

<p class=MsoNormal>The evidence network for ACR response in the overall PsA
population (biologic-naive or experienced) is shown in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig08/?report=objectonly"
target=object>Figure 8</a>. All 34 studies reported data for ACR 20; 33 studies
reported data for ACR 50; and 31 studies reported data for ACR 70 (number of
patients not reported). Based on the multinomial model used in this analysis,
the conclusions for ACR 50 and ACR 70 are the same as for ACR 20.</p>

<p class=MsoNormal>For the overall PsA population, the results of the baseline
risk-adjusted random-effects model suggest that patients who received
guselkumab every 8 weeks may || |||| |||||| || ||||||| || ||| || |||||||| ||||
||||| ||| |||||||| apremilast, abatacept, or placebo, given that the 95% CrI
for the pairwise comparisons excluded the null (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t27/?report=objectonly"
target=object>Table 27</a>). The ACR 20 results |||||||| ||||||||||| |||||||||
||| ||||||||||| ||| || |||||| |||||||||| |||. Comparisons between ||||||||||
||| ||| ||||| ||||||||| ||| ||| ||| |||| |||||||||| ||| |||| |||||| || ||||
|||||| ||| ||| ||| ||| ||||||||||| |||||| |||||||| ||| ||||||||||| ||
||||||||||| ||||||| |||||| ||||| ||||||||| ||| || |||||||||||| |||||||| |||
||||||| || |||| | ||||||||||.</p>

<p class=MsoNormal>In the analysis of biologic-naive patients (30
studies,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig09/?report=objectonly"
target=object>Figure 9</a>), the baseline risk-adjusted random-effects model
suggested patients who received guselkumab were |||| |||||| || ||||||| ||| ||
|||||||| |||| |||||||||| || ||||||| (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t28/?report=objectonly"
target=object>Table 28</a>). For other comparisons, the 95% CrI |||||||| |||
|||| |||||. In some cases, the 95% CrI was |||||||||| |||||||| ||| ||||||| ||
|||| | ||||||||||. The results in biologic-experienced patients (16
studies,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig10/?report=objectonly"
target=object>Figure 10</a>) |||||||| |||||||||| |||||| ||||||| ||||| || ||
|||||||||| |||||| ||||||| |||||| ||| ||| ||| ||| ||||| ||||||||||| ||||||||||
||| |||| ||||| ||| || ||| ||||| ||| ||| ||| ||| |||||||||| |||||||| ||| |||||||
|| |||| | |||||||||| (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t29/?report=objectonly"
target=object>Table 29</a>).</p>

<p class=MsoNormal><i>Change in HAQ-DI</i></p>

<p class=MsoNormal>The NMA of the change in HAQ-DI in the overall,
biologic-naive, and biologic-experienced populations were informed by data from
32 RCTs (unadjusted random-effects model), 21 RCTs (unadjusted random-effects
model), and 8 RCTs (unadjusted fixed-effects model), respectively. In all 3
populations, ||| |||||| || |||||| |||||||| |||||||||| |||||| |||||||| |||
||||||| |||||||| ||| ||||| |||| ||||| ||||||||||| |||||||| ||| ||||| |||||||||
|||| | |||| ||| |||| |||||||| ||| ||||||| || |||| | |||||||||| (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t27/?report=objectonly"
target=object>Table 27</a>,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t28/?report=objectonly"
target=object>Table 28</a>,&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t29/?report=objectonly"
target=object>Table 29</a>). ||| ||||||| |||||||| ||||||||| || ||||||
|||||||||| || ||| ||||||| ||| |||||||||||||| |||||||||||| ||| ||||||||
|||||||||| || || ||||| |||||| |||||| |||||||||| || ||| ||||||| ||||||||||.</p>

<p class=MsoNormal><i>PASI Response</i></p>

<p class=MsoNormal>Thirty RCTs provided PASI response data to inform the
ordinal baseline-adjusted random-effects Bayesian NMA. Based on this model, the
results of the PASI 90 response are the same for other PASI thresholds. |||
||||||| |||||||| |||||||||| |||||| ||||||||||| ||| ||| ||| ||||| ||||||||||
||||||| |||||||||||| ||| ||||||||||| |||||||||| |||||||||| ||| ||||||| (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t27/?report=objectonly"
target=object>Table 27</a>). ||| ||||||| |||||||| ||| ||||| |||||||||||
|||||||| ||| ||||| ||| ||| ||| ||| ||| ||||||||| |||||||||| |||||||| |||
||||||| || |||| | ||||||||||| ||| ||| |||||||| |||| ||||||| ||| |||
|||||||||||||| |||||||| || | || |||||||| (<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t28/?report=objectonly"
target=object>Table 28</a>).</p>

<p class=MsoNormal>|| ||| |||||||| || ||||||| || |||||||||||||||||||| ||||||||
|| | || ||||||||| ||| ||||||| |||||||| |||||||||| |||||| |||||||||||| |||||||||
||| ||||||| |||||| |||| ||| ||||||| ||| ||| ||||| ||||||||||| |||| ||||||||||
|||||||| ||| ||||||| || |||| | |||||||||||</p>

<p class=MsoNormal><i>Changes in SF-36 PCS and MCS</i></p>

<p class=MsoNormal>For the overall PsA population, ||| ||||||| ||||||||
|||||||||| ||| ||||||||| || |||||| |||||||||| ||| ||| |||||| || ||||| ||| |||
|||||||| ||| |||||||| |||||||||| ||| |||||||||| |||||| |||||||||| ||| |||
|||||| || ||||| ||| ||| ||||||||| |||| ||| ||||| |||||||| ||||||||||| |||||||||
||| |||| |||| |||||||| ||| |||| |||||| || |||||||||| |||||| ||||||| |||||||.
The findings were similar for the biologic-naive subgroup (MCS&nbsp;= 13
studies and PCS&nbsp;= 18 studies; unadjusted random-effects models). The NMAs
in the biologic-experienced population were conducted using unadjusted
fixed-effects models that included 6 trials for the MCS and 7 trials for the
PCS. ||| |||| ||||||||| ||| ||||||||||| ||||||| |||||||||| ||| ||||| |||||||||
|||||||| ||| |||| |||| |||||||| ||| ||||| |||| || ||||| |||| |||||||||.</p>

<p class=MsoNormal><i>Change in VdH-S Score</i></p>

<p class=MsoNormal>|| ||| ||||||| ||||||||||| ||| |||||||||| ||||| |||||| |||
||| |||||||| |||||||| |||||||||| ||| ||||||||| || |||||| |||||||||| ||| |||
|||||| |||| |||||||| || ||| ||||| |||||| ||| ||||| ||||||||||| |||||||| ||| |||
|||| |||||||| ||| ||||| ||| |||||||| |||| ||||||| ||| ||| ||||||||||||||
||||||||| |||| ||||||| ||| ||| |||||||| || ||| ||||||||||||||||||||
|||||||||||||.</p>

<p class=MsoNormal><i>Serious Adverse Events</i></p>

<p class=MsoNormal>The NMA of serious adverse events in the overall population
included data from 32 RCTs and was analyzed using a baseline risk-adjusted,
random-effects model. ||| ||||||| ||||||| |||||||||| ||| |||| | ||||| |||| ||
||||||| ||||||| |||||| |||| |||||||||| ||| |||||||||||| ||||| |||| ||| |||||
||||||||||| ||||||| |||||||||| ||| ||||||| || ||||||||| |||||||| ||||||||| |||
|||| |||| |||||||||| ||| ||||| |||||||| ||| ||||||| || |||| ||||||||||| ||||||
|||| ||| ||||||||||| ||||||| |||||||||| ||| ||||||| || ||||||||| || ||| ||| ||
|||||||| ||| |||| |||||||||||||| || | || |||||||| ||||| ||| ||
|||||||||||||||||||| || | | |||||||| ||||| ||| |||||| ||| |||| |||| ||||
|||||||||| ||||| |||||| ||| ||||||| || |||| | |||||||||| |||| ||||| ||||.</p>

<p class=MsoNormal><i>Adverse Events</i></p>

<p class=MsoNormal>The NMA of adverse events was conducted using a baseline
risk-adjusted, random-effects model for the overall population (32 studies) and
biologic-naive populations (17 studies). ||| ||||||| ||||||| |||| ||||||||||
||| |||| | ||||| |||| || |||||||||| ||||||| |||||| |||| ||||||||||| ||||||||||
|| ||||||||||| ||| ||||| ||||||||||| |||||| ||| |||| |||| |||||||| ||| |||||
||| || |||| ||||| |||| |||||||||| || ||| |||||||||||||| ||||||||||| |||
||||||||||| ||||||| |||||||||| ||| ||||||||| |||||||| ||| ||| |||| |||||||| |||
|||| ||| |||| |||||||||| ||| ||| || ||| |||||||||||||||||||| |||||||||| ||
|||||||| |||||||||| ||||| |||||| |||||| ||||||||| |||| ||||||||||| ||| |||| |
||||| |||| || ||||||| |||||| |||| |||||||||| ||| ||| |||||||||||| |||||
||||||||||| |||||||| ||| |||| |||| |||||||| ||| ||||| |||| |||| |||||||
||||||||| |||||||.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig08/?report=objectonly"
title="&quot;Figure 8&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=157 height=80 id="Picture 82"
src="psoriasis%20test_files/image029.gif"
alt="A predominantly star-shaped network with 24 different treatment nodes and placebo to link most trials."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig08/?report=objectonly"
target=object>Figure 8</a></b></p>

<p class=MsoNormal>Evidence Network for ACR Response in the Overall PsA
Population.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t27/?report=objectonly"
title="&quot;Table 27&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 81"
src="psoriasis%20test_files/image030.png"
alt="Table 27. Key NMA Results for the Overall PsA Population — Guselkumab Every 8 Weeks Versus Biologics."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t27/?report=objectonly"
target=object>Table 27</a></b></p>

<p class=MsoNormal>Key NMA Results for the Overall PsA Population — Guselkumab
Every 8 Weeks Versus Biologics.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig09/?report=objectonly"
title="&quot;Figure 9&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=153 height=80 id="Picture 80"
src="psoriasis%20test_files/image031.gif"
alt="A predominantly star-shaped network with 23 different treatment nodes using a placebo to link most trials."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig09/?report=objectonly"
target=object>Figure 9</a></b></p>

<p class=MsoNormal>Evidence Network for ACR Response in Biologic-Naive PsA
Population.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t28/?report=objectonly"
title="&quot;Table 28&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 79"
src="psoriasis%20test_files/image032.png"
alt="Table 28. Key NMA Results for the Biologic-Naive Population — Guselkumab Every 8 Weeks Versus Biologics."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t28/?report=objectonly"
target=object>Table 28</a></b></p>

<p class=MsoNormal>Key NMA Results for the Biologic-Naive Population —
Guselkumab Every 8 Weeks Versus Biologics.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig10/?report=objectonly"
title="&quot;Figure 10&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=142 height=80 id="Picture 78"
src="psoriasis%20test_files/image033.gif"
alt="A predominantly star-shaped network with 16 different treatment nodes using placebo to link most trials."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig10/?report=objectonly"
target=object>Figure 10</a></b></p>

<p class=MsoNormal>Evidence Network for ACR Response in Biologic-Experienced
PsA Population.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t29/?report=objectonly"
title="&quot;Table 29&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 77"
src="psoriasis%20test_files/image034.png"
alt="Table 29. Key NMA Results for the Biologic-Experienced Population — Guselkumab Every 8 Weeks Versus Biologics."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t29/?report=objectonly"
target=object>Table 29</a></b></p>

<p class=MsoNormal>Key NMA Results for the Biologic-Experienced Population —
Guselkumab Every 8 Weeks Versus Biologics.</p>

<p class=MsoNormal><b>Critical Appraisal of Sponsor-Submitted ITC</b></p>

<p class=MsoNormal>The ITC was based on a systematic literature review that
used standard methods to conduct the literature search, screen articles, and
extract data. The protocol for the review was registered, and the inclusion
criteria were clearly defined. However, the risk of bias was assessed by a
single reviewer and not assessed by outcome — an approach that is not aligned
with the highest standards for evidence synthesis. Thus, there is uncertainty
regarding the methodological rigour of the trials. It is noteworthy that 46
studies that met the criteria for inclusion in the systematic review were
excluded from the NMA, which had a narrower scope than the systematic review.
The authors did not provide a rationale for the exclusion criteria applied to
the NMA, and it was unclear if the criteria were determined a priori. Further,
there was some uncertainty regarding which dosages of drugs were eligible for
inclusion, and it appears that some dosage regimens that are relevant to the
Canadian context were excluded from the NMA (e.g., etanercept 50 mg weekly).
According to the ITC authors’ ratings, the quality of the included studies was
generally good; however, it is unclear how the overall risk of bias was
assessed, given that 53% the studies were at unclear risk of bias and 18% were
at high risk of bias in at least 1 domain. Specifically, 24% of the studies had
an unclear risk of bias related to randomization or allocation concealment, 18%
had an risk of bias was categorized as unclear and 3% had a high risk of bias
related to blinding. Also of note, the report provided little information on
the extent of withdrawals and or on the imputation methods for missing data.</p>

<p class=MsoNormal>There is some uncertainty as to whether the transitivity
assumption has been met for the NMAs. There was heterogeneity across trials in
the distribution of sexes, the durations of PsA, the number of tender and
swollen joints, the proportions of patients with psoriasis affecting more than
3% of their BSA, and patients’ baseline PASI scores. For each study, there was
limited information about the co-interventions patients received, the extent of
withdrawals, or how patients with missing data were handled in the analyses.</p>

<p class=MsoNormal>The NMA pooled data from different time points ranging from
12 weeks to 24 weeks. According to the sponsor, this was done to align with the
decision problem and Canadian practice. McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;notes
that this is a significant source of heterogeneity, particularly for outcomes
that require a higher degree of improvement (e.g., PASI 100 versus PASI 75).
For the higher-response end points, the relative efficacy has been shown to
increase over time, and McInnes et al. (2022) state that pooling data reported
at different time points biases the results against drugs that are studied over
a shorter period.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;Moreover,
many of the longer-term studies allowed for early escape for nonresponders.
This may be another source of heterogeneity, given that it is unclear how these
patients were analyzed and whether the approach was consistent across trials.</p>

<p class=MsoNormal>The authors of the ITC used different methods in an attempt
to control for heterogeneity in the NMA. The authors used a baseline
risk-adjusted, random-effects model as the preferred model in most NMAs.
Adjusting for the variation in placebo response rates across trials is a
practice that has been endorsed by the National Institute for Health and Care
Excellence and others, given that the placebo rate and the relative effect
versus placebo may be related in psoriasis.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>71</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>72</sup></a>&nbsp;This
method assumes that study and patient characteristics that are effect modifiers
of the relative treatment effect are also prognostic factors of the outcome
with placebo.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>73</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>74</sup></a>&nbsp;The
use of a placebo response rate is an attempt to account for potential
variability in effect modifiers, but it is unclear if these effect modifiers
have the same level of effect on the active arms. Given that it is unclear to
what extent placebo response is an adequate proxy for specific characteristics
or effect modifiers, uncertainty remains in these analyses.</p>

<p class=MsoNormal>To minimize heterogeneity related to prior treatments,
subgroup analyses were conducted in patients who were biologic-naive and
biologic-experienced. Prior exposure to biologics has been identified as an
important effect modifier for psoriasis, and limiting networks to more
homogeneous subgroups is a strategy that has been used by others to reduce
heterogeneity.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>75</sup></a>&nbsp;In
this ITC, the subgroup analyses in the biologic-naive population were generally
consistent with the overall population in terms of direction of effect compared
with guselkumab, but the networks included a smaller number of trials, and data
were not available for all relevant comparators for each population. The
networks in the biologic-experienced population were sparse, with only 6 of 16
RCTs reporting data on serious adverse events. The lack of a robust evidence
network may contribute to uncertainty in the findings in this population. Among
the potential sources of heterogeneity, the ITC did not conduct any subgroup or
specific sensitivity analyses to explore the potential impact of differences in
the timing of outcome assessment, duration of disease, background therapies, or
year of study. Of these, the clinical expert consulted for this review
identified disease duration and prior biologic therapy as important potential
effect modifiers.</p>

<p class=MsoNormal>There was limited information available to assess whether
the consistency assumption was met, given that there were only 4 head-to-head
studies and few closed loops within the networks (no closed loops with
guselkumab). Although the authors of the NMA took steps to assess consistency,
these methods had low power to detect differences. Based on the model fit data
presented and the authors’ explanation of the criteria used to assess fit, it
appears the models selected for the primary analyses were appropriate.</p>

<p class=MsoNormal>ACR and PASI responses were analyzed using an ordinal model,
which assumed that the relative treatment effects were the same for each
response level. Thus, although data were reported separately for each response
level, the inferences for each comparison are the same across the ACR 20, ACR
50, and ACR 70 levels. It is not clear if this assumption of the model holds
true (i.e., relative treatment effects are consistent across response levels),
given that data were pooled for different time points. No sensitivity analyses
were run to examine the impacts of this assumption. There was greater
uncertainty in the PASI response results, with some comparisons showing wide
95% CrIs. In most of the PsA clinical trials, assessments of PASI end points
were based on a subgroup of patients with skin lesions at baseline. It is not
known if randomization was stratified by this factor or if groups were balanced
for potential confounders.</p>

<p class=MsoNormal>Regarding the NMA of the change in HAQ-DI, McInnes et al.
(2022)<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;stated
that the HAQ-DI may be affected by the presence of comorbidities and the
duration of PsA. Given the variability in the duration of PsA across the
trials, this could affect the findings of the ITC.</p>

<p class=MsoNormal>Across all networks, many comparisons showed imprecise 95%
CrIs that included the possibility of appreciable benefit and/or worse
outcomes, and no difference between guselkumab and other biologics.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>70</sup></a>&nbsp;Imprecision
was an issue for all outcomes for the biologic-experienced population in
particular, and for serious adverse events in all populations; this imprecision
limits the ability to draw conclusions from these data. With regards to
external validity, the comparators included in the model were relevant to the
Canadian context, although not all comparators were available in all NMAs. The
trials enrolled predominantly White patients; thus, the trials may not reflect
the racial distribution of the population in Canada with PsA. Due to the
availability of data, the NMAs assessed short-term treatment effects; thus, the
comparative evidence on longer-term safety and efficacy is unclear. Although
the NMA addressed outcomes of interest to patients, in many cases the
uncertainty in the results limits the ability to draw conclusions on the
comparative safety and efficacy of guselkumab.</p>

<p class=MsoNormal><b>Summary of Published ITC</b></p>

<p class=MsoNormal>The objective of the ITC by McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;was
to evaluate the safety and efficacy of bDMARDs licensed for psoriasis or PsA.
This report was funded by Leo Pharma A/S. The ITC was based on a systematic
literature review (last search August 2020) of English-language RCTs that
included licensed and unlicensed DMARDs for the treatment of active PsA
(abatacept, apremilast, adalimumab, bimekizumab, brodalumab, certolizumab
pegol, etanercept, filgotinib, golimumab, guselkumab, infliximab, ixekizumab,
netakimab, risankizumab, secukinumab, tildrakizumab, tofacitinib, upadacitinib,
and ustekinumab). The authors conducted a Bayesian NMA of ACR and PASI response
rates, resolution of enthesitis and dactylitis (measured at 12 weeks to 16
weeks or up to 26 weeks, if an early time point was not available), and discontinuation
due to adverse events (at study end point). ACR and PASI response were analyzed
using a multinomial probit model, and other outcomes were based on a binomial
likelihood with logit link. Both random and fixed effects, as well as
placebo-adjusted models, were analyzed for the overall population with PsA.
Subgroup analyses for biologic-naive and biologic-experienced patients were run
for ACR response only. Inconsistency between direct and indirect estimates was
assessed for closed loops in the network using the 2-stage Bucher method.</p>

<p class=MsoNormal>A total of 64 studies were included in the systematic
review, and 46 studies were included in the NMAs. The authors noted differences
across trials in the duration of PsA, percentage of female patients, and prior
exposure to biologic therapies or cDMARDs. Also, there was variation in the
timing of the end points, particularly PASI response, with approximately 40% of
studies reporting data at 24 weeks and 60% of studies reporting at week 12 to
week 16. Discontinuations due to adverse events were not reported consistently
across studies, with some reporting discontinuation of the study drug and
others reporting discontinuation from the trial.</p>

<p class=MsoNormal>Overall, the results of the ITC by McInnes et al.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;were
generally consistent with the sponsor-submitted ITC. The odds ratios of ACR 20
response for guselkumab every 8 weeks versus most comparators at week 12 to
week 16 showed 95% CrIs that overlapped the null and were imprecise, limiting
the ability to draw a conclusion. The ACR 20 results favoured guselkumab versus
ustekinumab 45 mg and apremilast 30 mg, but favoured infliximab versus
guselkumab. The results for the NMA of PASI 90 response favoured guselkumab
versus several comparators (ixekizumab, secukinumab, tildrakizumab,
ustekinumab, adalimumab, certolizumab pegol, etanercept, golimumab, abatacept,
apremilast, and tocilizumab). Guselkumab showed favourable resolution of
enthesitis or dactylitis versus apremilast, but not versus 9 other active
comparators with available data. No comparative results for guselkumab were
reported for discontinuation due to adverse events; however, the results versus
placebo showed wide CrIs (median odds ratio&nbsp;= 0.77; 95% CrI, 0.25 to
2.31).</p>

<p class=MsoNormal>The key limitation of the ITC was the heterogeneity in
patient and study characteristics across trials. The authors noted several
differences in patient demographics, disease, or treatment history. Also noted
were differences in outcome definitions (discontinuations) and in the timing of
PASI response and the resolution of enthesitis and dactylitis end points, which
could not be addressed in the analysis. Although a placebo-adjusted model was
run for some outcomes, it is unclear if these methods can adequately control
for heterogeneity. Also noteworthy was the uncertainty in the NMA results for
ACR 20, PASI response, and discontinuations — as shown in some comparisons with
wide 95% CrIs — which limits the ability to draw a conclusion. In this NMA,
there was limited ability to assess the consistency between direct and indirect
evidence, given that there were few closed loops (only 6 head-to-head studies),
and the statistical tests for inconsistency were generally underpowered.
Further, most of the contributing trials were judged to be at high or unclear
risk of bias in at least 1 domain, including 65% and 33% of trials with unclear
risk of bias related to allocation concealment and random sequence generation,
respectively. With respect to external validity, the NMA did not address
outcomes of interest to patients, such as HRQoL, disability, or safety.</p>

<p class=MsoNormal><b>Other Relevant Evidence</b></p>

<p class=MsoNormal>This section includes the uncontrolled extension period of
the phase III RCTs DISCOVER-1, DISCOVER-2, and COSMOS, which are summarized and
appraised. These provide an overview of the long-term (&gt;&nbsp;24 weeks)
efficacy and safety of guselkumab every 8 weeks among patients with active PsA.</p>

<p class=MsoNormal><b>Extension Phase of the Sponsor-Submitted Phase III
Studies</b></p>

<p class=MsoNormal><i>Description of Studies</i></p>

<p class=MsoNormal>The extension period for DISCOVER-1 was from week 24 to week
52, with a safety follow-up phase of 8 weeks after week 52. For DISCOVER-2, the
active treatment phase was from week 24 to week 100, with follow-up for
efficacy at week 52 and week 100 and a safety follow-up phase of 12 weeks after
week 100. For the COSMOS study, the extension period was from week 24 to week
48, with a safety follow-up phase of 8 weeks.</p>

<p class=MsoNormal>In all 3 trials, during the extension period, groups of
patients who had been randomized to receive guselkumab 100 mg every 8 weeks or
every 4 weeks continued on the same regimen, whereas those randomized to
placebo switched to guselkumab 100 mg every 8 weeks or every 4 weeks. Data from
the guselkumab every-4-weeks groups in the DISCOVER-1 and DISCOVER-2 studies
(including patients who crossed over from placebo to guselkumab every 4 weeks
at 24 weeks) have not been summarized in this section because this dose is not
consistent with the Health Canada–recommended dose and dose adjustment, as
mentioned earlier in the report. Results for the patients in the placebo group
of the COSMOS trial who crossed over to guselkumab 100 mg every 8 weeks at 24
weeks have been provided as supporting information (hereafter referred to as
the placebo crossover group).</p>

<p class=MsoNormal><i>Statistical Analysis</i></p>

<p class=MsoNormal>For the extension periods in the DISCOVER-1, DISCOVER-2, and
COSMOS studies, no hypothesis testing of treatment differences was conducted.
Descriptive statistics were used to summarize most efficacy data. Analyses of
end points were conducted according to randomized treatment groups and based on
observed data.</p>

<p class=MsoNormal><i>Results</i></p>

<p class=MsoNormal><i>Patient Disposition</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t30/?report=objectonly"
target=object>Table 30</a>&nbsp;describes the patient disposition for the
extension period. For DISCOVER-1 (week 52), 13 patients (10%) discontinued from
the study early, whereas 13 patients (5%) and 27 patients (11%) discontinued
the study early in DISCOVER-2 (week 52) and DISCOVER-2 (week 100),
respectively. Moreover, in DISCOVER-1 (week 52), DISCOVER-2 (week 52), and
DISCOVER-2 (week 100), 11 patients (9%), 14 patients (6%) and 25 patients (10%)
discontinued the study drug before end of the study, respectively. The rates of
discontinuation of the study drug were higher for DISCOVER-1 and for DISCOVER-2
during the active treatment period compared to the randomized phase.</p>

<p class=MsoNormal>In the COSMOS study, the rates of discontinuation of the
study drug were 12% in the guselkumab-every-8-weeks group and 14% in the
placebo group before week 44. However, the rates for early discontinuation of
the study drugs were lower during the randomized phase, with 15 patients (8%)
and 10 patients (10%) for the guselkumab-every-8-weeks and placebo groups,
respectively.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t30/?report=objectonly"
title="&quot;Table 30&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 76"
src="psoriasis%20test_files/image035.png"
alt="Table 30. Patient Disposition for the Extension Period."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t30/?report=objectonly"
target=object>Table 30</a></b></p>

<p class=MsoNormal>Patient Disposition for the Extension Period.</p>

<p class=MsoNormal><i>Efficacy</i></p>

<p class=MsoNormal><i>Clinical Response in PsA Symptoms</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t31/?report=objectonly"
target=object>Table 31</a>&nbsp;describes ACR and MDA responses for the active
treatment period. In the DISCOVER-1 study, 67.9%, 43.4%, and 28.9% of patients
achieved an ACR 20, ACR 50, and ACR 70 responses, respectively, at week 52. In
the DISCOVER-2 study, 79.1%, 51.3%, and 29.5% of patients achieved ACR 20, ACR
50, and ACR 70 responses, respectively, at week 52. At week 100, the
corresponding values were 82.1%, 60.7%, and 39.3%.</p>

<p class=MsoNormal>For COSMOS, 69.8%, 47.1%, and 27.9% of patients achieved ACR
20, ACR 50, and ACR 70 responses, respectively, at week 48.</p>

<p class=MsoNormal>Although differences were not tested statistically, in all
cases, the rate of response appeared to increase numerically with longer
follow-ups. The proportions of patients who maintained ACR 20, ACR 50, and ACR
70 responses at week 52 were 88.5%, 83.8%, and 80.0%, respectively, in
DISCOVER-1, and were 91.7%, 87.2%, and 82.6%, respectively, in DISCOVER-2. The
proportions of patients who maintained ACR 20, ACR 50, and ACR 70 responses at
week 100 were 90.4%, 81.9%, and 80.9% in DISCOVER-2. The proportions of patients
who maintained ACR 20, ACR 50, and ACR 70 responses at week 48 were 85.6%,
85.4%, and 81.3% in COSMOS.</p>

<p class=MsoNormal>The proportions of patients with an MDA response at week 24
were 23.6% in DISCOVER-1, 26.5% in DISCOVER-2, and 17.4% in COSMOS. At 52
weeks, the proportions of patients with MDA responses were 33.9% in DISCOVER-1
and 32.9% in DISCOVER-2. At 100 weeks, 44.6% of patients had an MDA response in
DISCOVER-2. At 48 weeks, 32.5% of patients had an MDA response in COSMOS.
Although the differences were not tested statistically, in all cases, the rate
of response appeared to increase numerically with longer follow-up.</p>

<p class=MsoNormal>For the COSMOS study, the proportions of patients with MDA
response were 32.5% in the guselkumab-every-8-weeks group and 29.8% in the
placebo group at week 48. The proportions of patients who maintained MDA
response at week 52 were 75.9% and 82.5% in DISCOVER-1 and DISCOVER-2,
respectively. The proportions of patients who maintained MDA response at week
100 were 78.3% (based on patients achieving MDA response at week 24) and 85.3%
(based on patients achieving MDA response at week 52) for DISCOVER-2.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t31/?report=objectonly"
title="&quot;Table 31&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 75"
src="psoriasis%20test_files/image036.png"
alt="Table 31. ACR and MDA Response for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t31/?report=objectonly"
target=object>Table 31</a></b></p>

<p class=MsoNormal>ACR and MDA Response for the Extension Period (FAS).</p>

<p class=MsoNormal><i>Function or disability</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t32/?report=objectonly"
target=object>Table 32</a>&nbsp;describes the changes from baseline in HAQ-DI
scores for the active treatment period. The mean changes in HAQ-DI at week 24
were –0.34 (SD&nbsp;= 0.57), –0.40 (SD&nbsp;= 0.54), and –0.29 (SD&nbsp;= 0.55)
for DISCOVER–1, DISCOVER–2, and COSMOS, respectively. The mean changes from
baseline at 52 weeks were –0.44 (SD&nbsp;= 0.56) and –0.48 (SD&nbsp;= 0.56) for
DISCOVER–1 and DISCOVER–2, respectively. The mean changes from baseline at week
48 and week 100 were –0.47 (SD&nbsp;= 0.60) and –0.59 (SD&nbsp;= 0.58) for
COSMOS and DISCOVER-2, respectively.</p>

<p class=MsoNormal>The proportions of patients who achieved a clinically
meaningful HAQ-DI response (defined as a score greater than or equal to 0.35
improvement from baseline) were 53.2% at week 24 and 57.4% at week 52 for
DISCOVER-1 and 52.5% at week 24, 60.9% at week 52, and 70.7% at week 100 for
DISCOVER-2. For COSMOS, the proportions of patients achieving an improvement of
greater than or equal to 0.35 from baseline were 47.4% at week 24 and 62.3% at
week 48 for the guselkumab-every-8-weeks group, and 39.3% at week 24 and 48.7%
at week 48 for the placebo crossover group.</p>

<p class=MsoNormal>The proportions of patients who maintained an improvement of
greater than or equal to 0.35 from baseline in HAQ-DI score at week 52 were
84.9% and 92.0% in DISCOVER-1 and DISCOVER-2, respectively. The proportions of
patients who maintained an improvement of greater than or equal to 0.35 from
baseline in HAQ-DI score at week 100 were 88.7% (based on patients with HAQ-DI
response at week 24) and 90.4% (based on patients with HAQ-DI response at week
52) in DISCOVER-2.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t32/?report=objectonly"
title="&quot;Table 32&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 74"
src="psoriasis%20test_files/image037.png"
alt="Table 32. Change From Baseline in HAQ-DI Scores for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t32/?report=objectonly"
target=object>Table 32</a></b></p>

<p class=MsoNormal>Change From Baseline in HAQ-DI Scores for the Extension
Period (FAS).</p>

<p class=MsoNormal><i>Health-Related Quality of Life</i></p>

<p class=MsoNormal>The mean changes from baseline in SF-36 PCS and MCS scores
from week 24 through the long-term follow-up period are provided in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t33/?report=objectonly"
target=object>Table 33</a>. The mean changes from baseline in the SF-36 PCS for
week 24 were 6.51 (SD&nbsp;= 7.71), 7.84 (SD&nbsp;= 8.03), and 5.83 (SD&nbsp;=
7.17) for DISCOVER-1, DISCOVER-2, and COSMOS, respectively. The mean changes
from baseline at 52 weeks were 7.28 (SD&nbsp;= 8.07) and 9.51 (SD&nbsp;= 8.32)
for DISCOVER-1 and DISCOVER-2, respectively. The mean changes from baseline at
week 48 and week 100 were 8.44 (SD&nbsp;= 7.27) and 11.28 (SD&nbsp;= 9.28) for
COSMOS and DISCOVER-2, respectively.</p>

<p class=MsoNormal>The proportions of patients who achieved a clinically
meaningful SF-36 PCS score (&#8805;&nbsp;5-point improvement from baseline)
were 53.7% at week 24 and 53.5% at week 52 for DISCOVER-1; for DISCOVER-2, they
were 63.4% at week 24, 67.1% at week 52, and 70.1% at week 100. For COSMOS, the
proportions of patients achieving a greater than or equal to 5-point
improvement from baseline in SF-36 PCS were 46.0% at week 24 and 55.6% at week
48 for the group receiving guselkumab every 8 weeks, and 22.9% and 26.0% at
week 24 and week 48, respectively, for the placebo crossover group.</p>

<p class=MsoNormal>The proportions of patients who maintained a greater than or
equal to 5-point improvement in SF-36 PCS scores at week 52 were 74.1% and
81.8% in DISCOVER-1 and DISCOVER-2, respectively. The proportions of patients
who maintained a greater than or equal to 5-point improvement from baseline in
SF-36 PCS scores at week 100 were 82.0% (based on SF-36 responders at week 24)
and 85.4% (based on responders at week 52).</p>

<p class=MsoNormal>The mean changes from baseline in SF-36 MCS for week 24 were
3.03 (SD&nbsp;= 10.62), 4.45 (SD&nbsp;= 9.96), and 2.59 (SD&nbsp;= 10.18) for
DISCOVER-1, DISCOVER-2, and COSMOS, respectively. The mean changes from
baseline at 52 weeks were 5.14 (SD&nbsp;= 9.17) and 4.47 (SD&nbsp;= 9.78) for
DISCOVER-1 and DISCOVER-2, respectively. The mean changes from baseline at week
48 and week 100 were 4.98 (SD&nbsp;= 9.94) and 3.64 (SD&nbsp;= 10.95) for
COSMOS and DISCOVER-2, respectively. The change from baseline in the SF-36 MCS
was either maintained or increased numerically (i.e., was not tested
statistically) at the various time points evaluated in the 3 studies.</p>

<p class=MsoNormal>The proportions of patients who achieved a clinically
meaningful (&#8805;&nbsp;5-point improvement from baseline) SF-36 MCS score
were 39.0% at week 24 and 46.5% at week 52 for DISCOVER-1, and 40.3% at week
24, 44.9% at week 52, and 46.4% at week 100 for DISCOVER-2. For COSMOS, the
proportions of patients achieving a greater than or equal to 5-point
improvement from baseline in SF-36 MCS were 36.6% at week 24 and 42.7% at week
48 for the group receiving guselkumab every 8 weeks, and 30.1% and 45.9%, respectively,
at week 24 and week 48 for the placebo crossover group.</p>

<p class=MsoNormal>The proportions of patients who maintained a greater than or
equal to 5-point improvement in SF-36 MCS scores at week 52 were 82.2% and
82.3% in DISCOVER-1 and DISCOVER-2, respectively. The proportions of patients
who maintained a greater than or equal to 5-point improvement from baseline in
SF-36 MCS scores at week 100 were 79.1% (based on SF-36 responders at week 24)
and 77.2% (based on responders at week 52).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t33/?report=objectonly"
title="&quot;Table 33&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 73"
src="psoriasis%20test_files/image038.png"
alt="Table 33. Change From Baseline in SF-36 PCS and MCS for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t33/?report=objectonly"
target=object>Table 33</a></b></p>

<p class=MsoNormal>Change From Baseline in SF-36 PCS and MCS for the Extension
Period (FAS).</p>

<p class=MsoNormal><i>Psoriasis Skin Disease</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t34/?report=objectonly"
target=object>Table 34</a>&nbsp;shows patients’ IGA and PASI responses for the
active treatment period. In all trials, psoriasis skin disease outcome measures
were analyzed in the subgroup of patients who had psoriasis affecting greater
than or equal to 3% of their BSA and an IGA score of greater than or equal to 2
at baseline for the randomized phase. Although the difference was not tested
statistically, the proportions of patients who achieved an IGA response at week
52 were numerically higher than at week 24 in the DISCOVER-1 and DISCOVER-2
studies (58.0% versus 69.3%, and 72.1% versus 77.1%, respectively). For the
COSMOS study, the proportions of patients who achieved an IGA response at week
48 were 81.0% for the group receiving guselkumab every 8 weeks and 78.4% for
the placebo crossover group.</p>

<p class=MsoNormal>The proportions of patients who maintained their IGA
responses at week 52 were 81.8% and 85.4% in the DISCOVER-1 and DISCOVER-2
studies; at week 100 in the DISCOVER-2 study, these proportions were 88.2% and
89.1% at week 24 and week 52, respectively.</p>

<p class=MsoNormal>The proportions of patients who achieved PASI 100, PASI 90,
and PASI 75 responses at week 24 were 25.9%, 50.6%, and 76.5% in DISCOVER-1;
46.5%, 70.3%, and 80.8% in DISCOVER-2; and 41.1%, 65.1%, and 76.0% for COSMOS,
respectively. For DISCOVER-1 and DISCOVER-2, the proportions of patients who
achieved PASI 100, PASI 90, and PASI 75 responses at week 52 were 48%, 66.7%,
and 80.0%; and 54.7%, 77.1%, and 88.8%, respectively. For DISCOVER-2, the
proportions at week 100 were 57.3%, 75.0%, and 87.8% for PASI 100, PASI 90, and
PASI 75, respectively. For COSMOS, the proportions achieving PASI 100, PASI 90,
and PASI 75 responses at week 48 were 66.1%, 84.3%, and 93.4%, respectively,
for the group receiving guselkumab every 8 weeks, and 49.0%, 66.7%, and 88.2%,
respectively, for the placebo crossover group.</p>

<p class=MsoNormal>The proportions of patients who maintained PASI 100, PASI
90, and PASI 75 responses at week 52 were 80.0%, 84.6%, and 86.2% in
DISCOVER-1; and 75.9%, 88.3%, and 97.1% in DISCOVER-2, respectively. For
DISCOVER-2, the proportions of patients who maintained PASI 100, PASI 90, and
PASI 75 responses at week 100 were 76.3%, 86.2%, and 93.9% at week 24 and
86.7%, 88.2%, and 94.5% at week 52.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t34/?report=objectonly"
title="&quot;Table 34&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 72"
src="psoriasis%20test_files/image039.png"
alt="Table 34. IGA and PASI Response for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t34/?report=objectonly"
target=object>Table 34</a></b></p>

<p class=MsoNormal>IGA and PASI Response for the Extension Period (FAS).</p>

<p class=MsoNormal><i>Other Musculoskeletal Disease</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t35/?report=objectonly"
target=object>Table 35</a>&nbsp;presents enthesitis and dactylitis outcomes for
the extension period. The proportions of patients with resolution of enthesitis
and dactylitis at week 52 were 56.3% and 79.5% for DISCOVER-1; these were 65.5%
and 81.9% for DISCOVER-2, respectively. The proportions of patients with
resolution of enthesitis and dactylitis at week 100 were 77.5% and 91.1% for
DISCOVER-2, respectively. For COSMOS, the proportions of patients with
resolution of enthesitis and dactylitis at week 48 were 67.5% and 80.0%, respectively.</p>

<p class=MsoNormal>The mean reductions from baseline in enthesitis scores
(based on the LEI) and dactylitis scores (based on observed data) at week 52
were –1.8 (SD&nbsp;= 1.66) and –7.8 (SD&nbsp;= 10.55) for DISCOVER-1, and –1.9
(SD&nbsp;= 1.65) and –7.3 (SD&nbsp;= 9.74) for DISCOVER-2, respectively; at
week 100, these scores were –2.1 (SD&nbsp;= 1.65) and –7.9 (SD&nbsp;= 10.12)
for DISCOVER-2, respectively. For COSMOS, the mean reductions from baseline in
enthesitis scores and dactylitis scores were –2.0 (SD&nbsp;= 1.92) and –6.1
(SD&nbsp;= 6.41) for the group receiving guselkumab every 8 weeks, and –1.8
(SD&nbsp;= 1.70) and –7.3 (SD&nbsp;= 7.04) for the placebo crossover group,
respectively.</p>

<p class=MsoNormal>The proportions of patients who maintained resolution of
enthesitis (based on the LEI) and dactylitis at week 52 were 74.1% and 96.4% in
DISCOVER-1, and 88.4% and 92.2% in DISCOVER-2, respectively. For DISCOVER-2,
the proportions of patients who maintained resolution of enthesitis (based on
the LEI) and dactylitis at week 100 were 94.0% and 95.7%, respectively, at week
24, and 96.8% and 96.4%, respectively, at week 52.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t35/?report=objectonly"
title="&quot;Table 35&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 71"
src="psoriasis%20test_files/image040.png"
alt="Table 35. Enthesitis and Dactylitis Outcomes for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t35/?report=objectonly"
target=object>Table 35</a></b></p>

<p class=MsoNormal>Enthesitis and Dactylitis Outcomes for the Extension Period
(FAS).</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t36/?report=objectonly"
target=object>Table 36</a>&nbsp;shows the improvement in BASDAI scores for the
active treatment period. The changes in BASDAI scores were analyzed for the
subgroup of patients who had spondylitis and peripheral joint PsA with BASDAI
scores greater than 0 as their primary presentation at baseline. The
proportions of patients with a greater than or equal to 50% improvement at week
24 were |||||| ||||| ||| ||||| in DISCOVER-1, DISCOVER-2, and COSMOS,
respectively. The proportions at week 52 were ||||| ||| ||||| in DISCOVER-1 and
DISCOVER-2; the proportions at week 100 were ||||| in DISCOVER-2; and at week
48, the proportions were ||||| ||| ||||| for the group receiving guselkumab
every 8 weeks and the placebo crossover group in the COSMOS study,
respectively.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t36/?report=objectonly"
title="&quot;Table 36&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 70"
src="psoriasis%20test_files/image041.png"
alt="Table 36. Improvement in BASDAI Scores for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t36/?report=objectonly"
target=object>Table 36</a></b></p>

<p class=MsoNormal>Improvement in BASDAI Scores for the Extension Period (FAS).</p>

<p class=MsoNormal><i>PsA Symptoms</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t37/?report=objectonly"
target=object>Table 37</a>&nbsp;shows the changes in FACIT-Fatigue scores for
the active treatment period. The mean improvements from baseline in
FACIT-Fatigue scores at week 24 were 5.86 (SD&nbsp;= 10.39), 8.03 (SD&nbsp;=
9.89), and 5.9 (SD&nbsp;= 9.56) in DISCOVER-1, DISCOVER-2, and COSMOS,
respectively. The mean improvements from baseline in FACIT-Fatigue scores at
week 52 were 7.48 (SD&nbsp;= 9.63) and 8.93 (SD&nbsp;= 9.47) in DISCOVER-1 and
DISCOVER-2; at week 100, these were ||||| ||| | |||||| in DISCOVER-2; and at
week 48, these were ||| ||| | |||||| ||| ||| ||| | |||||| for the group
receiving guselkumab every 8 weeks and the placebo crossover group in the
COSMOS study, respectively.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t37/?report=objectonly"
title="&quot;Table 37&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 69"
src="psoriasis%20test_files/image042.png"
alt="Table 37. Change From Baseline in FACIT-Fatigue Score for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t37/?report=objectonly"
target=object>Table 37</a></b></p>

<p class=MsoNormal>Change From Baseline in FACIT-Fatigue Score for the
Extension Period (FAS).</p>

<p class=MsoNormal><i>Radiologic Outcomes</i></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t38/?report=objectonly"
target=object>Table 38</a>&nbsp;shows the modified vdH-S scores for PsA for the
DISCOVER-2 study at week 52 and week 100, based on the smallest detectable
change.</p>

<p class=MsoNormal>The proportion of patients with no progression (defined as a
change from baseline that was less than or equal to the smallest detectable
change for the modified vdH-S total score) was ||||| from week 24 to week 52,
and ||||| from week 52 to week 100 during the extension period. These results
were consistent with the results for the group receiving guselkumab every 8
weeks ||||||| during the randomized phase.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t38/?report=objectonly"
title="&quot;Table 38&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 68"
src="psoriasis%20test_files/image043.png"
alt="Table 38. Modified vdH-S Scores of PsA (Based on the Smallest Detectable Change) for the Extension Period (FAS)."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t38/?report=objectonly"
target=object>Table 38</a></b></p>

<p class=MsoNormal>Modified vdH-S Scores of PsA (Based on the Smallest
Detectable Change) for the Extension Period (FAS).</p>

<p class=MsoNormal><i>Harms</i></p>

<p class=MsoNormal>The summary of harms is presented in&nbsp;<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t39/?report=objectonly"
target=object>Table 39</a>. More than half of patients had at least 1 adverse
event through the end of the studies in DISCOVER-1 (69%) and DISCOVER-2 (63%
after 52 weeks and 72% after 100 weeks). In the COSMOS study, the proportions
of patients with at least 1 adverse event (cumulative) in the group receiving
guselkumab every 8 weeks and the placebo crossover group were 50% and 46%,
respectively. The most common events were nasopharyngitis, upper respiratory
tract infection, bronchitis, enthesopathy, arthralgia, increase of alanine aminotransferase
and aspartate aminotransferase, neutropenia, hypertension, and headache. No
deaths were reported during the active treatment period. The rates of patients
with at least 1 adverse or serious adverse event increased numerically through
the end of study versus week 24. No deaths were reported through the end of the
study. There were few serious adverse events in all trials through the end of
the extension period.</p>

<p class=MsoNormal>The rate of infections was highest (43%) in the DISCOVER-1
study (week 52), following 38% and 29% in the DISCOVER-2 study (week 100 and
week 52, respectively). In the COSMOS study, the rates of infection
(cumulative) were 22% and 14% for the group receiving guselkumab every 8 weeks
and the placebo crossover group, respectively. All other notable harms occurred
only rarely during the long-term follow-up period. Some may have increased
numerically, but the frequency was still quite low.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t39/?report=objectonly"
title="&quot;Table 39&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 67"
src="psoriasis%20test_files/image044.png"
alt="Table 39. Summary of Harms (Safety Set) for the Extension Period."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t39/?report=objectonly"
target=object>Table 39</a></b></p>

<p class=MsoNormal>Summary of Harms (Safety Set) for the Extension Period.</p>

<p class=MsoNormal><i>Critical Appraisal</i></p>

<p class=MsoNormal><i>Internal Validity</i></p>

<p class=MsoNormal>Although the treatment responses appeared to improve or be
maintained, for the most part, there was no statistical testing; therefore,
definitive conclusions could not be drawn from the extension period. Because
this portion of the trial remained blinded, there is a low risk of bias in the
measurement of the outcomes. Rates of early discontinuation from study were
higher through the end of the DISCOVER-1 and DISCOVER-2 trials. Given that the
reason for discontinuation was mainly unspecified (because the highest number
of participants fell under the discontinued-from-study category, but completed
the protocol-required follow-up), it is difficult to fully address any
potential attrition bias. The same validity, reliability, and responsiveness
concerns for the tools used to measure the outcomes described for the
randomized phase also apply to the extension period. As with the randomized
phase, there is no evidence for the validity or reliability of the IGA, PASI,
or BASDAI in patients with PsA.</p>

<p class=MsoNormal>Because no hypothesis testing of treatment differences was
conducted for the active treatment period, it is not possible to draw causal
conclusions based on the descriptive results. The lack of a comparator group
also poses a risk of confounding. Without a randomized comparator, it is not
possible to draw causal conclusions (i.e., changes following the randomized
phase cannot be attributed to the treatment with any certainty).</p>

<p class=MsoNormal><i>External Validity</i></p>

<p class=MsoNormal>The external validity of the extension phase is equivalent
to that reported for the randomized phase. As with the randomized phase, per
the clinical expert, there are no major concerns regarding the generalizability
of the findings to Canadian clinical practice.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Discussion</b></p>

<p class=MsoNormal><b>Summary of Available Evidence</b></p>

<p class=MsoNormal>Three double-blind, placebo-controlled RCTs met the
inclusion criteria for the systematic review. Two trials included patients with
active PsA who were either biologic-naive (DISCOVER-2, N&nbsp;= 741) or were
intolerant to or had experienced an inadequate response to TNF alpha inhibitors
(COSMOS, N&nbsp;= 285). One trial included a mixed population of biologic-nave
or TNF inhibitor-experienced patients (DISCOVER-1, N&nbsp;= 381). Patients were
randomized to receive placebo or guselkumab 100 mg SC at week 0, week 4, and every
8 weeks thereafter for 24 weeks. The DISCOVER trials also included a third
treatment group of patients who received guselkumab 100 mg every 4 weeks. This
dosage was not consistent with the Health Canada–recommended dose; therefore,
it has not been included in this report. The total trial durations were 52
weeks (DISCOVER-1), 100 weeks (DISCOVER-2), and 48 weeks (COSMOS), with
patients on placebo switching to guselkumab at week 24. During the trials,
patients could continue stable doses of methotrexate, leflunomide,
hydroxychloroquine, sulfasalazine, oral corticosteroids, or NSAIDs up to the
protocol-specified maximum doses. The primary outcome in all trials was the
proportion of patients who achieved ACR 20 at week 24. Other outcomes of
interest included changes from baseline in HAQ-DI and SF-36 PCS scores and the
impact on plaque psoriasis (as measured by IGA or PASI response).</p>

<p class=MsoNormal>The mean age of patients enrolled ranged from 44.9 years
(SD&nbsp;= 11.9) to 49.1 years (SD&nbsp;= 12.3) across treatment groups in the
3 trials. The proportion of female patients ranged from 46% to 55%, and most
patients were White (89% to 98% in the DISCOVER trials; not reported for
COSMOS). The mean number of swollen joints ranged from 9.0 (SD&nbsp;= 5.7) to
12.3 (SD&nbsp;= 6.9) and the mean number of tender joints ranged from 18.2
(SD&nbsp;= 10.7) to 21.6 (SD&nbsp;= 13.1). Approximately 2-thirds of patients
had&nbsp;<b>psoriatic</b>&nbsp;involvement affecting at least 3% of their BSA.
Two-thirds of patients reported enthesitis, while approximately 40% had
dactylitis at baseline. The majority of patients in the studies were receiving
methotrexate at baseline (54% to 63%). In the DISCOVER trials, 14% to 20% of
patients were receiving oral corticosteroids at baseline, compared with 4% to
5% of patients in the COSMOS study.</p>

<p class=MsoNormal>Supportive data on longer-term efficacy and safety were
available from the uncontrolled extension phase of the 3 trials that included
data from approximately 530 patients who received guselkumab for 48 weeks to
100 weeks.</p>

<p class=MsoNormal>In addition, the sponsor submitted an ITC that examined the
comparative efficacy and safety of guselkumab versus other bDMARDs available in
Canada. Another published ITC of patients with PsA is also summarized in this
report.</p>

<p class=MsoNormal><b>Interpretation of Results</b></p>

<p class=MsoNormal><b>Efficacy</b></p>

<p class=MsoNormal>Among patients who were biologic-naive, intolerant to, or
had an inadequate response to TNF alpha inhibitors, and among a mixed
population that included both biologic-naive and TNF inhibitor-experienced
patients with active PsA, guselkumab every 8 weeks showed clinically important
differences in the proportion of patients who achieved ACR 20 at 24 weeks.
Secondary and exploratory measures of PsA activity (ACR 50, ACR 70, and MDA)
also favoured guselkumab every 8 weeks versus placebo, except for ACR 70 in the
DISCOVER-1 trial. However, most of the end points were not controlled for
multiple testing; thus, these should be interpreted with consideration for the
potential for inflated type I error rate. While an ACR 20 threshold may be the
minimum change that may be considered important, the expert noted that higher
thresholds, such as ACR 50 or MDA, are goals of therapy.</p>

<p class=MsoNormal>Other outcomes, such as the change from baseline in HAQ-DI,
also showed improvement favouring guselkumab every 8 weeks versus placebo;
however, the within-group changes for only 1 of the guselkumab groups, and none
of the between-group differences versus placebo exceeded the clinically
important difference of 0.35 points reported by the sponsor. Thus, the clinical
relevance of the change in disability is uncertain. The change from baseline in
the SF-36 PCS showed improvements that favoured guselkumab versus placebo in
all studies, with both within- and between-group differences that exceeded some
estimates of the MID that, in the DISCOVER trials, may be considered clinically
relevant. No differences between groups were detected from the change from
baseline in the SF-36 MCS; however, it should be noted that the baseline scores
(46.1 points to 48.7 points) were near the US population average (50 points).
Thus, there may be limited room for improvement. The changes from baseline in
the FACIT-Fatigue scores suggest a reduction in fatigue relative to placebo,
but this outcome was not controlled for type I error rate.</p>

<p class=MsoNormal>Among patients with psoriasis affecting greater than or
equal to 3% of their BSA at baseline, the IGA and PASI response end points
favoured guselkumab versus placebo, with 20% to 42% more patients achieving the
PASI 100 threshold at week 24 across trials. However, these data should be
interpreted with consideration for the potential for inflated type I error
rate, given that only the IGA response in the DISCOVER trials and the PASI 100
response in the COSMOS study were controlled for multiple testing.</p>

<p class=MsoNormal>The DISCOVER-2 study failed to detect a difference between
guselkumab every 8 weeks and placebo in radiographic progression. Although the
study was powered for this end point, the 24-week duration may have limited the
trial’s ability to detect a change. The results of the enthesitis and
dactylitis end points in the DISCOVER-1 study failed to detect a difference
between guselkumab and placebo, while the DISCOVER-2 and COSMOS study data
suggest a favourable effect with guselkumab; however, none of these end points
were controlled for multiple testing. To increase statistical power, a
preplanned pooled analysis of the DISCOVER trials was conducted for the
proportion of patients with resolution of enthesitis and dactylitis. The pooled
analyses suggest that more patients who receive guselkumab every 8 weeks may
have their enthesitis or dactylitis resolved by 24 weeks versus patients who
receive placebo. No differences were detected between groups in the proportions
of patients who achieved at least a 50% improvement in BASDAI scores. As with
the skin-related end points, these analyses were conducted in subgroups of the
overall population, which were not stratified at baseline. Thus, there is
potential that the groups differed in their baseline demographic and disease
characteristics.</p>

<p class=MsoNormal>The trials compared guselkumab plus background therapy
(cDMARDs, corticosteroids, or NSAIDs) with placebo plus background therapy.
Thus, direct evidence for guselkumab versus other DMARDs used to treat PsA is
not available. Indirect evidence was available from 1 published and 1
unpublished NMA in adults with PsA. The sponsor submitted an NMA that evaluated
the short-term (12-week to 24-week) efficacy and safety of guselkumab in the
treatment of PsA compared with other biologic treatments. The NMA was based on
a systematic review of the literature; data from 34 RCTs was used to inform the
Bayesian models. The NMA by McInnes et al. (2022)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>15</sup></a>&nbsp;evaluated
the short-term safety and efficacy of bDMARDs licensed for psoriasis or PsA and
used Bayesian methods to pool data from 46 RCTs. These reports suggest that
PASI response may favour guselkumab versus some comparators. However, generally
— due to imprecision in the results comparing guselkumab to other biologics —
the ability to draw conclusions about ACR response rates and changes in HAQ-DI
scores, SF-36 PCS and MCS scores, and vdH-S scores was limited. The findings
for the subgroup of patients who were biologic-naive were generally similar to
those for the overall population in the sponsor-submitted NMA. The NMAs in the
biologic-experienced population were sparse and showed imprecision in their
results. Both NMAs were limited by the heterogeneity across trials, which
included differences in prior exposure to biologic or non-biologic therapies,
duration of disease, study years, timing of outcome assessments, and placebo
response rates. Due to this heterogeneity, the NMAs used a baseline risk-adjusted
model for some analyses; however, it is uncertain whether this approach is
adequate to control for differences in patient characteristics that may bias
results. Other limitations include the inability to assess consistency (due to
the lack of closed loops in the network) and the unclear or high risk of bias
of the RCTs used to inform the networks. Given these limitations and the
imprecision of the results, it is difficult to draw conclusions from the NMAs
about the comparative efficacy of guselkumab.</p>

<p class=MsoNormal>The direct comparative evidence versus placebo and indirect
evidence versus other biologics was limited to short-term outcomes. Although
results from the extension phase of the trials suggest that treatment effects
may be maintained up to 100 weeks, these data are difficult to interpret due to
the lack of a comparator group and bias due to attrition. The treatment effects
observed may be inflated relative to the broader population with PsA.</p>

<p class=MsoNormal>With regards to external validity, the clinical expert did
not identify any major issues that may limit the generalizability of the
trials. However, the clinical expert did note that the use of oral
corticosteroids in the DISCOVER trials was higher than would be expected in
Canada (14% to 20%), where chronic corticosteroid use is generally avoided. The
trials excluded patients who had previously been treated with biologics other
than TNF inhibitors; thus, the efficacy in patients with intolerance or inadequate
response to other biologics, such as JAK inhibitors or other IL inhibitors, is
not known.</p>

<p class=MsoNormal><b>Harms</b></p>

<p class=MsoNormal>Guselkumab was first approved in Canada in 2017. Thus, its
safety profile is familiar to clinicians. No new safety signals were identified
in the controlled and extension phases of the clinical trials in patients with
PsA. Generally, the frequency of adverse events was similar in the guselkumab
and placebo groups, including the risk of infection. The proportion of patients
who stopped treatment due to adverse events, or who reported serious adverse
events, was generally low. However, due to the sample sizes and follow-up
durations, the studies may not detect rare events or those that take a longer
time to develop. Of note, most patients in the active and placebo groups were
receiving background therapies; thus, some adverse events reported may be
attributable to these other drugs. No conclusions could be drawn regarding the
comparative safety of guselkumab based on the indirect evidence, which reported
imprecise results and was limited by the clinical heterogeneity across trials.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Conclusions</b></p>

<p class=MsoNormal>Based on data from 3 double-blind RCTs, adults with active
PsA who received guselkumab 100 mg every 8 weeks were more likely to show
clinically relevant improvements in PsA disease activity and tender and swollen
joint counts than patients who received placebo, based on the proportion who
achieved an ACR 20 response at week 24. Favourable clinical responses in PsA
activity and symptoms were observed among patients who were biologic-naive or
had experienced prior intolerance or inadequate response to TNF alpha
inhibitors and among a mixed population of patients with and without exposure
to a prior TNF inhibitor.</p>

<p class=MsoNormal>Guselkumab also showed statistically significant
improvements in disability as measured using the HAQ-DI; however, the clinical
relevance of the difference versus placebo is uncertain. Improvements in the
PCS but not the MCS of the SF-36 were observed, favouring guselkumab versus
placebo. Outcomes related to&nbsp;<b>psoriatic</b>&nbsp;skin lesions
demonstrated superiority of guselkumab every 8 weeks versus placebo at 24
weeks. Among patients with enthesitis or dactylitis at baseline, pooled data
from the pivotal trials suggest that patients who receive guselkumab every 8
weeks may be more likely to have enthesitis or dactylitis resolved at 24 weeks
than those receiving placebo. The impact of guselkumab on radiographic
progression is unclear because no statistically significant differences were
detected between guselkumab every 8 weeks and placebo for the change in the
modified vdH-S score at 24 weeks among patients with active PsA who were
biologic-naive.</p>

<p class=MsoNormal>No new safety signals were identified in the controlled and
extension phases of the PsA trials. The frequency of infection was similar in
the guselkumab and placebo groups up to 24 weeks.</p>

<p class=MsoNormal>There is no direct evidence comparing guselkumab to other
bDMARDs available in Canada. The indirect evidence for ACR response rates,
change in HAQ-DI scores, change in SF-36 PCS and MCS, and risk of adverse
events or serious adverse events for guselkumab versus most biologic
comparators showed imprecise results, which limits the ability to draw
conclusions from these data. Based on the indirect evidence, short-term PASI
response rates may favour guselkumab versus some other biologics. However,
there is uncertainty in these findings, given that several sources of
heterogeneity were identified across the trials included in the NMAs and
because it is unclear whether the methods used to control for potential bias
were adequate. In addition, many of the studies included in the NMAs were at an
unclear or high risk of bias in 1 or more study domains.</p>

<p class=MsoNormal>The direct comparative evidence versus placebo and indirect
evidence versus other biologics was limited to short-term outcomes (up to 24
weeks). Although results from the extension phase of the trials suggest that
treatment effects may be maintained up to 100 weeks, these data are difficult
to interpret due to the lack of comparator group and bias due to attrition.
Thus, the longer-term comparative efficacy and safety of guselkumab in patients
with PsA are unclear.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Abbreviations</b></p>

<p class=MsoNormal><b>ACR</b></p>

<p class=MsoNormal>American College of Rheumatology</p>

<p class=MsoNormal><b>ACR 20</b></p>

<p class=MsoNormal>American College of Rheumatology 20% improvement</p>

<p class=MsoNormal><b>ACR 50</b></p>

<p class=MsoNormal>American College of Rheumatology 50% improvement</p>

<p class=MsoNormal><b>ACR 70</b></p>

<p class=MsoNormal>American College of Rheumatology 70% improvement</p>

<p class=MsoNormal><b>ANCOVA</b></p>

<p class=MsoNormal>analysis of covariance</p>

<p class=MsoNormal><b>ASQoL</b></p>

<p class=MsoNormal>Ankylosing Spondylitis Quality of Life</p>

<p class=MsoNormal><b>BASDAI</b></p>

<p class=MsoNormal>Bath Ankylosing Spondylitis Disease Activity Index</p>

<p class=MsoNormal><b>bDMARD</b></p>

<p class=MsoNormal>biologic disease-modifying antirheumatic drug</p>

<p class=MsoNormal><b>BSA</b></p>

<p class=MsoNormal>body surface area</p>

<p class=MsoNormal><b>CAPA</b></p>

<p class=MsoNormal>Canadian Arthritis Patient Alliance</p>

<p class=MsoNormal><b>CAPP</b></p>

<p class=MsoNormal>Canadian Association of Psoriasis Patients</p>

<p class=MsoNormal><b>CDEC</b></p>

<p class=MsoNormal>CADTH Canadian Drug Expert Committee</p>

<p class=MsoNormal><b>cDMARD</b></p>

<p class=MsoNormal>conventional disease-modifying antirheumatic drug</p>

<p class=MsoNormal><b>CI</b></p>

<p class=MsoNormal>confidence interval</p>

<p class=MsoNormal><b>CMH</b></p>

<p class=MsoNormal>Cochran-Mantel-Haenszel</p>

<p class=MsoNormal><b>CPN</b></p>

<p class=MsoNormal>Canadian Psoriasis Network</p>

<p class=MsoNormal><b>CrI</b></p>

<p class=MsoNormal>credible interval</p>

<p class=MsoNormal><b>CRP</b></p>

<p class=MsoNormal>C-reactive protein</p>

<p class=MsoNormal><b>CSR</b></p>

<p class=MsoNormal>Clinical Study Report</p>

<p class=MsoNormal><b>DAPSA</b></p>

<p class=MsoNormal>Disease Activity Index for&nbsp;<b>Psoriatic</b>&nbsp;Arthritis</p>

<p class=MsoNormal><b>DAS 28</b></p>

<p class=MsoNormal>Disease Activity Score 28</p>

<p class=MsoNormal><b>DAS 28 CRP</b></p>

<p class=MsoNormal>Disease Activity Score 28 using C-reactive protein</p>

<p class=MsoNormal><b>DLQI</b></p>

<p class=MsoNormal>Dermatology Life Quality Index</p>

<p class=MsoNormal><b>DMARD</b></p>

<p class=MsoNormal>disease-modifying antirheumatic drug</p>

<p class=MsoNormal><b>ESR</b></p>

<p class=MsoNormal>erythrocyte sedimentation rate</p>

<p class=MsoNormal><b>EULAR</b></p>

<p class=MsoNormal>European League Against Rheumatism</p>

<p class=MsoNormal><b>FACIT-Fatigue</b></p>

<p class=MsoNormal>Functional Assessment of Chronic Illness Therapy – Fatigue
Scale</p>

<p class=MsoNormal><b>FAS</b></p>

<p class=MsoNormal>full analysis set</p>

<p class=MsoNormal><b>GRAPPA</b></p>

<p class=MsoNormal>Group for Research and Assessment of Psoriasis and&nbsp;<b>Psoriatic</b>&nbsp;Arthritis</p>

<p class=MsoNormal><b>HAQ-DI</b></p>

<p class=MsoNormal>Health Assessment Questionnaire Disability Index</p>

<p class=MsoNormal><b>HRQoL</b></p>

<p class=MsoNormal>health-related quality of life</p>

<p class=MsoNormal><b>ICC</b></p>

<p class=MsoNormal>intra-class correlation coefficient</p>

<p class=MsoNormal><b>IGA</b></p>

<p class=MsoNormal>Investigator’s Global Assessment of Psoriasis</p>

<p class=MsoNormal><b>IL</b></p>

<p class=MsoNormal>interleukin</p>

<p class=MsoNormal><b>ITC</b></p>

<p class=MsoNormal>indirect treatment comparison</p>

<p class=MsoNormal><b>JAK</b></p>

<p class=MsoNormal>Janus kinase</p>

<p class=MsoNormal><b>LEI</b></p>

<p class=MsoNormal>Leeds Enthesitis Index</p>

<p class=MsoNormal><b>LS</b></p>

<p class=MsoNormal>least squares</p>

<p class=MsoNormal><b>MCS</b></p>

<p class=MsoNormal>Mental Component Summary</p>

<p class=MsoNormal><b>MDA</b></p>

<p class=MsoNormal>minimal disease activity</p>

<p class=MsoNormal><b>MID</b></p>

<p class=MsoNormal>minimal important difference</p>

<p class=MsoNormal><b>MMRM</b></p>

<p class=MsoNormal>mixed-effects model for repeated measures</p>

<p class=MsoNormal><b>NMA</b></p>

<p class=MsoNormal>network meta-analysis</p>

<p class=MsoNormal><b>NSAID</b></p>

<p class=MsoNormal>nonsteroidal anti-inflammatory drug</p>

<p class=MsoNormal><b>PASI</b></p>

<p class=MsoNormal>Psoriasis Area and Severity Index</p>

<p class=MsoNormal><b>PASI 75</b></p>

<p class=MsoNormal>75% improvement from baseline in Psoriasis Area and Severity
Index score</p>

<p class=MsoNormal><b>PASI 90</b></p>

<p class=MsoNormal>90% improvement from baseline in Psoriasis Area and Severity
Index score</p>

<p class=MsoNormal><b>PASI 100</b></p>

<p class=MsoNormal>100% improvement from baseline in Psoriasis Area and
Severity Index score</p>

<p class=MsoNormal><b>PCS</b></p>

<p class=MsoNormal>Physical Component Summary</p>

<p class=MsoNormal><b>PsA</b></p>

<p class=MsoNormal><b>psoriatic</b>&nbsp;arthritis</p>

<p class=MsoNormal><b>PsAID-FC</b></p>

<p class=MsoNormal><b>Psoriatic</b>&nbsp;Arthritis Impact of Disease Instrument
Functional Capacity</p>

<p class=MsoNormal><b>RCT</b></p>

<p class=MsoNormal>randomized controlled trial</p>

<p class=MsoNormal><b>SC</b></p>

<p class=MsoNormal>subcutaneous</p>

<p class=MsoNormal><b>SD</b></p>

<p class=MsoNormal>standard deviation</p>

<p class=MsoNormal><b>SF-36</b></p>

<p class=MsoNormal>Short Form (36) Health Survey</p>

<p class=MsoNormal><b>SRM</b></p>

<p class=MsoNormal>standardized response mean</p>

<p class=MsoNormal><b>TNF</b></p>

<p class=MsoNormal>tumour necrosis factor</p>

<p class=MsoNormal><b>VAS</b></p>

<p class=MsoNormal>visual analogue scale</p>

<p class=MsoNormal><b>vdH-S</b></p>

<p class=MsoNormal>van der Heijde-Sharp</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Appendix 1. Literature Search Strategy</b></p>

<p class=MsoNormal>Note that this appendix has not been copy-edited.</p>

<p class=MsoNormal><b>Clinical Literature Search</b></p>

<p class=MsoNormal><b>Overview</b></p>

<p class=MsoNormal><b>Interface</b>: Ovid</p>

<p class=MsoNormal><b>Databases</b>:</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>MEDLINE All (1946-present)</li>
 <li class=MsoNormal>Embase (1974-present)</li>
</ul>

<p class=MsoNormal>Note: Subject headings and search fields have been
customized for each database. Duplicates between databases were removed in
Ovid.</p>

<p class=MsoNormal><b>Date of search</b>: May 31, 2022</p>

<p class=MsoNormal><b>Alerts</b>: Bi-weekly search updates until project
completion</p>

<p class=MsoNormal><b>Search filters applied</b>: No filters were applied to
limit the retrieval by study type.</p>

<p class=MsoNormal><b>Limits</b>:</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>Publication date limit: none</li>
 <li class=MsoNormal>Language limit: none</li>
 <li class=MsoNormal>Conference abstracts: excluded</li>
</ul>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t40/?report=objectonly"
title="&quot;Table 40&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 66"
src="psoriasis%20test_files/image045.png" alt="Table 40. Syntax Guide."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t40/?report=objectonly"
target=object>Table 40</a></b></p>

<p class=MsoNormal>Syntax Guide.</p>

<p class=MsoNormal><b>Multi-Database Strategy</b></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal>(tremfya* or guselkumab* or cnto 1959 or cnto1959 or
     089658A12D).ti,ab,kf,ot,hw,rn,nm.</li>
 <li class=MsoNormal>1 use medall</li>
 <li class=MsoNormal>*guselkumab/</li>
 <li class=MsoNormal>(tremfya* or guselkumab* or cnto 1959 or
     cnto1959).ti,ab,kf,dq.</li>
 <li class=MsoNormal>or/3-4</li>
 <li class=MsoNormal>5 use oemezd</li>
 <li class=MsoNormal>6 not (conference abstract or conference review).pt.</li>
 <li class=MsoNormal>2 or 7</li>
 <li class=MsoNormal>remove duplicates from 8</li>
</ol>

<p class=MsoNormal><b>Clinical Trials Registries</b></p>

<p class=MsoNormal><i>ClinicalTrials.gov</i></p>

<p class=MsoNormal>Produced by the US National Library of Medicine. Targeted
search used to capture registered clinical trials.</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>[Search – Studies with results | tremfya OR guselkumab OR
     cnto-1959 OR cnto1959 |&nbsp;<b>Psoriatic</b>&nbsp;Arthritis]</li>
</ul>

<p class=MsoNormal><i>WHO ICTRP</i></p>

<p class=MsoNormal>International Clinical Trials Registry Platform, produced by
the WHO. Targeted search used to capture registered clinical trials.</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>[Search terms – (tremfya OR guselkumab OR cnto-1959 OR
     cnto1959) AND&nbsp;<b>psoriatic</b>&nbsp;arthritis]</li>
</ul>

<p class=MsoNormal><i>Health Canada’s Clinical Trials Database</i></p>

<p class=MsoNormal>Produced by Health Canada. Targeted search used to capture
registered clinical trials.</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>[Search terms – tremfya OR guselkumab]</li>
</ul>

<p class=MsoNormal><i>EU Clinical Trials Register</i></p>

<p class=MsoNormal>European Union Clinical Trials Register, produced by the
European Union. Targeted search used to capture registered clinical trials.</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>[Search terms – guselkumab AND&nbsp;<b>psoriatic</b>&nbsp;arthritis]</li>
</ul>

<p class=MsoNormal><b>Grey Literature</b></p>

<p class=MsoNormal><b>Search dates</b>: May 18, 2022 – May 31, 2022</p>

<p class=MsoNormal><b>Keywords</b>: [tremfya OR guselkumab OR cnto-1959 OR
cnto1959 OR&nbsp;<b>psoriatic</b>&nbsp;arthritis OR psoriasis OR arthritis]</p>

<p class=MsoNormal><b>Limits</b>: Publication years: none</p>

<p class=MsoNormal><b>Updated</b>: Search updated before the meeting of the
CADTH CDEC</p>

<p class=MsoNormal>Relevant websites from the following sections of the CADTH
grey literature checklist&nbsp;<a href="https://www.cadth.ca/grey-matters">Grey
Matters: A Practical Tool for Searching Health-Related Grey Literature</a>&nbsp;were
searched:</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>Health Technology</li>
 <li class=MsoNormal>Advisories and Warnings</li>
 <li class=MsoNormal>Drug Class Reviews</li>
 <li class=MsoNormal>Clinical Trials Registries</li>
 <li class=MsoNormal>Databases (free)</li>
 <li class=MsoNormal>Internet Search.</li>
</ul>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Appendix 2. Excluded Studies</b></p>

<p class=MsoNormal>Note that this appendix has not been copy-edited.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t41/?report=objectonly"
title="&quot;Table 41&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 65"
src="psoriasis%20test_files/image046.png" alt="Table 41. Excluded Studies."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t41/?report=objectonly"
target=object>Table 41</a></b></p>

<p class=MsoNormal>Excluded Studies.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Appendix 3. Detailed Outcome Data</b></p>

<p class=MsoNormal>Note this appendix has not been copy-edited.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t42/?report=objectonly"
title="&quot;Table 42&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 64"
src="psoriasis%20test_files/image047.png"
alt="Table 42. ACR Response at Week 16."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t42/?report=objectonly"
target=object>Table 42</a></b></p>

<p class=MsoNormal>ACR Response at Week 16.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t43/?report=objectonly"
title="&quot;Table 43&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 63"
src="psoriasis%20test_files/image048.png"
alt="Table 43. Change From Baseline in DAS 28 CRP Scores at Week 24."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t43/?report=objectonly"
target=object>Table 43</a></b></p>

<p class=MsoNormal>Change From Baseline in DAS 28 CRP Scores at Week 24.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig11/?report=objectonly"
title="&quot;Figure 11&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=21 id="Picture 62"
src="psoriasis%20test_files/image049.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig11/?report=objectonly"
target=object>Figure 11</a></b></p>

<p class=MsoNormal>ACR 20 Response for Subgroups Based on Prior Treatment
History — DISCOVER-1 (FAS) — Redacted.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig12/?report=objectonly"
title="&quot;Figure 12&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=21 id="Picture 61"
src="psoriasis%20test_files/image049.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig12/?report=objectonly"
target=object>Figure 12</a></b></p>

<p class=MsoNormal>ACR 20 Response for Subgroups Based on Baseline Treatments —
DISCOVER-1 (FAS) — Redacted.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig13/?report=objectonly"
title="&quot;Figure 13&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=21 id="Picture 60"
src="psoriasis%20test_files/image049.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig13/?report=objectonly"
target=object>Figure 13</a></b></p>

<p class=MsoNormal>ACR 20 Response for Subgroups Based on Prior Treatment
History — DISCOVER-2 (FAS) — Redacted.</p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig14/?report=objectonly"
title="&quot;Figure 14&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=200 height=21 id="Picture 59"
src="psoriasis%20test_files/image049.gif" alt="Redacted figure."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/figure/tr8269861151140733_ch01_fig14/?report=objectonly"
target=object>Figure 14</a></b></p>

<p class=MsoNormal>ACR 20 Response for Subgroups Based on Baseline Treatments —
DISCOVER-2 (FAS) — Redacted.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>Appendix 4. Description and Appraisal of Outcome Measures</b></p>

<p class=MsoNormal>Note this appendix has not been copy-edited.</p>

<p class=MsoNormal><b>Aim</b></p>

<p class=MsoNormal>To describe the following 13 outcome measures and review
their measurement properties (validity, reliability, responsiveness to change,
and MID):</p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal>ACR 20, ACR 50, ACR 70</li>
 <li class=MsoNormal>BASDAI</li>
 <li class=MsoNormal>DAS 28 CRP</li>
 <li class=MsoNormal>FACIT-Fatigue</li>
 <li class=MsoNormal>HAQ-DI</li>
 <li class=MsoNormal>IGA</li>
 <li class=MsoNormal>LEI</li>
 <li class=MsoNormal>MDA</li>
 <li class=MsoNormal>PASI 75, PASI 90, PASI 100)</li>
 <li class=MsoNormal>Resolution of Dactylitis – Dactylitis score</li>
 <li class=MsoNormal>vdH-S score</li>
 <li class=MsoNormal>SF-36 MCS and PCS.</li>
</ul>

<p class=MsoNormal><b>Findings</b></p>

<p class=MsoNormal><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t44/?report=objectonly"
title="&quot;Table 44&quot; t "><span style='color:windowtext;text-decoration:
none'><img border=0 width=204 height=134 id="Picture 58"
src="psoriasis%20test_files/image050.png"
alt="Table 44. Summary of Outcome Measures and Their Measurement Properties."></span></a></p>

<p class=MsoNormal><b><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/table/tr8269861151140733_ch01_t44/?report=objectonly"
target=object>Table 44</a></b></p>

<p class=MsoNormal>Summary of Outcome Measures and Their Measurement
Properties.</p>

<p class=MsoNormal><b>American College of Rheumatology 20, 50, 70</b></p>

<p class=MsoNormal>The ACR criteria for assessing joint status was originally
developed for patients with rheumatoid arthritis, and provides a composite
measure of &#8805;&nbsp;20%, &#8805;&nbsp;50%, or &#8805;&nbsp;70% improvement
in both swollen and tender joint counts and at least 3 of 5 additional disease
criteria including: patient’s global assessment of disease activity using a
10-cm VAS, physician’s global assessment of disease activity on VAS, HAQ-DI,
patient assessment of pain intensity, and an acute-phase reactant value (CRP or
erythrocyte sedimentation rate [ESR]).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>88</sup></a>&nbsp;The
ACR joint count assesses 68 joints for tenderness and 66 joints for swelling.
Assessment of the proximal interphalangeal and distal interphalangeal joints of
the hands and feet (i.e., 78 joints for tenderness and 76 for swelling) is not
typically included for PsA because of difficulty distinguishing proximal and
distal interphalangeal joint inflammation in the toes.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>118</sup></a>&nbsp;The
ACR is a general measure of clinical response of peripheral joint disease and
does not include assessment of enthesitis, dactylitis, the spine, or the skin.
Consequently, it represents only part of the clinical features of PsA;
therefore, the use of additional assessment instruments to assess other
clinical features is necessary.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>88</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>118</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>The ACR tender and swollen joint counts have been deemed as
appropriate for disease activity in patients with rheumatoid arthritis by the
ACR expert committee and shown to be a valid outcome measure in RCTs in terms
of content and construct validity, inter-rater reliability, and responiiveness.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>44</sup></a>&nbsp;The
construct validity was also assessed using the known-group approach in a study
of 164 patients with PsA and peripheral arthritis from 2 randomized
placebo-controlled trials of TNF inhibitors (IMPACT trial, N&nbsp;= 104;
etanercept trial, N&nbsp;= 60).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a>&nbsp;The
number of patients who achieved ACR 20, 50, 70 in both active drug groups was
significantly higher than the placebo groups.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a>&nbsp;The
ACR criteria has demonstrated to have poor to substantial inter-observer
reliability in PsA. Gladman and colleagues<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>90</sup></a>&nbsp;conducted
study of 10 patients with PsA who represented a broad range of joint
inflammation, joint damage, and spinal involvement. The study was based on a
Latin Square design. Each patient was examined by each of 10 rheumatologists
who were members of the Spondyloarthritis Research Consortium of Canada.
Generally, the study reported that the inter-observer reliability was poor to
substantial (intra-class correlation coefficients [ICC] ranged from 0.10 to
0.80). However, right grip strength, number of damaged joints, left lateral
flexion, and cervical flexion demonstrated almost perfect agreement (ICC ranged
from 0.81 to 0.92).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>90</sup></a></p>

<p class=MsoNormal>The responsiveness of the ACR criteria was in the same study
that assessed construct validity.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a>&nbsp;The
study compared responsiveness and discriminative capacity of the&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
Response Criteria, ACR, European League Against Rheumatism (EULAR) response
criteria, the DAS, and core-set measures. The ACR improvement criteria with
20%, 50% and 70% (ACR 20, 50, 70) cut-off points, EULAR response criteria, and
the&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Response Criteria were used as
criteria for improvement. Standardized response mean (SRM) and effect size were
calculated as statistics for responsiveness. In both active drug groups, the
SRM ranged from –1.98 to –0.61 and effect size ranged from –2.84 to –0.57 while
the SRM ranged from –0.40 to 0.02 and effect size ranged from –0.37 to 0.15 in
the placebo groups.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a></p>

<p class=MsoNormal><i>Minimal Important Difference</i></p>

<p class=MsoNormal>The MID for ACR has not been estimated in patients with PsA,
however, the ACR 20 is generally accepted as the MID indicating a response to
treatment, while the ACR 50 and 70 more likely reflect truly important change
for the long-term management of arthropathy.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>43</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>44</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>91</sup></a></p>

<p class=MsoNormal><b>Bath Ankylosing Spondylitis Disease Activity Index</b></p>

<p class=MsoNormal>The most common and widely used validated measure of
inflammatory activity of ankylosing spondylitis is the BASDAI.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>57</sup></a>&nbsp;This
instrument for disease activity is a self-administered patient questionnaire.
The BASDAI is a composite index that records patients’ responses to major
symptoms of ankylosing spondylitis. It includes 6 questions addressing 5 major
symptoms: fatigue, axial (spinal) and peripheral joint pain, localized
tenderness and morning stiffness (both degree of stiffness and length of time
for which stiffness persists).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>56</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>57</sup></a>&nbsp;Patients’
responses for each question are recorded on a 10 cm VAS. The final BASDAI score
has a range from 0 to 10. The higher the score, the greater the degree of
disease activity. A reduction in the BASDAI score is considered improvement.
The definition of treatment response includes a change in the BASDAI value
defined as 2 units (on a scale of 0 to 10) of the BASDAI.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>92</sup></a>&nbsp;The
recall period for BASDAI is “past week.”</p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>No studies were found that validated BASDAI in PsA patients.
In previous research, the BASDAI has been shown to have good validity,
test-retest reliability, and responsiveness in patients with ankylosing
spondylitis.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a>&nbsp;Haywood
and colleagues conducted study of patients with a confirmed diagnosis of
ankylosing spondylitis (N&nbsp;= 349) in England and Scotland assessing the
validity, reliability, and responsiveness of the BASDAI.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a>&nbsp;Convergent
validity of the BASDAI was assessed by testing a priori hypotheses about the
strength of correlation with the Ankylosing Spondylitis Quality of Life
Questionnaire (ASQoL). A high level of correlation (Pearson’s correlation
coefficient r &gt;&nbsp;0.70) was hypothesized between the BASDAI and ASQoL. A
strong correlation was observed between the BASDAI and ASQoL (r&nbsp;= 0.79).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a>&nbsp;The
construct validity was assessed using the known-group approach. Patients who
were able to work had significantly higher BASDAI scores compared with those
unable to work due to ill health.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a>&nbsp;The
BASDAI demonstrated strong internal consistency (Cronbach alpha&nbsp;= 0.87)
and 2-week test-retest reliability (ICC 0.87, 95% 0.83 to 0.91).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a>&nbsp;The
BASDAI were compared for responsiveness to change over the 6-month period by
calculating the modified SRM were calculated for patients reporting an
improvement or deterioration on health transition (general or ankylosing
spondylitis-specific). The BASDAI produced high levels of responsiveness for
groups of patients whose ankylosing spondylitis-specific (modified SRM ranged
from –0.47 to 0.60) or general health (modified SRM ranged from –1.02 to 0.75)
had improved or deteriorated according to transition question responses.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>93</sup></a></p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>The MID for the BASDAI has been determined based on data
from 1 RCT (n&nbsp;= 205) as a change of &#8722;1.96 on the 10-point BASDAI
scale in patients with ankylosing spondylitis.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>94</sup></a>&nbsp;The
MID for BASDAI has not been estimated in patients with PsA.</p>

<p class=MsoNormal><b>DAS in 28 Joints Calculated Using CRP</b></p>

<p class=MsoNormal>The DAS 28 is a measure of disease activity in rheumatoid
arthritis based on a count of 28 swollen and tender joints.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>46</sup></a>&nbsp;The
set of 28 joint count is based on evaluation of the shoulder, elbow, wrist,
metacarpophalangeal joints 1 to 5, proximal interphalangeal joints 1 to 5 of
both the upper right extremity and the upper left extremity as well as the knee
joints of lower right and lower left extremities.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>13</sup></a>&nbsp;The
DAS 28 is a modified version of DAS, which includes 2 comprehensive joint
counts, the Ritchie Articular Index, and a 44-swollen-joint count, plus the ESR
or CRP, and a general health assessment using VAS.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>46</sup></a>&nbsp;The
features of the original DAS generally apply to the DAS 28, due to the same
developmental procedure. However, the DAS and DAS 28 values are not directly
interchangeable.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>46</sup></a>&nbsp;The
DAS 28 CRP was developed as an alternative of DAS 28 based on ESR.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>47</sup></a>&nbsp;The
range of the DAS 28 is 0 to 9.4 and higher scores indicating more active
disease.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>47</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>No studies were found that validated DAS 28 in PsA patients.
The validity and responsiveness of the DAS 28 was assessed in a study of 391
patients with active rheumatoid arthritis from 2 RCTs of abatacept (ATTAIN
trial, N&nbsp;= 258; AIM trial, N&nbsp;= 133).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>47</sup></a>&nbsp;The
k coefficients with quadratic weights were calculated as statistic for
criterion validity. There was general agreement in classifying patients as
none, moderate and good EULAR responders using DAS 28 CRP and ESR, with a k of
0.80 (95% CI 0.76 to 0.83) indicating good agreement. Healy and colleagues
conducted a study of 28 patients with PsA underwent clinical assessment over a
period of 6 months. Convergent validity was assessed using Spearman’s
correlation was used to determine the relationship between the entheseal
indices and disease activity as measured by the swollen and tender joint
counts, patient and physician global VAS, CRP level, HAQ, and LEI. Strong to
moderate correlations were observed between DAS 28 and the previously mentioned
measures (r ranged from 0.344 to 0.651).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>95</sup></a></p>

<p class=MsoNormal>Responsiveness was assessed for the DAS 28 CRP using EULAR
response criteria as anchors, the treatment difference was –18.83; the
percentage improvement was –14.42%, the SRM was –0.31, and the relative
efficiency was 1.93.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>47</sup></a></p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>No evidence of MID for DAS 28 was identified in patients
with PsA. A study of 105 patients with early rheumatoid arthritis from a RCT
assessed the thresholds for DAS 28 using an absolute level of disease activity,
the study reported a value of &#8804;&nbsp;3.2 defined as the threshold for a
low disease activity state and &lt;&nbsp;2.6 as the threshold for remission.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>88</sup></a></p>

<p class=MsoNormal><b>Functional Assessment of Chronic Illness Therapy –
Fatigue (FACIT-Fatigue)</b></p>

<p class=MsoNormal>The FACIT-Fatigue scale was originally developed for use in
patients with cancer. It is 1 of a series of symptom subscales in the
Functional Assessment of Chronic Illness Therapy measurement system and has
since been validated for use in patients with rheumatoid and PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;FACIT-Fatigue
is a patient self-report measure consisting of 13 statements. Patients are
asked to indicate to what extent the statement applies to them over the course
of the previous 7 days.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;Each
statement has 5 possible levels of response, scored on a scale of 0 to 4 (0
representing “not at all” and 4 representing “very much”), resulting in scores
ranging from 0 to 52. Lower scores indicate higher levels of fatigue.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>The FACIT-Fatigue demonstrated good content validity. Cella
et al. (2005) completed a qualitative study with 12 patients; 2 (17%) had mild,
8 (67%) had moderate, and 2 (17%) had severe PsA disease activity; 7 (58%)
attributed fatigue to PsA, and 7 (58%) rated fatigue as important or extremely
important. Most patients considered the FACIT-Fatigue items relevant to their
PsA experience and understood the item content and response options well.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>96</sup></a>&nbsp;A
Toronto PsA cohort study of 135 patients with PsA assessed the validity and
reliability of FACIT-Fatigue.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>97</sup></a>&nbsp;The
study reported high levels of internal consistency (Cronbach alpha&nbsp;= 0.96)
and 1-week test-retest reliability (ICC&nbsp;= 0.95).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>97</sup></a>&nbsp;A
strong correlation was observed between the FACIT-Fatigue and modified Fatigue
Severity (r&nbsp;= &#8722;0.79, 95% CI &#8722;0.85 to &#8722;0.72) indicating
good convergent validity.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>97</sup></a>&nbsp;Construct
validity was assessed using the known-group approach, FACIT-Fatigue scores were
lower in patients with overwhelming fatigue and fibromyalgia than in those
without (P&nbsp;&lt;&nbsp;0.001).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>97</sup></a>&nbsp;FACIT-Fatigue
demonstrated good internal consistency (Cronbach coefficient alpha
&#8805;&nbsp;0.90) and test-retest reliability (ICC&nbsp;= 0.95).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>96</sup></a>&nbsp;Apart
from the Health Transition Item (which has a recall period of 1&#8201;year),
correlations between FACIT-Fatigue and SF-36 domains generally exceeded 0.60
(all were &gt;&nbsp;0.50; P&nbsp;&lt;&nbsp;0.0001). There was a strong
correlation with SF-36 Vitality (&#961; &gt;&nbsp;0.80).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>96</sup></a></p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>A suggested MID for the FACIT-Fatigue in patients with
rheumatoid arthritis is between 3 and 4 points using the Multidimensional
Assessment of Fatigue and SF-36 Vitality as anchors.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;This
MID was found in a sample of 271 patients (77% female, 81% White) with a median
age of 56 years (range&nbsp;= 28 years to 84 years), a median tender joint
count of 26 (range&nbsp;= 9 to 68), and a median swollen joint count of 15
(range&nbsp;= 2 to 43).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>8</sup></a>&nbsp;Using
disease activity measured by Patient’s Global Assessment of Psoriasis and
Arthritis and SF-36 Vitality domain as anchors, a minimal clinically important
difference for the FACIT-Fatigue total score was estimated as 3.1 points in
patients with PsA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>96</sup></a></p>

<p class=MsoNormal><b>Health Assessment Questionnaire Disability Index</b></p>

<p class=MsoNormal>The HAQ was originally developed in 1978 at Stanford
University.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>98</sup></a>&nbsp;It
was 1 of the first self-reported functional status (disability) measures and
has become the dominant instrument in many disease areas, including arthritis.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>119</sup></a>&nbsp;The
full HAQ collects data on 5 generic patient-centred health dimensions: 1) to
avoid disability, 2) to be free of pain and discomfort, 3) to avoid adverse
treatment effects, 4) to keep dollar costs of treatment low, and 5) to postpone
death.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>120</sup></a></p>

<p class=MsoNormal>The HAQ-DI is the disability assessment component of the
HAQ. It assesses a patient’s level of functional ability. There are 20
questions in 8 categories to assess a patient’s physical functional status:
dressing, arising, eating, walking, hygiene, reach, grip, and common
activities.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>121</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>122</sup></a>&nbsp;For
each of these categories, patients report the amount of difficulty they have in
performing specific activities, and their responses are made on a scale from 0
(no difficulty) to 3 (unable to do). The 8 category scores are averaged into an
overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely
disabled). The HAQ-DI was developed to assess physical disability and pain in
rheumatoid arthritis<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>98</sup></a>&nbsp;and
has been used extensively in RCTs in arthritis, including for PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>99</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>The HAQ-DI, PCS score of the 12-Item Short Form Survey (PCS
12) and the&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Impact of Disease instrument
functional capacity score (PsAID-FC) were assessed for construct validity. The
3 patient-reported outcome measures correlated strongly with each other (&#961;
&gt;&nbsp;0.7); and moderately to strongly with patient global assessments for
arthritis (&#961;&nbsp;= 0.61 to 0.78), pain (&#961;&nbsp;= 0.61 to 0.77);
moderately with tender joint count (P&nbsp;=&nbsp;0.39 to 0.51) and DAPSA
(&#961;&nbsp;= 0.55 to 0.72); weakly with swollen joint count (&#961;&nbsp;=
0.19 to 0.32); and very weakly with patient global assessment for skin (&#961;&nbsp;=
0.24 to 0.36).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a>&nbsp;Leung
et al. (2021) analyzed data available from a longitudinal study in 14 countries
of consecutive adults with definite PsA of at least 2 years in duration.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a>&nbsp;A
total of 414 patients (52% male) were analyzed. They reported an internal
consistency measured by Cronbach alpha of 0.92 for HAQ-DI. Ceiling effects were
noted in a third of patients.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>99</sup></a>&nbsp;A
study collected data from 2 studies conducted in UK and Singapore,
respectively. A total of 69 patients with PsA (UK study, N&nbsp;= 31; Singapore
study, N&nbsp;= 38) were assessed for test-retest reliability.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>100</sup></a>&nbsp;The
study reported almost perfect test-retest reliability in the UK study (ICC
0.90, 95% CI 0.79 to 0.95) in a 1-week interval and Singapore study (ICC 0.94,
95% CI 0.89 to 0.97) in a 2-week interval.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>100</sup></a>&nbsp;All
3 patient-reported outcome measures for physical function were more sensitive
for worsening than improvement. Moderate effect sizes (Cohen d) were seen in
all 3 patient-reported outcome measures in measurement of worsening (HAQ-DI
0.46,95% CI 0.12 to 0.78; PCS12&nbsp;&#8722;&nbsp;0.57, 95% CI &#8722;0.92 to
&#8722;0.24; PsAID-FC 0.51, 95% CI 0.16 to 0.87). The SRM for worsening for
HAQ-DI, PCS12, and PsAID-FC were 0.37(95% CI 0.10 to 0.61), &#8722;0.45(95% CI
0. &#8722;0.74 to &#8722;0.19), and 0.38(95% CI 0.12 to 0.66) respectively.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a></p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>Mease et al. (2011)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>6</sup></a>&nbsp;have
estimated that the MID for the HAQ-DI in PsA patients using anchor-based
methods is 0.35 (unlike 0.22 for rheumatoid arthritis), while the MID has been
estimated to be 0.131 in PsA patients using an anchor-based approach (equal
bidirectional magnitudes for improvement and worsening) by Kwok and Pope
(2010).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>49</sup></a>&nbsp;Discrepancies
in the MID estimates may partly be explained by differences in the HAQ-DI score
of the patients studied at baseline.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>123</sup></a>&nbsp;In
the study by Mease et al. (2011),<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>6</sup></a>&nbsp;patients
had a mean HAQ-DI score at baseline of 1.16, corresponding to moderate
functional impairment. In contrast, patients in the study by Kwok and Pope
(2010) had less functional impairment at baseline, with a mean HAQ-DI score of
0.732.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a>&nbsp;Blackmore
and colleagues (1995) have shown the HAQ-DI adequately captures clinically
important changes in functional status and pain in patients with PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>124</sup></a>&nbsp;However,
the HAQ-DI focuses on physical disability and may not adequately capture
disability in patients with predominantly skin disease.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>124</sup></a>&nbsp;Modified
versions of the HAQ to include spinal domains or skin disease assessment have
not proven to be significantly better in assessment of health status in PsA
than the original HAQ-DI.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>124</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>125</sup></a>&nbsp;Leung
et al. (2020), reported the MID for improvement and worsening for HAQ-DI were
–0.16 (SD: 0.87) for improvement, and 0.30 (SD: 0.81) for worsening using
patient-rated “improved” or “worse” disease status as anchors in patients with
PsA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>99</sup></a></p>

<p class=MsoNormal><b>Investigator’s Global Assessment</b></p>

<p class=MsoNormal>The IGA, also known as the Physician Global Assessment, is a
simple measurement of the clinical signs of psoriasis, frequently used as a
co-primary end point with the PASI score in psoriasis clinical trials.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>126</sup></a>&nbsp;Various
IGAs have been used in psoriasis with different descriptions and scores, with
the most common IGA versions using 5- to 6-point scales.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>111</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>126</sup></a>&nbsp;The
5-point scale is reported to have a more strict criteria for the score of 1
(“almost clear”) than the 6-point scale score of 1 (“minimal”).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>53</sup></a>&nbsp;There
are 2 types of IGAs, a static form which measures the physician’s measurement
of the disease at a given time point, and a dynamic form in which the physician
evaluates the level of improvement or deterioration from a baseline.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>103</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>126</sup></a>&nbsp;The
static form of the IGA is preferred as it does not rely on the investigator’s
recall of the patient’s disease severity observed at baseline or a previous
visit.</p>

<p class=MsoNormal><i>Validity</i></p>

<p class=MsoNormal>The most recent study assessing the validity of the IGA
evaluated data from 4 phase III clinical studies of tofacitinib in patients
with psoriasis (N&nbsp;= 3,641).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a>&nbsp;Construct
validity was assessed using a known-group approach, measuring the relationship
between IGA and PASI through a repeated measures model. Using the PASI score as
a categorical anchor, the differences in the IGA scores between the ‘clear’ group
(PASI score of 0) and the other groups (PASI score &gt;&nbsp;0) were
statistically significant, and increased as psoriasis became more severe (i.e.,
with larger PASI scores), indicating that the IGA could discriminate between
different degrees of disease severity.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a></p>

<p class=MsoNormal>Convergent validity was assessed in the aforementioned study
by comparing the IGA with 3 additional outcome measures: the PASI, patient
global assessment, and Dermatology Life Quality Index (DLQI).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a>&nbsp;Pearson
correlation coefficients between IGA and the 3 scales ranged from 0.4 to 0.79
at primary assessment time points in the 4 clinical studies. Results showed a
strong correlation between the IGA and the PASI (r ranged from 0.77 to 0.79)
even though the IGA does not consider the amount of BSA affected by psoriasis.
A moderately strong correlation was found between the IGA and DLQI (0.44 to
0.57). None of the correlations were large (&gt;&nbsp;0.8), indicating that the
IGA considers some different information than the PASI and DLQI. Baseline
correlations were smaller likely due to the limited range of responses from
relatively homogeneous patients. An earlier study by Cappelleri et al. (2013)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>102</sup></a>&nbsp;conducted
a psychometric validation of the IGA using data from a phase II study of
tofacitinib among 197 patients. Results found a relatively high correlation
between the IGA and Patient Global Assessment as well as the IGA and PASI with
correlation coefficient r &gt;&nbsp;0.5, except for at baseline. The study also
examined correlations between the IGA and the Ocular Comfort Index (OCI) and
the pain/discomfort assessment with all correlation coefficient r
&lt;&nbsp;0.2, indicating relatively high divergent validity. These findings
were consistent with several other studies examining the 6-point IGA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a><sup>-</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>111</sup></a></p>

<p class=MsoNormal><i>Reliability</i></p>

<p class=MsoNormal>A recent systematic review noted that the 5-point IGA
appears to be based on a formative model where a change in the severity of the
disease does not necessarily mean a change in all 3 components of erythema,
induration, and scaling; therefore, an assessment of internal consistency would
not be applicable.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>127</sup></a>&nbsp;However,
Callis Duffin et al. (2019)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a>&nbsp;assessed
the internal consistency reliability, demonstrating that the scoring items
(erythema, induration, and scaling) were highly consistent with each other
(Cronbach coefficient alpha &#8805;&nbsp;0.90) at the primary assessment points
in all 4 trials. The internal consistency reliability was less convincing
(Cronbach coefficient alpha 0.50 to 0.63) for the values observed at baseline,
likely a result of the specific inclusion criteria of the trials.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a>&nbsp;This
study also evaluated the consistency of IGA measurements between screening and
baseline visits, when no change in terms of disease severity was expected. The
ICC for the pooled data was 0.70, suggesting an acceptable test-retest
reliability over a stable period.</p>

<p class=MsoNormal>Cappellleri et al. (2013)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>102</sup></a>&nbsp;also
examined the test-retest reliability of IGA scores at baseline and week 2 among
patients with little to no change in their PASI scores, resulting in a high ICC
of 0.80. The study also examined internal consistency reliability of the IGA,
with Cronbach coefficient alpha &gt;&nbsp;0.80 at all time points from week 2
onwards, indicating high correlations after baseline. Langley et al. (2013)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>111</sup></a>&nbsp;conducted
an analysis of variance to examine the variability in the IGA and PASI. The
intra-rater variation in the 6-point IGA was lower than the PASI with SDs of
0.2 and 2.5, respectively.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>111</sup></a>&nbsp;The
systematic review by Puzenat et al. also reported low intra-observer
variability but moderate inter-observer variability for the IGA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>128</sup></a></p>

<p class=MsoNormal><i>Responsiveness</i></p>

<p class=MsoNormal>No evidence regarding the responsiveness of the IGA was
identified from the literature at this time.</p>

<p class=MsoNormal>The validity, reliability, and responsiveness of the IGA
instrument have not been evaluated in patients with PsA.</p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>The MID for IGA has not been estimated in patients with PsA.
It is generally accepted that a clinically meaningful score in the IGA is a
score of 0 (“clear”) or 1 (“almost clear” or “minimal”).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>53</sup></a>&nbsp;Furthermore,
some trials of patients with moderate to severe psoriasis define efficacy as a
2-point reduction in the total IGA score.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>103</sup></a>&nbsp;Both
Cappellleri et al. (2013)<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>102</sup></a>&nbsp;and
Callis Duffin et al. (2019)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>101</sup></a>&nbsp;assessed
the clinically important difference for the IGA. Both studies used the patient
global assessment score as a continuous anchor and determined a clinically
important difference score of 0.52 (95% CI, 0.42 to 0.56) and 0.55 (95% CI,
0.546 to 0.563) in each study, respectively. It should be noted that the
clinically important difference does not necessarily imply a minimum clinically
important difference and although it is not possible to measure less than 1
category difference for an individual on the IGA scale, the clinically
important difference was deemed appropriate to determine a group difference.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>102</sup></a></p>

<p class=MsoNormal><b>Leeds Enthesitis Index</b></p>

<p class=MsoNormal>Enthesitis, the inflammation at the bone insertion of a
tendon or ligament, is common in PsA. The LEI is an enthesitis index designed
for use in PsA and has been adopted for use in randomized controlled studies
involving patients with PsA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>55</sup></a>&nbsp;Enthesitis
was assessed by examining 6 sites, i.e., the lateral humeral epicondyles
(elbows), medial femoral epicondyles (knees), and Achilles tendons (heels)
bilaterally and scored as 0 (no pain) and 1 (painful), with an overall range of
0 to 6.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>55</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>Healy and colleagues conducted a study of 28 patients with
PsA underwent clinical assessment over a period of 6 months. Convergent
validity was assessed using Spearman’s correlation was used to determine the
relationship between the entheseal indices and disease activity as measured by
the swollen and tender joint counts, patient and physician global VAS, CRP
level, HAQ, and DAS 28. Moderate to weak correlations were observed between LEI
and the previously mentioned measures (r ranged from –0.157 to 0.462).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>55</sup></a>&nbsp;The
LEI index showed a large effect size of 0.82 at 6 months and signi&#64257;cant
response to change indicating adequate responsiveness.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>55</sup></a>&nbsp;No
evidence was identified to support the reliability of the LEI for patients with
PsA.</p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>The MID for LEI has not been estimated in patients with PsA.</p>

<p class=MsoNormal><b>Minimal Disease Activity</b></p>

<p class=MsoNormal>MDA is a composite outcome measure that was developed as a
target of treatment for patients with PsA that encompasses the different
aspects of disease domains.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>45</sup></a>&nbsp;Patients
are considered as achieving MDA if they fulfilled the following 5 of 7 outcome
measures: &#8804;&nbsp;1 tender joint count, &#8804;&nbsp;1 swollen joint
count, PASI &#8804;&nbsp;1 or BSA &#8804;&nbsp;3%, patient pain VAS
&#8804;&nbsp;15, patient global VAS &#8804;&nbsp;20, HAQ-DI &#8804;&nbsp;0.5,
tender entheseal points &#8804;&nbsp;1.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>105</sup></a>&nbsp;These
criteria for MDA were validated in patients with active PsA using
interventional trial data.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>50</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>Construct validity was assessed using the know-group
approach in an observational PsA cohort study of 344 patients, it was found
that patients who achieved sustained MDA (sustained MDA was defined as
achieving MDA on consecutive visits for a minimum duration of 12 months) had a
reduction in joint damage progression, where 69% of patients who achieved
sustained MDA showed no progression of joint damage, compared with 51% in the
control group, in addition the mean change in damaged joint counts was 0.931 in
the sustained MDA group and 2.245 in the controls (P&nbsp;&lt;&nbsp;0.001).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>104</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>105</sup></a>&nbsp;In
addition, Queiro et al. (2017) reported the relationship between MDA and
presence of radiographic erosions in the hands and feet in a cross-sectional
study. Patients in MDA were less likely to have evidence of hand erosions
compared with those who were not (P&nbsp;&lt;&nbsp;0.05); however, there were
no significant differences among patients when evaluating presence of erosions
in the feet.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>106</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>129</sup></a>&nbsp;Coates
et al.(2019) conducted a review of 20 studies evaluated the relationship
between MDA and disease activity reported by the patient (measured as a
patient-reported overall indicator of disease activity). The &#954; coefficient
between MDA and patients’ rating of whether they were in a minimal disease
state was 0.30 indicating weak convergent validity.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>106</sup></a>&nbsp;Coates
and colleagues also reported moderate agreement (&#954; ranged from 0.73 to
0.75) with 3 alternative definitions of treatment responses: PASDAS,
Composite&nbsp;<b>Psoriatic</b>&nbsp;Disease Activity Index-4 and
Composite&nbsp;<b>Psoriatic</b>&nbsp;Disease Activity Index-3 to assess
convergent validity in the same study assessed the construct validity of MDA.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>130</sup></a>&nbsp;Agreement
was also strong for the MDA skin domain (MDA-joints) (&#954;&nbsp;= 0.86)
indicating adequate internal consistency.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>106</sup></a></p>

<p class=MsoNormal><i>Threshold for MDA</i></p>

<p class=MsoNormal>The MDA-5, defined as meeting 5 of 7 of the cut-offs for the
previously mentioned MDA domains, is generally accepted as the threshold for
achieving MDA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>105</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>107</sup></a></p>

<p class=MsoNormal><b>Psoriasis Area and Severity Index</b></p>

<p class=MsoNormal>The PASI is the most used instrument for the assessment of
psoriasis severity.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>107</sup></a>&nbsp;It
is a single estimate of disease severity based on lesion characteristics
weighted by area of body involvement.&nbsp;<b>Psoriatic</b>&nbsp;lesion
characteristics are assessed separately for erythema, induration, and scaling
in the 4 major body areas: head, upper extremities, trunk, and lower
extremities. Severity of each item is graded on a scale of 0 to 4 (0&nbsp;=
clear, 1&nbsp;= mild, 2&nbsp;= slight, 3&nbsp;= moderate, 4&nbsp;= severe),
which is then summed by body region and weighted by the percentage of BSA
involvement converted on a scale of 0 to 6 (0&nbsp;= no involvement, 1&nbsp;=
1&#8210;9%, 2&nbsp;= 10&#8210;29%, 3&nbsp;= 30&#8210;49%, 4&nbsp;=
50&#8210;69%, 5&nbsp;= 70&#8210;89%, 6&nbsp;= 90&#8210;100%). The individual
body region scores are then multiplied by weighting factors representing their
respective proportion of the total BSA (0.1 for head, 0.2 for upper
extremities, 0.3 for trunk and 0.4 for lower extremities), as in the following
formula<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>131</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>132</sup></a>:</p>

<p class=MsoNormal>The generated PASI score is a numeric score ranging from 0
to 72, with a score greater than 10 representing more severe disease.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>131</sup></a>&nbsp;In
clinical trials, PASI is often reported as an overall mean percentage
improvement with treatment, and is used most commonly for responder analyses.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>133</sup></a>&nbsp;A
75% reduction in the PASI score, i.e., PASI 75, is used as a benchmark in
clinical trials in psoriasis.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>134</sup></a>&nbsp;While
the PASI 75 is still used for legacy drugs, the treatment goal in clinical
practice for newer treatment should be the achievement of PASI 90, according to
the clinical expert consulted for this review. A recent systematic review noted
that achieving a PASI 100 indicates total clearing of the skin and is commonly
used in clinical trials, although more real-world evidence is required to
determine its role in daily practice.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>135</sup></a></p>

<p class=MsoNormal><i>Validity</i></p>

<p class=MsoNormal>Simpson et al. (2015)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>108</sup></a>&nbsp;studied
data from a phase III clinical trial (N&nbsp;= 445) in patients with plaque
psoriasis to validate 3 systems of physician-scoring psoriasis severity, which
included the PASI, static IGA, and Lattice System IGA measures. Construct
validity of PASI was assessed by evaluating the correlation between the PASI
score and the DLQI score, a skin-related HRQoL measure in grading psoriasis
severity. The PASI correlated moderately with both the DLQI overall score as
well as a single item of DLQI related to psoriasis symptoms (0.36
&#8804;&nbsp;r &#8804;&nbsp;0.54), demonstrating that psoriasis severity is
correlated with the DLQI score. The same study also investigated the content
validity of the 3 measures by assessing the relative impact of the individual
components of the measures on HRQoL using multiple linear regression analysis;
BSA was most consistently associated with DLQI scores, followed by plaque
induration and erythema. The scaling score was found to be minimally and
inconsistently associated with DLQI scores which may be in part due to the
static measurement of scaling which does not encompass the flaking of the skin
over time which can be very distressing to patients.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>108</sup></a>&nbsp;The
authors therefore concluded that weighing erythema, induration and scaling
equally would not accurately capture the varying degrees to which these factors
affect the patient’s rating of quality of life. Lastly, the construct and
content validity of the PASI were found to be stronger during active treatment
compared to pre-therapy.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>108</sup></a></p>

<p class=MsoNormal>Another study of 10 trained dermatologists evaluating 9
adult patients with plaque-type psoriasis assessed the correlations of PASI
with other commonly used instruments in psoriasis, including the BSA and the
IGA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>108</sup></a>&nbsp;The
authors reported a strong correlation with both measures (Pearson correlation
coefficient &gt;&nbsp;0.78 and &gt;&nbsp;0.61, respectively).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>110</sup></a>&nbsp;Similarly,
Berth-Jones et al. (2016) (14 trained dermatologists, 16 patients with chronic
plaque psoriasis) reported a strong correlation between PASI and the Lattice
System IGA (Spearman’s rank correlation, r&nbsp;= 0.92), and a moderate
correlation with the IGA (r&nbsp;= 0.73).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a>&nbsp;Berth-Jones
et al. (2016) also found that the PASI and IGA were in good agreement for the
clearance state (kappa&nbsp;= 0.64) but poor agreement for the severe state
(kappa&nbsp;= 0.18).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a></p>

<p class=MsoNormal><i>Reliability</i></p>

<p class=MsoNormal>The reliability of the PASI measure has been assessed in
several studies.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a><sup>-</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>112</sup></a>&nbsp;Bo&#380;ek
et al. (2017) reported the ICCs for all components of the PASI to be
&gt;&nbsp;0.75, indicating very good intra-rater reliability, except for
scaling (ICC&nbsp;= 0.72) in 9 patients with plaque-type psoriasis. The highest
ICC was observed for the area score (ICC&nbsp;= 0.97). The coefficient of
variation for the PASI was 36.9 overall, indicating moderate inter-rater
reliability. The highest variability was observed for the head and neck
(coefficients of variation&nbsp;= 117.8) and the lowest variability was for the
area score (coefficients of variation&nbsp;= 26.8).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a><sup>-</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>112</sup></a>&nbsp;Langley
et al. (2004) (17 physicians, 25 patients with psoriasis) reported similar
results, with higher variability observed in the PASI scores derived by
inexperienced physicians compared with experienced investigators (&#963;&nbsp;=
3.2 versus 1.2).<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>111</sup></a>&nbsp;Berth-Jones
et al. (2016) found excellent intra-rater and inter-rater reliability for the
PASI score (ICCs &gt;&nbsp;0.81) in.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>109</sup></a>&nbsp;Fink
et al. (2018) validated the methodology of ‘image-based’ versus commonly used
‘live’ PASI measurements in a pilot study, followed by validating in an
observational cohort study.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>112</sup></a>&nbsp;They
investigated the precision and reproducibility of automated, computer- guided
PASI measurements in comparison with 3 trained physicians. PASI scores of 120
patients affected by plaque psoriasis of various severities were prospectively
evaluated by 3 formally trained physicians by means of total body images. Each
observer independently performed 2 rounds of image-based PASI calculations in
all patients at 2 different time points.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>112</sup></a>&nbsp;Overall,
720 image-based PASI scores were calculated with a mean PASI of 8.8 (range 0.7
to 34.8). An inter-rater variability with an ICC of 0.895 and mean absolute
difference of 3.3 PASI points were observed. Intra-rater variability showed a
mean ICC of 0.877 and a mean absolute difference of 2.2 points.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>112</sup></a></p>

<p class=MsoNormal><i>Responsiveness</i></p>

<p class=MsoNormal>The PASI score was found to have a moderate sensitivity to
change in psoriasis patients (ICC ranged from 0.5 to 0.8).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>113</sup></a>&nbsp;In
a review by Spuls et al. (2010)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>136</sup></a>&nbsp;the
authors commented on the responsiveness of PASI being weak when less than 10%
of the BSA is affected given that the PASI score would be entirely dependent on
the plaque severity scores, and therefore may underestimate the general degree
of improvement.</p>

<p class=MsoNormal><i>Minimal Important Difference</i></p>

<p class=MsoNormal>The MID for PASI has not been estimated in patients with
PsA. A systematic review by Mattei et al. (2013)<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>114</sup></a>&nbsp;including
13 RCTs evaluating biologics in psoriasis, reported that a &#8805;&nbsp;75%
reduction in the PASI score translates to clinically-significant HRQoL
improvement in patients assessed using the DLQI. This is based on the several
studies that have demonstrated that a reduction in PASI scores can predict a
reduction in DLQI scores, particularly when the patients were achieving a PASI
75 or higher (PASI 75 versus PASI 50 to 75 versus mean difference of 3.24).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>114</sup></a></p>

<p class=MsoNormal><b>Resolution of Dactylitis – Dactylitis Score</b></p>

<p class=MsoNormal>Dactylitis score is a total score of presence and severity
of dactylitis in each digit using a scoring system from 0 (no dactylitis) to 3
(severe dactylitis). The final dactylitis score ranges from 0 to 60. A negative
change from baseline indicates improvement. Dactylitis resolution at a visit is
established when a participant with a baseline non-zero dactylitis score has a
score of 0 at the analysis visit.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>13</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>No evidence of validity, reliability, and responsiveness is
identified for the dactylitis score in patients with PsA.</p>

<p class=MsoNormal><i>MID</i></p>

<p class=MsoNormal>The MID for the dactylitis score has not been estimated in
patients with PsA.</p>

<p class=MsoNormal><b>Short Form-36 Health Survey Mental Component and Physical
Component Scores (SF-36 MCS/PCS)</b></p>

<p class=MsoNormal>The SF-36 is a 36-item, general health status instrument
that has been used extensively in clinical trials in many disease areas.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>115</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>116</sup></a>&nbsp;The
SF-36 consists of 8 health domains: physical functioning, role physical, bodily
pain, general health, vitality, social functioning, role emotional, and mental
health. For each of the 8 domains, a subscale score can be calculated. The
SF-36 also provides 2 component summaries, the PCS and the MCS, derived from
aggregating the 8 domains according to a scoring algorithm. All scores are
based on a scale of 0 to 100, with higher scores indicating higher HRQoL. The
scores can also be standardized to the general US population, where an average
score is 50, with a SD of 10 (t score). Version 2 of the SF-36 was made
available to researchers in 1996<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>137</sup></a>&nbsp;and
was developed to address the shortcomings of the version 1 of the survey;
including changing response options for role function scales from dichotomous
to 5-point scale responses and altering the wording of certain items to make
them easier to understand.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>138</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>Validity and reliability were assessed in a study of 168
patients with PsA.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a>&nbsp;Construct
validity was assessed using the known-group approach, patients with PsA were
grouped under severe disease based on HAQ &gt;&nbsp;1.0, BASDAI &gt;&nbsp;50
and DAS 28 &gt;&nbsp;5.1. All 8 scales and summary scores in the severe groups
were significantly worse than the less severe groups.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a>&nbsp;Inter-scale
coefficients (Cronbach alpha) were calculated to assess internal reliability,
substantial to moderate levels of agreement were observed for most of scales of
SF-36 (Cronbach alpha ranged from 0.33 to 0.70).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a>&nbsp;Leung
and colleagues (2021) analyzed data of 31 patients with PsA in a UK
observational study. The study reported that SF-36 physical function domain
demonstrated almost perfect test-retest reliability in patients with PsA (ICC
0.96, 95% CI 0.92 to 0.98).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>100</sup></a>&nbsp;The
responsiveness has been assessed for the SF-36 in RCTs in patients with PsA.
The median effect sizes were 0.77 (95% CI 0.60 to 0.93) and 0.23 (95% CI 0.09
to 0.36) for intervention and control groups, respectively.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>139</sup></a><sup>-</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>141</sup></a></p>

<p class=MsoNormal><i>Minimal Important Difference</i></p>

<p class=MsoNormal>The MID for either the PCS or MCS of the SF-36 is typically
between 2.5 and 5 points.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a>&nbsp;Leung
and colleagues (2010) reported MIDs of 3.74 and 1.77 for the PCS and MCS
subsections, respectively, in PsA patients treated with anti-TNF alpha drugs
using an anchor-based approach.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>7</sup></a><sup>,</sup><a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>52</sup></a></p>

<p class=MsoNormal><b>Modified vdH-S Score</b></p>

<p class=MsoNormal>The modified vdH-S score is based on the Sharp–van der
Heijde method. The original scoring system evaluates erosions and joint space
narrowing of joints of hands and feet in rheumatoid arthritis. The proposed
method for PsA evaluates erosions, joint space narrowing, subluxation,
ankylosis, gross osteolysis, and pencil-in-cup lesions. Erosions are assessed
in 20 joints of hands and wrists: 10 distal interphalangeal joints and
interphalangeal joints of the thumbs, 10 metacarpophalangeal joints, 2 first metacarpal
bones, 2 radial and ulnar bones, 2 multangular units (trapezium and trapezoid
combined) and in 12 joints of the feet (10 metatarsophalangeal joints and 2
interphalangeal joints of the big toes, joint space narrowing, subluxation,
ankylosis, gross osteolysis and pencil in cup are assessed in the hands in 10
distal interphalangeal joints and interphalangeal joints of the thumbs, 10
metacarpophalangeal joints, second, third, fourth, and fifth carpometacarpal
joints, 2 multangular units, 2 capitate-navicular-lunate joints, 2 radiocarpal
joints, 10 metatarsophalangeal joints, and 2 interphalangeal joints of the big
toes. The maximum score for erosions is 5 in the joints of the hands and 10 in
the joints of the feet. Scores for erosions are as follows: 0&nbsp;= no
erosions; 1&nbsp;= discrete erosions; 2&nbsp;= large erosions not passing the
midline; 3&nbsp;= large erosions passing the midline. A combination of these
scores leads to a maximum of 5 for a whole joint in the hands, and 5 at each
site of the joint (for the entire joint a maximum of 10) in the feet. The joint
space narrowing scoring is: 0&nbsp;= normal; 1&nbsp;= asymmetric or minimal
narrowing up to a maximum of 25%; 2&nbsp;= definite narrowing with loss of up
to 50% of the normal space; 3&nbsp;= definite narrowing with loss of 50% to 99%
of the normal space or subluxation; 4&nbsp;= absence of a joint space,
presumptive evidence of ankylosis, or complete luxation. Gross osteolysis and
pencil in cup are scored separately. If present, these lesions are scored with
the maximum score for both erosions and joint space narrowing. The maximum
possible score for erosions is 200 for the hands and 120 for the feet; the
maximum possible score for joint space narrowing is 160 for the hands and 48
for the feet. Finally, the maximum possible score is 528.<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>10</sup></a></p>

<p class=MsoNormal><i>Assessment of Validity, Reliability, and Responsiveness</i></p>

<p class=MsoNormal>In a study of 105 patients with PsA (mean age&nbsp;= 50.2,
SD&nbsp;= 12.1), the vdH-S method showed strong convergent validity, when
correlated with Simplified&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Radiographic
Score (SPARS) (r&#8201;&nbsp;= 0.926, P&#8201; &lt;&nbsp;0.0001).<a
href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>117</sup></a></p>

<p class=MsoNormal>In 1 study, hand and feet radiographs from 50 patients with
PsA were scored at 2 time points by 2 assessors for the modified vdH-S score.
The radiographs of 10 patients were scored by both the readers using all 4
techniques in random order to assess inter-rater reliability and then scored 1
month later to estimate intra-rater reliability using ICCs. Sensitivity to
change was estimated using a SRM and smallest detectable change. The inter- and
intra-rater reliability were almost perfect agreement: ICC&nbsp;= 0.95 (95% CI
0.83 to 0.99) at baseline and 0.99 (95% CI 0.96 to 1.00) at follow-up (mean: 26
months, SD: 9.6 months) for inter-rater reliability; Rater 1 ICC&nbsp;= 0.97
(95% CI 0.90 to 0.99) and Rater 2 0.99 (95% CI 0.98 to 0.99) for intra-rater
reliability. The modified vdH-S score has the ability to detect change at 1.2%.
The sensitivity to change of the methods using the SRM demonstrated the
modified vdH-S as having the greatest ability to detect change at a level of
0.79. The feasibility of the modified vdH-S method was estimated based on the
mean time taken to score each film. The modified vdH-S method took 14.4 minutes
to score.<a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"><sup>117</sup></a></p>

<p class=MsoNormal><i>Minimal Important Difference</i></p>

<p class=MsoNormal>No reported MID was found for PsA patients.</p>

<p class=MsoNormal><a href="https://www.ncbi.nlm.nih.gov/books/NBK601781/"
title="Go to other sections in this page">Go to:</a></p>

<p class=MsoNormal><b>References</b></p>

<p class=MsoNormal>1.</p>

<p class=MsoNormal>Gladman D, Ritchlin C. Clinical manifestations and diagnosis
of&nbsp;<b>psoriatic</b>&nbsp;arthritis. In: Post TW, ed.&nbsp;<i>UpToDate</i>.
Waltham (MA): UpToDate; 2022:&nbsp;<a
href="https://cadthcanada.sharepoint.com/sites/Pharmaceuticals/Active%20Reviews/SR0733%20Tremfya%20PsA/Clinical%20Review/www.uptodate.com">www&#8203;.uptodate.com</a>.
Accessed 2022 May 18.</p>

<p class=MsoNormal>2.</p>

<p class=MsoNormal>Ritchlin CT, Colbert RA, Gladman DD.&nbsp;<b>Psoriatic</b>&nbsp;Arthritis.
N Engl J Med. 2017;376(10):957-970. [<a
href="https://pubmed.ncbi.nlm.nih.gov/28273019">PubMed</a>]</p>

<p class=MsoNormal>3.</p>

<p class=MsoNormal>Eder L, Widdifield J, Rosen CF, et al. Trends in the
Prevalence and Incidence of Psoriasis and&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
in Ontario, Canada: A Population-Based Study. Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2019;71(8):1084-1091.
[<a href="https://pubmed.ncbi.nlm.nih.gov/30171803">PubMed</a>]</p>

<p class=MsoNormal>4.</p>

<p class=MsoNormal>Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR
recommendations for the management of&nbsp;<b>psoriatic</b>&nbsp;arthritis with
pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286048/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/32434812">PubMed</a>]</p>

<p class=MsoNormal>5.</p>

<p class=MsoNormal>Tremfya (guselkumab): 100 mg/1 mL sterile solution for
injection in pre-filled syringe or Tremfya One-pass (guselkumab): 100 mg/1 mL
sterile solution for injection in a patient-controlled [product monograph].
Toronto (ON): Janssen Inc.; 2022 Apr 13.</p>

<p class=MsoNormal>6.</p>

<p class=MsoNormal>Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A.
Minimally important difference of Health Assessment Questionnaire in&nbsp;<b>psoriatic</b>&nbsp;arthritis:
relating thresholds of improvement in functional ability to patient-rated
importance and satisfaction. J Rheumatol. 2011;38(11):2461-2465. [<a
href="https://pubmed.ncbi.nlm.nih.gov/21885498">PubMed</a>]</p>

<p class=MsoNormal>7.</p>

<p class=MsoNormal>Leung YY, Zhu TY, Tam LS, Kun EW, Li EK. Minimal important
difference and responsiveness to change of the SF-36 in patients with&nbsp;<b>psoriatic</b>&nbsp;arthritis
receiving tumor necrosis factor-alpha blockers. J Rheumatol.
2011;38(9):2077-2079. [<a href="https://pubmed.ncbi.nlm.nih.gov/21885524">PubMed</a>]</p>

<p class=MsoNormal>8.</p>

<p class=MsoNormal>Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober
J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue
Scale relative to other instrumentation in patients with rheumatoid arthritis.
J Rheumatol. 2005;32(5):811-819. [<a
href="https://pubmed.ncbi.nlm.nih.gov/15868614">PubMed</a>]</p>

<p class=MsoNormal>9.</p>

<p class=MsoNormal>Højgaard P, Klokker L, Orbai AM, et al. A systematic review
of measurement properties of patient reported outcome measures in&nbsp;<b>psoriatic</b>&nbsp;arthritis:
A GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2018;47(5):654-665. [<a
href="https://pubmed.ncbi.nlm.nih.gov/29037523">PubMed</a>]</p>

<p class=MsoNormal>10.</p>

<p class=MsoNormal>Salaffi F, Carotti M, Di Donato E, et al. Preliminary
validation of the Simplified&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Radiographic
Score (SPARS). Skeletal Radiol. 2019;48(7):1033-1041. [<a
href="https://pubmed.ncbi.nlm.nih.gov/30535825">PubMed</a>]</p>

<p class=MsoNormal>11.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3001. DISCOVER-1 24 week:
a phase 3, multicenter, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of guselkumab administered subcutaneously in
subjects with active&nbsp;<b>psoriatic</b>&nbsp;arthritis including those
previously treated with biologic anti-TNF&#945; agent(s) [internal sponsor's
report]. Raritan (NJ): Janssen Research &amp; Development, LLC; 2019 Aug 28.</p>

<p class=MsoNormal>12.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3002. DISCOVER-2 24 week:
a phase 3, multicenter, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of guselkumab administered subcutaneously in
subjects with active&nbsp;<b>psoriatic</b>&nbsp;arthritis [internal sponsor's
report]. Raritan (NJ): Janssen Research &amp; Development, LLC; 2019 Aug 28.</p>

<p class=MsoNormal>13.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3003. COSMOS week 24: a
phase 3b, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of guselkumab administered subcutaneously in
participants with active&nbsp;<b>psoriatic</b>&nbsp;arthritis and an inadequate
response to anti-tumor necrosis factor COSMOS [internal sponsor's report]. High
Wycombe (UK): Janssen-Cilag Ltd.; 2020 Sep 23.</p>

<p class=MsoNormal>14.</p>

<p class=MsoNormal>Coates LC, Gossec L, Theander E, et al. Efficacy and safety
of guselkumab in patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis who
are inadequate responders to tumour necrosis factor inhibitors: results through
one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis.
2022;81(3):359-369. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862038/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/34819273">PubMed</a>]</p>

<p class=MsoNormal>15.</p>

<p class=MsoNormal>McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C,
Helliwell PS. Targeted systemic therapies for&nbsp;<b>psoriatic</b>&nbsp;arthritis:
a systematic review and comparative synthesis of short-term articular,
dermatological, enthesitis and dactylitis outcomes.&nbsp;<i>RMD Open.</i>&nbsp;2022;8(1):03.
[<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943739/">PMC free
article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35321874">PubMed</a>]</p>

<p class=MsoNormal>16.</p>

<p class=MsoNormal>Van den Bosch F, Coates L. Clinical management of&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Lancet. 2018;391(10136):2285-2294. [<a
href="https://pubmed.ncbi.nlm.nih.gov/29893227">PubMed</a>]</p>

<p class=MsoNormal>17.</p>

<p class=MsoNormal>Eder L, Haddad A, Rosen CF, et al. The Incidence and Risk
Factors for&nbsp;<b>Psoriatic</b>&nbsp;Arthritis in Patients With Psoriasis: A
Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915-923. [<a
href="https://pubmed.ncbi.nlm.nih.gov/26555117">PubMed</a>]</p>

<p class=MsoNormal>18.</p>

<p class=MsoNormal>Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research
and Assessment of Psoriasis and&nbsp;<b>Psoriatic</b>&nbsp;Arthritis 2015
Treatment Recommendations for&nbsp;<b>Psoriatic</b>&nbsp;Arthritis. Arthritis
Rheumatol. 2016;68(5):1060-1071. [<a
href="https://pubmed.ncbi.nlm.nih.gov/26749174">PubMed</a>]</p>

<p class=MsoNormal>19.</p>

<p class=MsoNormal>Coates LC, Soriano ER, Corp N, et al. Group for Research and
Assessment of Psoriasis and&nbsp;<b>Psoriatic</b>&nbsp;Arthritis (GRAPPA):
updated treatment recommendations for&nbsp;<b>psoriatic</b>&nbsp;arthritis
2021. Nat Rev Rheumatol. 2022;18(8):465-479. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244095/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/35761070">PubMed</a>]</p>

<p class=MsoNormal>20.</p>

<p class=MsoNormal>Drug Reimbursement Review sponsor submission: Tremfya
(guselkumab), 100 mg/mL solution for injection [internal sponsor's package].
Toronto (ON): Janssen Inc.; 2022 May 17.</p>

<p class=MsoNormal>21.</p>

<p class=MsoNormal>CADTH Canadian Drug Expert Committee (CDEC) final
recommendation: guselkumab (Tremfya — Janssen Inc.) for moderate-to-severe
plaque psoriasis. Ottawa (ON): CADTH; 2018 Feb 21:&nbsp;<a
href="https://www.cadth.ca/sites/default/files/cdr/complete/SR0530_Tremfya_complete_Feb-23-18.pdf">https://www&#8203;.cadth.ca&#8203;/sites/default/files&#8203;/cdr/complete/SR0530&#8203;_Tremfya_complete_Feb-23-18.pdf</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>22.</p>

<p class=MsoNormal>Humira (adalimumab injection): 50 mg/mL or 100 mg/mL of
sterile solution for subcutaneous injection [product monograph]. St-Laurent
(QC): AbbVie Corporation; 2021 Apr 21:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00061690.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00061690.PDF</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>23.</p>

<p class=MsoNormal>Taltz (ixekizumab): 80 mg /1.0 mL solution for injection
[product monograph]. Toronto (ON): Eli Lilly Canada Inc.; 2021 Mar 29:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00060574.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00060574.PDF</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>24.</p>

<p class=MsoNormal>Stelara (ustekinumab): 45 mg/0.5 mL or 90 mg/1.0 mL solution
for subcutaneous injection or Stelara I.V. (ustekinumab): 130 mg/26 mL (5
mg/mL) solution for intravenous infusion [product monograph]. Toronto (ON):
Janssen Inc.; 2021 Sep 9:&nbsp;<a href="https://pdf.hres.ca/dpd_pm/00062938.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00062938.PDF</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>25.</p>

<p class=MsoNormal>Cosentyx (secukinumab): 75 mg/0.5 mL or 150 mg/1 mL solution
for injection or 150 mg powder for solution for injection [product monograph].
Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2022 Apr 08:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00065374.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00065374.PDF</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>26.</p>

<p class=MsoNormal>Skyrizi (risankizumab): 90 mg/mL or 150 mg/mL, sterile
solution subcutaneous injection [product monograph]. St-Laurent (QC): AbbVie
Corporation; 2022 Mar 16:&nbsp;<a href="https://pdf.hres.ca/dpd_pm/00065082.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00065082.PDF</a>.
Accessed 2022 May 25.</p>

<p class=MsoNormal>27.</p>

<p class=MsoNormal>Xeljanz (as tofacitinib citrate): 5 mg or 10 mg, oral
tablets or Xeljanz XR (as tofacitinib citrate): 11 mg, extended-release oral
tablets [product monograph]. Kirkland (QC): Pfizer Canada ULC; 2022 May
09:&nbsp;<a href="https://pdf.hres.ca/dpd_pm/00065725.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00065725.PDF</a>.
Accessed 2022 May 25.</p>

<p class=MsoNormal>28.</p>

<p class=MsoNormal>Cimzia (certolizumab pegol): 200 mg/mL solution for
injection [product monograph]. Oakville (ON): UCB Canada Inc; 2019 Nov
13:&nbsp;<a href="https://pdf.hres.ca/dpd_pm/00053920.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00053920.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>29.</p>

<p class=MsoNormal>Enbrel (etanercept): 50 mg/mL solution in a prefilled
syringe or Enbrel (etanercept): 25 mg/vial of lyophilized powder in a vial for
reconstitution for subcutaneous injection [product monograph]. Mississauga
(ON): Amgen Canada Inc.; 2021 Mar 19:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00060454.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00060454.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>30.</p>

<p class=MsoNormal>Simponi (golimumab injection): 50 mg/0.5 mL or 100 mg/1.0 mL
solution for subcutaneous injection or Simponi (golimumab for injection): 50
mg/4.0 mL solution for intravenous infusion [product monograph]. Toronto (ON):
Janssen Inc.; 2019 Jun 19:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00052895.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00052895.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>31.</p>

<p class=MsoNormal>Remicade (infliximab): 100 mg/vial sterile lyophilized
powder for solution, for intravenous infusion [product monograph]. Toronto
(ON): Janssen Inc.; 2021 Oct 15:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00063218.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00063218.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>32.</p>

<p class=MsoNormal>Rinvoq (upadacitinib): 15 mg or 30 mg, oral extended-release
tablets [product monograph]. St-Laurent (QC): AbbVie Corporation; 2022 Jan
27:&nbsp;<a href="https://pdf.hres.ca/dpd_pm/00064540.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00064540.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>33.</p>

<p class=MsoNormal>Orencia (abatacept): 250 mg /vial for intravenous infusion
or Orencia (abatacept): 125 mg /mL solution for subcutaneous injection [product
monograph]. Montreal (QC): Bristol-Myers Squibb Canada; 2019 Sep 09:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00052970.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00052970.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>34.</p>

<p class=MsoNormal>Otezla (apremilast): 10 mg, 20 mg, and 30 mg oral tablets
[product monograph]. Mississauga (ON): Amgen Canada Inc.; 2020 Aug 05:&nbsp;<a
href="https://pdf.hres.ca/dpd_pm/00057499.PDF">https://pdf&#8203;.hres.ca/dpd_pm/00057499.PDF</a>.
Accessed 2022 Jun 28.</p>

<p class=MsoNormal>35.</p>

<p class=MsoNormal>McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V,
Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline
Statement. J Clin Epidemiol. 2016;75:40-46. [<a
href="https://pubmed.ncbi.nlm.nih.gov/27005575">PubMed</a>]</p>

<p class=MsoNormal>36.</p>

<p class=MsoNormal>Grey matters: a practical tool for searching health-related
grey literature. Ottawa (ON): CADTH; 2019:&nbsp;<a
href="https://www.cadth.ca/grey-matters">https://www&#8203;.cadth.ca/grey-matters</a>.
Accessed 2022 May 13.</p>

<p class=MsoNormal>37.</p>

<p class=MsoNormal>Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in
patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis who were
biologic-naive or had previously received TNFalpha inhibitor treatment
(DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet. 2020;395(10230):1115-1125. [<a
href="https://pubmed.ncbi.nlm.nih.gov/32178765">PubMed</a>]</p>

<p class=MsoNormal>38.</p>

<p class=MsoNormal>Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab
demonstrated an independent treatment effect in reducing fatigue after
adjustment for clinical response-results from two phase 3 clinical trials of
1120 patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis. Arthritis Res
Ther. 2021;23(1):190. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278683/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/34261541">PubMed</a>]</p>

<p class=MsoNormal>39.</p>

<p class=MsoNormal>Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in
biologic-naive patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis
(DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet. 2020;395(10230):1126-1136. [<a
href="https://pubmed.ncbi.nlm.nih.gov/32178766">PubMed</a>]</p>

<p class=MsoNormal>40.</p>

<p class=MsoNormal>Health Canada reviewer's report: Tremfya (guselkumab)
[internal sponsor's report]. In: Drug Reimbursement Review sponsor submission:
Tremfya (guselkumab), 100 mg/mL solution for injection. Toronto (ON): Janssen
Inc.; 2022 May 17.</p>

<p class=MsoNormal>41.</p>

<p class=MsoNormal>Committee for Medicinal Products for Human Use. Extension of
indication variation assessment report: Tremfya (guselkumab). Amsterdam (NL):
European Medicines Agency; 2020 Oct 15:&nbsp;<a
href="https://www.ema.europa.eu/en/documents/variation-report/tremfya-h-c-4271-ii-17-epar-assessment-report-variation_en.pdf">https://www&#8203;.ema.europa&#8203;.eu/en/documents/variation-report&#8203;/tremfya-h-c-4271-ii-17-epar-assessment-report-variation_en.pdf</a>.
Accessed 2022 Jun 09.</p>

<p class=MsoNormal>42.</p>

<p class=MsoNormal>Janssen Inc. response to July 11, 2022 DRR request for
additional information regarding Tremfya (guselkumab) DRR review [internal
additional sponsor's information]. Toronto (ON): Janssen Inc.; 2022 Jul 18.</p>

<p class=MsoNormal>43.</p>

<p class=MsoNormal>Fransen J, Antoni C, Mease PJ, et al. Performance of
response criteria for assessing peripheral arthritis in patients with&nbsp;<b>psoriatic</b>&nbsp;arthritis:
analysis of data from randomised controlled trials of two tumour necrosis
factor inhibitors. Ann Rheum Dis. 2006;65(10):1373-1378. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798317/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/16644783">PubMed</a>]</p>

<p class=MsoNormal>44.</p>

<p class=MsoNormal>Albert DA, Huang G, Dubrow G, Brensinger CM, Berlin JA,
Williams HJ. Criteria for improvement in rheumatoid arthritis: alternatives to
the American College of Rheumatology 20. J Rheumatol. 2004;31(5):856-866. [<a
href="https://pubmed.ncbi.nlm.nih.gov/15124243">PubMed</a>]</p>

<p class=MsoNormal>45.</p>

<p class=MsoNormal>Coates LC, Fransen J, Helliwell PS. Defining minimal disease
activity in&nbsp;<b>psoriatic</b>&nbsp;arthritis: a proposed objective target
for treatment. Ann Rheum Dis. 2010;69(1):48-53. [<a
href="https://pubmed.ncbi.nlm.nih.gov/19147615">PubMed</a>]</p>

<p class=MsoNormal>46.</p>

<p class=MsoNormal>van Riel PL. The development of the disease activity score
(DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp
Rheumatol. 2014;32(5 Suppl 85):S-65-74. [<a
href="https://pubmed.ncbi.nlm.nih.gov/25365092">PubMed</a>]</p>

<p class=MsoNormal>47.</p>

<p class=MsoNormal>Wells G, Becker JC, Teng J, et al. Validation of the
28-joint Disease Activity Score (DAS28) and European League Against Rheumatism
response criteria based on C-reactive protein against disease progression in
patients with rheumatoid arthritis, and comparison with the DAS28 based on
erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954-960. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674547/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/18490431">PubMed</a>]</p>

<p class=MsoNormal>48.</p>

<p class=MsoNormal>Duarte-García A, Leung YY, Coates LC, et al. Endorsement of
the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity:
OMERACT 2018&nbsp;<b>Psoriatic</b>&nbsp;Arthritis Workshop Report. J Rheumatol.
2019;46(8):996-1005. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776995/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/30770518">PubMed</a>]</p>

<p class=MsoNormal>49.</p>

<p class=MsoNormal>Kwok T, Pope JE. Minimally important difference for
patient-reported outcomes in&nbsp;<b>psoriatic</b>&nbsp;arthritis: Health
Assessment Questionnaire and pain, fatigue, and global visual analog scales. J
Rheumatol. 2010;37(5):1024-1028. [<a
href="https://pubmed.ncbi.nlm.nih.gov/20231193">PubMed</a>]</p>

<p class=MsoNormal>50.</p>

<p class=MsoNormal>Leung YY, Holland R, Mathew AJ, et al. Clinical trial
discrimination of physical function instruments for&nbsp;<b>psoriatic</b>&nbsp;arthritis:
A systematic review. Semin Arthritis Rheum. 2020;50(5):1158-1181. [<a
href="https://pubmed.ncbi.nlm.nih.gov/32927377">PubMed</a>]</p>

<p class=MsoNormal>51.</p>

<p class=MsoNormal>Ware JE, Jr. SF-36 health survey update. Spine (Phila Pa
1976)<i>.</i>&nbsp;2000;25(24):3130-3139. [<a
href="https://pubmed.ncbi.nlm.nih.gov/11124729">PubMed</a>]</p>

<p class=MsoNormal>52.</p>

<p class=MsoNormal>Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK. Testing
scaling assumptions, reliability and validity of medical outcomes study
short-form 36 health survey in&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Rheumatology (Oxford)<i>.</i>&nbsp;2010;49(8):1495-1501. [<a
href="https://pubmed.ncbi.nlm.nih.gov/20421216">PubMed</a>]</p>

<p class=MsoNormal>53.</p>

<p class=MsoNormal>Langley RG, Feldman SR, Nyirady J, van de Kerkhof P,
Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A
modified tool for evaluating plaque psoriasis severity in clinical trials. J
Dermatolog Treat. 2015;26(1):23-31. [<a
href="https://pubmed.ncbi.nlm.nih.gov/24354461">PubMed</a>]</p>

<p class=MsoNormal>54.</p>

<p class=MsoNormal>Mrowietz U, Kragballe K, Reich K, et al. Definition of
treatment goals for moderate to severe psoriasis: a European consensus. Arch
Dermatol Res. 2011;303(1):1-10. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016217/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/20857129">PubMed</a>]</p>

<p class=MsoNormal>55.</p>

<p class=MsoNormal>Healy PJ, Helliwell PS. Measuring clinical enthesitis
in&nbsp;<b>psoriatic</b>&nbsp;arthritis: Assessment of existing measures and
development of an instrument specific to&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2008;59(5):686-691. [<a
href="https://pubmed.ncbi.nlm.nih.gov/18438903">PubMed</a>]</p>

<p class=MsoNormal>56.</p>

<p class=MsoNormal>Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H,
Dougados M. Defining disease activity in ankylosing spondylitis: is a
combination of variables (Bath Ankylosing Spondylitis Disease Activity Index)
an appropriate instrument? Rheumatology (Oxford)<i>.</i>&nbsp;1999;38(9):878-882.
[<a href="https://pubmed.ncbi.nlm.nih.gov/10515650">PubMed</a>]</p>

<p class=MsoNormal>57.</p>

<p class=MsoNormal>Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P,
Calin A. A new approach to defining disease status in ankylosing spondylitis:
the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol.
1994;21(12):2286-2291. [<a href="https://pubmed.ncbi.nlm.nih.gov/7699630">PubMed</a>]</p>

<p class=MsoNormal>58.</p>

<p class=MsoNormal>Zochling J, van der Heijde D, Burgos-Vargas R, et al.
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann
Rheum Dis. 2006;65(4):442-452. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798102/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/16126791">PubMed</a>]</p>

<p class=MsoNormal>59.</p>

<p class=MsoNormal>Janssen Research &amp; Development, LLC. NCT01077362: A
Study of the Safety and Efficacy of Ustekinumab in Patients With&nbsp;<b>Psoriatic</b>&nbsp;Arthritis
With and Without Prior Exposure to Anti-TNF Agents.&nbsp;<i>ClinicalTrials.gov</i>.
Bethesda (MD): U.S. National Library of Medicine; 2014:&nbsp;<a
href="https://www.clinicaltrials.gov/ct2/show/results/NCT01077362">https://www&#8203;.clinicaltrials&#8203;.gov/ct2/show/results/NCT01077362</a>.
Accessed 2022 Aug 08.</p>

<p class=MsoNormal>60.</p>

<p class=MsoNormal>Gladman DD, Orbai AM, Gomez-Reino J, et al. Network
Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs,
and Apremilast for the Treatment of&nbsp;<b>Psoriatic</b>&nbsp;Arthritis. Curr
Ther Res Clin Exp. 2020;93:100601. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494680/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/32983284">PubMed</a>]</p>

<p class=MsoNormal>61.</p>

<p class=MsoNormal>Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y.
Comparative efficacy and safety of targeted DMARDs for active&nbsp;<b>psoriatic</b>&nbsp;arthritis
during induction therapy: A systematic review and network meta-analysis. Semin
Arthritis Rheum. 2019;49(3):381-388. [<a
href="https://pubmed.ncbi.nlm.nih.gov/31272807">PubMed</a>]</p>

<p class=MsoNormal>62.</p>

<p class=MsoNormal>Mease PJ, McInnes IB, Tam LS, et al. Comparative
effectiveness of guselkumab in&nbsp;<b>psoriatic</b>&nbsp;arthritis: results
from systematic literature review and network meta-analysis. Rheumatology
(Oxford)<i>.</i>&nbsp;2021;60(5):2109-2121. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121447/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/33844022">PubMed</a>]</p>

<p class=MsoNormal>63.</p>

<p class=MsoNormal>Qiu M, Xu Z, Gao W, et al. Fourteen small molecule and
biological agents for&nbsp;<b>psoriatic</b>&nbsp;arthritis: A network
meta-analysis of randomized controlled trials. Medicine. 2020;99(31):e21447. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402795/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/32756163">PubMed</a>]</p>

<p class=MsoNormal>64.</p>

<p class=MsoNormal>Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and
safety of biologics in&nbsp;<b>psoriatic</b>&nbsp;arthritis: a systematic
literature review and network meta-analysis.&nbsp;<i>RMD Open.</i>&nbsp;2020;6(1):02.
[<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046955/">PMC free
article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32094304">PubMed</a>]</p>

<p class=MsoNormal>65.</p>

<p class=MsoNormal>Song GG, Lee YH. Relative efficacy and safety of apremilast,
secukinumab, and ustekinumab for the treatment of&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Z Rheumatol. 2018;77(7):613-620. [<a
href="https://pubmed.ncbi.nlm.nih.gov/28791450">PubMed</a>]</p>

<p class=MsoNormal>66.</p>

<p class=MsoNormal>Torres T, Barcelos A, Filipe P, Fonseca JE. A Systematic
Review With Network Meta-Analysis of the Available Biologic Therapies for&nbsp;<b>Psoriatic</b>&nbsp;Disease
Domains. Front Med (Lausanne)<i>.</i>&nbsp;2020;7:618163. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843938/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/33521024">PubMed</a>]</p>

<p class=MsoNormal>67.</p>

<p class=MsoNormal>Wu D, Yue J, Tam LS. Efficacy and safety of biologics
targeting interleukin-6, &#8722;12/23 and &#8722;17 pathways for
peripheral&nbsp;<b>psoriatic</b>&nbsp;arthritis: a network meta-analysis.
Rheumatology (Oxford)<i>.</i>&nbsp;2018;57(3):563-571. [<a
href="https://pubmed.ncbi.nlm.nih.gov/29244162">PubMed</a>]</p>

<p class=MsoNormal>68.</p>

<p class=MsoNormal>Guselkumab (Tremfya®) for&nbsp;<b>psoriatic</b>&nbsp;arthritis:
systematic review and network metaanalyses. Global NMA technical report
[internal sponsor's report]. In: Drug Reimbursement Review sponsor submission:
Tremfya (guselkumab), 100 mg/mL solution for injection. Toronto (ON): Janssen
Inc.; 2022.</p>

<p class=MsoNormal>69.</p>

<p class=MsoNormal>CADTH Reimbursement Review clinical guidance and
pharmacoeconomic reports: upadacitinib (Rinvoq) for&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Can J Health Technol. 2021;1(10).&nbsp;<a
href="https://www.cadth.ca/sites/default/files/DRR/2021/SR0658-combined-report.pdf">https://www&#8203;.cadth.ca&#8203;/sites/default/files&#8203;/DRR/2021/SR0658-combined-report.pdf</a>.
Accessed 2022 Aug 02.</p>

<p class=MsoNormal>70.</p>

<p class=MsoNormal>Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6.
Rating the quality of evidence--imprecision. J Clin Epidemiol.
2011;64(12):1283-1293. [<a href="https://pubmed.ncbi.nlm.nih.gov/21839614">PubMed</a>]</p>

<p class=MsoNormal>71.</p>

<p class=MsoNormal>Wade R, Grosso A, South E, et al. Brodalumab for the
treatment of moderate-to-severe plaque psoriasis: an evidence review group
evaluation of a NICE single technology appraisal. Pharmacoeconomics.
2019;37(2):131-139. [<a href="https://pubmed.ncbi.nlm.nih.gov/30112635">PubMed</a>]</p>

<p class=MsoNormal>72.</p>

<p class=MsoNormal>Cameron C, Hutton B, Druchok C, et al. Importance of
assessing and adjusting for cross-study heterogeneity in network meta-analysis:
a case study of psoriasis. J Comp Eff Res. 2018;7(11):1037-1051. [<a
href="https://pubmed.ncbi.nlm.nih.gov/30277080">PubMed</a>]</p>

<p class=MsoNormal>73.</p>

<p class=MsoNormal>Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect
treatment comparison/network meta-analysis study questionnaire to assess
relevance and credibility to inform health care decision making: an
ISPOR-AMCP-NPC Good Practice Task Force report. Value Health.
2014;17(2):157-173. [<a href="https://pubmed.ncbi.nlm.nih.gov/24636374">PubMed</a>]</p>

<p class=MsoNormal>74.</p>

<p class=MsoNormal>Jansen JP, Schmid CH, Salanti G. Directed acyclic graphs can
help understand bias in indirect and mixed treatment comparisons. J Clin
Epidemiol. 2012;65(7):798-807. [<a
href="https://pubmed.ncbi.nlm.nih.gov/22521579">PubMed</a>]</p>

<p class=MsoNormal>75.</p>

<p class=MsoNormal>Wade R, Sharif-Hurst S, Dias S. Patient characteristics as
effect modifiers for psoriasis biologic treatment response: an assessment using
network meta-analysis subgroups. Syst Rev. 2020;9(1):132. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275463/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/32503632">PubMed</a>]</p>

<p class=MsoNormal>76.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3001. DISCOVER-1 60 week:
a phase 3, multicenter, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of guselkumab administered subcutaneously in
subjects with active&nbsp;<b>psoriatic</b>&nbsp;arthritis including those
previously treated with biologic anti-TNF&#945; agent(s) [internal sponsor's
report]. Raritan (NJ): Janssen Research &amp; Development, LLC; 2020 Apr 09.</p>

<p class=MsoNormal>77.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3002. DISCOVER-2 52 week:
a phase 3, multicenter, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of guselkumab administered subcutaneously in
subjects with active&nbsp;<b>psoriatic</b>&nbsp;arthritis [internal sponsor's
report]. Raritan (NJ): Janssen Research &amp; Development, LLC; 2020 Mar 27.</p>

<p class=MsoNormal>78.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3002. DISCOVER-2 112 week:
a phase 3, multicenter, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of guselkumab administered subcutaneously in
subjects with active&nbsp;<b>psoriatic</b>&nbsp;arthritis [internal sponsor's
report]. Raritan (NJ): Janssen Research &amp; Development, LLC; 2021 Jul 12.</p>

<p class=MsoNormal>79.</p>

<p class=MsoNormal>Clinical Study Report: CNTO1959PSA3003. COSMOS week 56:
phase 3b, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of guselkumab administered subcutaneously in
participants with active&nbsp;<b>psoriatic</b>&nbsp;arthritis and an inadequate
response to anti-tumor necrosis factor alpha (Anti-TNF&#945;) therapy COSMOS
[internal sponsor's report]. High Wycombe (UK): Janssen-Cilag Ltd.; 2021 Jul
12.</p>

<p class=MsoNormal>80.</p>

<p class=MsoNormal>McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and
Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody,
Through One Year in Biologic-Naive Patients With&nbsp;<b>Psoriatic</b>&nbsp;Arthritis.
Arthritis Rheumatol. 2021;73(4):604-616. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291746/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/33043600">PubMed</a>]</p>

<p class=MsoNormal>81.</p>

<p class=MsoNormal>McInnes IB, Rahman P, Gottlieb AB, et al. Long-Term Efficacy
and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of
Interleukin-23, Through Two Years: Results From a Phase III, Randomized,
Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients
With Active&nbsp;<b>Psoriatic</b>&nbsp;Arthritis. Arthritis Rheumatol.
2022;74(3):475-485. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305108/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/34719872">PubMed</a>]</p>

<p class=MsoNormal>82.</p>

<p class=MsoNormal>Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of
guselkumab on axial involvement in patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis
and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2
studies. Lancet Rheumatol. 2021;3(10):e715-e723. [<a
href="https://pubmed.ncbi.nlm.nih.gov/38287608">PubMed</a>]</p>

<p class=MsoNormal>83.</p>

<p class=MsoNormal>Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and
improved guselkumab response in patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis
regardless of baseline demographic and disease characteristics: pooled results
through week 52 of two phase III, randomised, placebo-controlled studies. RMD
Open. 2022;8(1). [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928386/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/35296534">PubMed</a>]</p>

<p class=MsoNormal>84.</p>

<p class=MsoNormal>Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab,
an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs
and symptoms of active&nbsp;<b>psoriatic</b>&nbsp;arthritis: 1 year results of
a phase III randomised study of patients who were biologic-naive or TNFalpha
inhibitor-experienced.&nbsp;<i>RMD Open.</i>&nbsp;2021;7(1):02. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880108/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/33568556">PubMed</a>]</p>

<p class=MsoNormal>85.</p>

<p class=MsoNormal>Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and
safety of guselkumab in patients with active&nbsp;<b>psoriatic</b>&nbsp;arthritis:
a randomised, double-blind, placebo-controlled, phase 2 study. Lancet.
2018;391(10136):2213-2224. [<a href="https://pubmed.ncbi.nlm.nih.gov/29893222">PubMed</a>]</p>

<p class=MsoNormal>86.</p>

<p class=MsoNormal>Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite
Measures of Disease Activity in&nbsp;<b>Psoriatic</b>&nbsp;Arthritis:
Comparative Instrument Performance Based on the Efficacy of Guselkumab in an
Interventional Phase II Trial. Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2020;72(11):1579-1588.
[<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702129/">PMC free
article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31421033">PubMed</a>]</p>

<p class=MsoNormal>87.</p>

<p class=MsoNormal>Mease PJ, Gladman DD, Deodhar A, et al. Impact of
guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and
dactylitis in patients with moderate to severe&nbsp;<b>psoriatic</b>&nbsp;arthritis:
results from a randomised, placebo-controlled, phase II study.&nbsp;<i>RMD
Open.</i>&nbsp;2020;6(2):07. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425189/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/32665433">PubMed</a>]</p>

<p class=MsoNormal>88.</p>

<p class=MsoNormal>van Gestel AM, Haagsma CJ, van Riel PL. Validation of
rheumatoid arthritis improvement criteria that include simplified joint counts.
Arthritis Rheum. 1998;41(10):1845-1850. [<a
href="https://pubmed.ncbi.nlm.nih.gov/9778226">PubMed</a>]</p>

<p class=MsoNormal>89.</p>

<p class=MsoNormal>Felson DT, Anderson JJ, Boers M, et al. The American College
of Rheumatology preliminary core set of disease activity measures for
rheumatoid arthritis clinical trials. The Committee on Outcome Measures in
Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729-740. [<a
href="https://pubmed.ncbi.nlm.nih.gov/8507213">PubMed</a>]</p>

<p class=MsoNormal>90.</p>

<p class=MsoNormal>Gladman D, Cook R, Schentag C, et al. The clinical
assessment of patients with&nbsp;<b>psoriatic</b>&nbsp;arthritis (PsA): Results
of a validation study of the Spondyloarthritis Research Consortium of Canada. J
Rheumatol. 2004;31(6):1126-1131. [<a
href="https://pubmed.ncbi.nlm.nih.gov/15170925">PubMed</a>]</p>

<p class=MsoNormal>91.</p>

<p class=MsoNormal>Felson DT, Anderson JJ, Boers M, et al. American College of
Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.
Arthritis Rheum. 1995;38(6):727-735. [<a
href="https://pubmed.ncbi.nlm.nih.gov/7779114">PubMed</a>]</p>

<p class=MsoNormal>92.</p>

<p class=MsoNormal>Braun J, Davis J, Dougados M, et al. First update of the
international ASAS consensus statement for the use of anti-TNF agents in
patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316-320. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798064/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/16096329">PubMed</a>]</p>

<p class=MsoNormal>93.</p>

<p class=MsoNormal>Haywood KL, A MG, Jordan K, Dziedzic K, Dawes PT.
Disease-specific, patient-assessed measures of health outcome in ankylosing
spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford)<i>.</i>&nbsp;2002;41(11):1295-1302.
[<a href="https://pubmed.ncbi.nlm.nih.gov/12422003">PubMed</a>]</p>

<p class=MsoNormal>94.</p>

<p class=MsoNormal>Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D.
Validity, reliability and responsiveness of the Work Productivity and Activity
Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford)<i>.</i>&nbsp;2010;49(4):812-819.
[<a href="https://pubmed.ncbi.nlm.nih.gov/20100797">PubMed</a>]</p>

<p class=MsoNormal>95.</p>

<p class=MsoNormal>Healy PJ, Helliwell PS.&nbsp;<b>Psoriatic</b>&nbsp;arthritis
quality of life instrument: an assessment of sensitivity and response to
change. J Rheumatol. 2008;35(7):1359-1361. [<a
href="https://pubmed.ncbi.nlm.nih.gov/18528964">PubMed</a>]</p>

<p class=MsoNormal>96.</p>

<p class=MsoNormal>Cella D, Wilson H, Shalhoub H, et al. Content validity and
psychometric evaluation of Functional Assessment of Chronic Illness
Therapy-Fatigue in patients with&nbsp;<b>psoriatic</b>&nbsp;arthritis. J
Patient Rep Outcomes. 2019;3(1):30. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527714/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/31111255">PubMed</a>]</p>

<p class=MsoNormal>97.</p>

<p class=MsoNormal>Chandran V, Bhella S, Schentag C, Gladman DD. Functional
assessment of chronic illness therapy-fatigue scale is valid in patients
with&nbsp;<b>psoriatic</b>&nbsp;arthritis. Ann Rheum Dis. 2007;66(7):936-939. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1955111/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/17324972">PubMed</a>]</p>

<p class=MsoNormal>98.</p>

<p class=MsoNormal>Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of
patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145. [<a
href="https://pubmed.ncbi.nlm.nih.gov/7362664">PubMed</a>]</p>

<p class=MsoNormal>99.</p>

<p class=MsoNormal>Leung YY, Orbai AM, de Wit M, et al. Comparing the
Patient-Reported Physical Function Outcome Measures in a Real-Life
International Cohort of Patients With&nbsp;<b>Psoriatic</b>&nbsp;Arthritis.
Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2021;73(4):593-602. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371516/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/31961492">PubMed</a>]</p>

<p class=MsoNormal>100.</p>

<p class=MsoNormal>Leung YY, Tillett W, Hojgaard P, et al. Test-retest
Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function
in&nbsp;<b>Psoriatic</b>&nbsp;Arthritis. J Rheumatol. 2021;15:15. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487911/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/33858982">PubMed</a>]</p>

<p class=MsoNormal>101.</p>

<p class=MsoNormal>Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L,
Mamolo C. A multi-item Physician Global Assessment scale to assess psoriasis
disease severity: validation based on four phase III tofacitinib studies. BMC
Dermatol. 2019;19(1):8. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555979/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/31174539">PubMed</a>]</p>

<p class=MsoNormal>102.</p>

<p class=MsoNormal>Cappelleri JC, Bushmakin AG, Harness J, Mamolo C.
Psychometric validation of the physician global assessment scale for assessing
severity of psoriasis disease activity. Qual Life Res. 2013;22(9):2489-2499. [<a
href="https://pubmed.ncbi.nlm.nih.gov/23475691">PubMed</a>]</p>

<p class=MsoNormal>103.</p>

<p class=MsoNormal>Robinson A, Kardos M, Kimball AB. Physician Global
Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A
systematic analysis of randomized controlled trials of biologic agents for
moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369-375. [<a
href="https://pubmed.ncbi.nlm.nih.gov/22041254">PubMed</a>]</p>

<p class=MsoNormal>104.</p>

<p class=MsoNormal>Coates LC, Cook R, Lee K-A, Chandran V, Gladman DD.
Frequency, predictors, and prognosis of sustained minimal disease activity in
an observational&nbsp;<b>psoriatic</b>&nbsp;arthritis cohort. Arthritis Care
Res (Hoboken)<i>.</i>&nbsp;2010;62(7):970-976. [<a
href="https://pubmed.ncbi.nlm.nih.gov/20191569">PubMed</a>]</p>

<p class=MsoNormal>105.</p>

<p class=MsoNormal>Coates LC, Helliwell PS. Validation of minimal disease
activity criteria for&nbsp;<b>psoriatic</b>&nbsp;arthritis using interventional
trial data. Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2010;62(7):965-969. [<a
href="https://pubmed.ncbi.nlm.nih.gov/20589696">PubMed</a>]</p>

<p class=MsoNormal>106.</p>

<p class=MsoNormal>Coates LC, Strand V, Wilson H, et al. Measurement properties
of the minimal disease activity criteria for&nbsp;<b>psoriatic</b>&nbsp;arthritis.
RMD Open. 2019;5(2):e001002. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744081/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/31565243">PubMed</a>]</p>

<p class=MsoNormal>107.</p>

<p class=MsoNormal>Coates LC, Helliwell PS. Defining Low Disease Activity
States in&nbsp;<b>Psoriatic</b>&nbsp;Arthritis using Novel Composite Disease
Instruments. J Rheumatol. 2016;43(2):371-375. [<a
href="https://pubmed.ncbi.nlm.nih.gov/26669918">PubMed</a>]</p>

<p class=MsoNormal>108.</p>

<p class=MsoNormal>Simpson MJ, Chow C, Morgenstern H, Luger TA, Ellis CN.
Comparison of three methods for measuring psoriasis severity in clinical
studies (Part 2 of 2): use of quality of life to assess construct validity of
the Lattice System Physician's Global Assessment, Psoriasis Area and Severity
Index and Static Physician's Global Assessment. J Eur Acad Dermatol Venereol.
2015;29(7):1415-1420. [<a href="https://pubmed.ncbi.nlm.nih.gov/25917214">PubMed</a>]</p>

<p class=MsoNormal>109.</p>

<p class=MsoNormal>Berth-Jones J, Grotzinger K, Rainville C, et al. A Study
examining inter- and intrarater reliability of three scales for measuring
severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global
Assessment and Lattice System Physician's Global Assessment. Br J Dermatol.
2006;155(4):707-713. [<a href="https://pubmed.ncbi.nlm.nih.gov/16965419">PubMed</a>]</p>

<p class=MsoNormal>110.</p>

<p class=MsoNormal>Bozek A, Reich A. The reliability of three psoriasis
assessment tools: psoriasis area and severity index, body surface area and
physician global assessment. Adv Clin Exp Med. 2017;26(5):851-856. [<a
href="https://pubmed.ncbi.nlm.nih.gov/29068583">PubMed</a>]</p>

<p class=MsoNormal>111.</p>

<p class=MsoNormal>Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis
Area and Severity Index, Psoriasis Global Assessment, and Lattice System
Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-569. [<a
href="https://pubmed.ncbi.nlm.nih.gov/15389191">PubMed</a>]</p>

<p class=MsoNormal>112.</p>

<p class=MsoNormal>Fink C, Alt C, Uhlmann L, Klose C, Enk A, Haenssle HA.
Intra- and interobserver variability of image-based PASI assessments in 120
patients suffering from plaque-type psoriasis. J Eur Acad Dermatol Venereol.
2018;32(8):1314-1319. [<a href="https://pubmed.ncbi.nlm.nih.gov/29569769">PubMed</a>]</p>

<p class=MsoNormal>113.</p>

<p class=MsoNormal>Puzenat E, Bronsard V, Prey S, et al. What are the best
outcome measures for assessing plaque psoriasis severity? A systematic review
of the literature. J Eur Acad Dermatol Venereol. 2010;24 (Suppl 2):10-16. [<a
href="https://pubmed.ncbi.nlm.nih.gov/20443995">PubMed</a>]</p>

<p class=MsoNormal>114.</p>

<p class=MsoNormal>Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity
Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation
between disease severity and psychological burden in patients treated with
biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-337. [<a
href="https://pubmed.ncbi.nlm.nih.gov/23425140">PubMed</a>]</p>

<p class=MsoNormal>115.</p>

<p class=MsoNormal>Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form
health survey (SF-36). I. Conceptual framework and item selection. Med Care.
1992;30(6):473-483. [<a href="https://pubmed.ncbi.nlm.nih.gov/1593914">PubMed</a>]</p>

<p class=MsoNormal>116.</p>

<p class=MsoNormal>Frendl DM, Ware JE, Jr. Patient-reported functional health
and well-being outcomes with drug therapy: a systematic review of randomized
trials using the SF-36 health survey. Med Care. 2014;52(5):439-445. [<a
href="https://pubmed.ncbi.nlm.nih.gov/24714581">PubMed</a>]</p>

<p class=MsoNormal>117.</p>

<p class=MsoNormal>Tillett W, Jadon D, Shaddick G, et al. Feasibility,
reliability, and sensitivity to change of four radiographic scoring methods in
patients with&nbsp;<b>psoriatic</b>&nbsp;arthritis. Arthritis Care Res
(Hoboken)<i>.</i>&nbsp;2014;66(2):311-317. [<a
href="https://pubmed.ncbi.nlm.nih.gov/23925955">PubMed</a>]</p>

<p class=MsoNormal>118.</p>

<p class=MsoNormal>Gladman DD, Mease PJ, Healy P, et al. Outcome measures
in&nbsp;<b>psoriatic</b>&nbsp;arthritis. J Rheumatol. 2007;34(5):1159-1166. [<a
href="https://pubmed.ncbi.nlm.nih.gov/17477479">PubMed</a>]</p>

<p class=MsoNormal>119.</p>

<p class=MsoNormal>Bruce B, Fries JF. The Health Assessment Questionnaire
(HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14-18. [<a
href="https://pubmed.ncbi.nlm.nih.gov/16273780">PubMed</a>]</p>

<p class=MsoNormal>120.</p>

<p class=MsoNormal>Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis
disease activity measures: American College of Rheumatology recommendations for
use in clinical practice. Arthritis Care Res (Hoboken)<i>.</i>&nbsp;2012;64(5):640-647.
[<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028066/">PMC free
article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22473918">PubMed</a>]</p>

<p class=MsoNormal>121.</p>

<p class=MsoNormal>Bruce B, Fries JF. The Stanford Health Assessment
Questionnaire: dimensions and practical applications. Health Qual Life
Outcomes. 2003;1:20. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165587/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/12831398">PubMed</a>]</p>

<p class=MsoNormal>122.</p>

<p class=MsoNormal>Bruce B, Fries JF. The Stanford Health Assessment
Questionnaire: a review of its history, issues, progress, and documentation. J
Rheumatol. 2003;30(1):167-178. [<a
href="https://pubmed.ncbi.nlm.nih.gov/12508408">PubMed</a>]</p>

<p class=MsoNormal>123.</p>

<p class=MsoNormal>Mease P, Strand V, Gladman D. Functional impairment
measurement in&nbsp;<b>psoriatic</b>&nbsp;arthritis: Importance and challenges.
Semin Arthritis Rheum. 2018;48(3):436-448. [<a
href="https://pubmed.ncbi.nlm.nih.gov/30029795">PubMed</a>]</p>

<p class=MsoNormal>124.</p>

<p class=MsoNormal>Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT.
Measuring health status in&nbsp;<b>psoriatic</b>&nbsp;arthritis: the Health
Assessment Questionnaire and its modification. J Rheumatol. 1995;22(5):886-893.
[<a href="https://pubmed.ncbi.nlm.nih.gov/8587077">PubMed</a>]</p>

<p class=MsoNormal>125.</p>

<p class=MsoNormal>Husted JA, Gladman DD, Long JA, Farewell VT. A modified
version of the Health Assessment Questionnaire (HAQ) for&nbsp;<b>psoriatic</b>&nbsp;arthritis.
Clin Exp Rheumatol. 1995;13(4):439-443. [<a
href="https://pubmed.ncbi.nlm.nih.gov/7586774">PubMed</a>]</p>

<p class=MsoNormal>126.</p>

<p class=MsoNormal>Feldman SR, Krueger GG. Psoriasis assessment tools in
clinical trials. Ann Rheum Dis. 2005;64 (Suppl 2):ii65-68. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766877/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/15708941">PubMed</a>]</p>

<p class=MsoNormal>127.</p>

<p class=MsoNormal>Perez-Chada LM, Salame NF, Ford AR, et al. Investigator and
Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic
Review on Measurement Properties from the International Dermatology Outcome
Measures (IDEOM) Initiative. Am J Clin Dermatol. 2020;21(3):323-338. [<a
href="https://pubmed.ncbi.nlm.nih.gov/31950353">PubMed</a>]</p>

<p class=MsoNormal>128.</p>

<p class=MsoNormal>Gourraud PA, Le Gall C, Puzenat E, Aubin F, Ortonne JP, Paul
CF. Why statistics matter: limited inter-rater agreement prevents using the
psoriasis area and severity index as a unique determinant of therapeutic
decision in psoriasis. J Invest Dermatol. 2012;139(9):2171-2175. [<a
href="https://pubmed.ncbi.nlm.nih.gov/22592157">PubMed</a>]</p>

<p class=MsoNormal>129.</p>

<p class=MsoNormal>Queiro R, Cañete JD, Montilla C, et al. Minimal disease
activity and impact of disease in&nbsp;<b>psoriatic</b>&nbsp;arthritis: a
Spanish cross-sectional multicenter study. Arthritis Res Ther. 2017;19(1):72. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372277/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/28356155">PubMed</a>]</p>

<p class=MsoNormal>130.</p>

<p class=MsoNormal>Lubrano E, Spadaro A. Pharmacoeconomic burden in the
treatment of&nbsp;<b>psoriatic</b>&nbsp;arthritis: from systematic reviews to
real clinical practice studies. BMC Musculoskelet Disord. 2014;15:25. [<a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901890/">PMC free article</a>]
[<a href="https://pubmed.ncbi.nlm.nih.gov/24444003">PubMe</a></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
